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ABSTRACT_________________________________________ 
Natural products offer vast structural and chemical diversity highly sought after 
in drug discovery research. Saccharomyces cerevisiae makes an ideal model 
eukaryotic organism for drug mode-of-action studies owing to ease of growth, 
sophistication of genetic tools and overall homology to higher eukaryotes. 
Equisetin and a closely related novel natural product, TA-289, are cytotoxic to 
fermenting yeast, but seemingly less so when yeast actively respire. Cell cycle 
analyses by flow cytometry revealed a cell cycle block at S-G2/M phase caused by 
TA-289; previously described oxidative stress-inducing compounds causing cell 
cycle delay led to further investigation in the involvement of equisetin and TA-
289 in mitochondrial-mediated generation of reactive oxygen species. Chemical 
genomic profiling involving genome-wide scans of yeast deletion mutant strains 
for TA-289 sensitivity revealed sensitization of genes involved in the 
mitochondria, DNA damage repair and oxidative stress responses, consistent with 
a possible mechanism-of-action at the mitochondrion. Flow cytometric detection 
of reactive oxygen species (ROS) generation caused by TA-289 suggests that the 
compound may induce cell death via ROS production. The generation of a mutant 
strain resistant to TA-289 also displayed resistance to a known oxidant, H2O2, at 
concentrations that were cytotoxic to wild-type cells. The resistant mutant 
displayed a higher basal level of ROS production compared to the wild-type 
parent, indicating that the resistance mutation led to an up-regulation of 
antioxidant capacity which provides cell survival in the presence of TA-289. 
Yeast mitochondrial morphology was visualized by confocal light microscopy, 
where it was observed that cells treated with TA-289 displayed abnormal 
mitochondria phenotypes, further indicating that the compound is acting 
primarily at the mitochondrion. Similar effects observed with equisetin treatment 
suggest that both compounds share the same mechanism, eliciting cell death via 
ROS production in the mitochondrial respiratory chain. 
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1. INTRODUCTION___________________________________ 
 
1.1 Drug discovery and drug mode-of-action 
Drug discovery research is an interdisciplinary endeavour with strong foundations 
in both biology and chemistry. Essential foundations of chemical theory strongly 
guided by pharmacology, biochemistry, and molecular biology saw a marked 
increase in the contribution of drug discovery to the progress of medicine in the last 
century (Laport, Santos et al. 2009). Advances in synthetic chemistry, especially 
diversity-oriented synthesis for production of natural product-like small molecule 
inhibitors in high-throughput (Schreiber 2000; Kumar, Kiuchi et al. 2005), and 
natural product isolation, coupled with improved technology available for structural 
elucidation has allowed the characterization of large libraries of distinct chemical 
entities with diverse skeletal structure. Biological assay development in combination 
with high-throughput screening technology (Bradner, McPherson et al. 2006) has 
enabled identification of numerous compounds with diverse biological activity, a 
significant proportion of which possess therapeutic properties. 
 
As modern medicine becomes increasingly dependent on drug-like compounds, the 
continuous discovery and development of new small molecule inhibitors for drug-
leads is crucial. As such, the discovery of novel compounds and especially 
compounds with novel biological activity greatly expands the pharmaceutical 
arsenal with which to combat disease, in particular, disease areas dearth in 
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competent drugs, or where current therapeutics are less effective now compared to 
when they were first applied. This is exemplified in the case of anti-bacterial, anti-
viral, anti-fungal, and anti-parasitic drugs that are prone to decreased or complete 
loss of efficacy as a result of natural evolutionary resistance (White, Marr et al. 1998; 
Walsh 2000). Penicillin, for example has been widely prescribed as an antibiotic, 
however growing resistance to penicillin has fuelled research into more potent 
analogues such as ampicillin, as well as the discovery of mechanistically similar 
antibiotics, like the cephalosporins (Wheeler 1977), and equally, mechanistically 
dissimilar antibiotics, such as the tetracyclines (Duggar 1948). In the case of cancer 
therapeutics, acquisition of resistance to anti-cancer drugs by cancer cells is a major 
problem, where the mechanism of resistance to anti-cancer agents appears to be 
multi-factorial, and varies greatly depending on the type of cancer (Gottesman 2002; 
Okuma, Kiguchi et al. 2003; Roos, Jost et al. 2011). For the drug discovery process, 
studies into mechanisms of resistance aid in the discovery of new anti-cancer drugs 
with differing mechanisms that are able to overcome resistance by cancer cells. 
 
Drug target selectivity is an important factor when considering a drug-like molecule 
for development in the drug discovery process. While greater target selectivity often 
means lesser side-effects, this is not always true. Dominating the cancer therapeutic 
setting are anti-microtubule drugs (Morris and Fornier 2008), drugs that arrest 
mitosis and cause cell death. Although these drugs have been proven useful in 
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targeting rapidly dividing cancer cells, non-tumorigenic cells that are actively 
dividing within the host, such as epithelial and hair follicle cells are also targeted 
(Botchkarev 2003). Therefore, there are several important factors when considering 
a drug-like molecule, especially one that is deserving of clinical follow-up. Drug 
discovery research has seen the evolution of the nature in which compounds are 
screen and selected for development as the need for drugs with greater efficacy, 
better target selectivity, and favourable pharmacokinetic properties is becoming 
increasingly apparent. Assays with greater sensitivity in identifying drug-target 
activity and specificity have become a necessity, and where possible, biological 
assays that mimicked settings in vivo are applied. 
 
Molecular biology has offered drug discovery a better understanding of disease 
processes and the dissection of potential targets and biological pathways, especially 
at the genomic level (Drews 2000). As more structurally and chemically diverse 
small molecules are discovered, there has been a considerable effort made towards 
applying these small molecules to dissect cellular pathways in a manner analogous to 
that applied in genetics. Small molecule inhibitors or activators are employed to 
produce phenotypes of interest, after which the target responsible for the induced 
phenotype is characterized. This approach is largely beneficial for the drug discovery 
process, as it simultaneously identifies proteins or cellular pathways that can be 
potential targets for therapeutic intervention, as well as small molecules that alter 
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the functions of these targets (Schreiber 2000). For instance, rapamycin, inhibitor of 
the target of rapamycin (TOR) proteins (Heitman, Movva et al. 1991), induces 
starvation responses in both yeast and mammalian cells (Singh, Sun et al. 1979). 
Overexpression studies in yeast revealed additional genes associated with cellular 
pathways of TOR, wherein these genes also display sensitivity to LY-83583, a small 
molecule suppressor of rapamycin-induced inhibition (Butcher, Bhullar et al. 2006). 
Through these studies, functional links between genes implicated in the TOR 
pathway affecting sensitivity to both rapamycin and LY-83583 facilitated the 
investigation of potential cellular targets of LY-83583, in addition to suggesting its 
mechanisms. 
 
The move from drug development programs predominantly screening purified 
enzymes and receptors in vitro (Sturgeon, Kemmer et al. 2006), to complex cell-
based phenotypic screens containing a multitude of potential targets has lead to 
greater emphasis on drug mode-of-action research. The development of cell-based 
assays therefore plays a pivotal role in targeted drug discovery, as compounds are 
screened for activity wherein target proteins are already in their native 
environment. In cell-based drug screens, the observed biological activity could be 
due to interactions with numerous potential targets, and so drug mode-of-action 
studies are often required to understand the basis of the activity of the drug, 
6 
 
especially in the case where this results in its advancement as a therapeutic drug in 
any disease setting. 
 
Drug target or mode-of-action identification is essential in the drug discovery 
process, especially in the case where side effects are concerned. Side effects often 
occur as a result of a drug having multiple targets, as it was in the case of the non-
steroidal anti-inflammatory drugs, salicylate and aspirin. While both drugs exert 
their anti-inflammatory effects through inhibition of cyclooxygenases (Vane 1994), 
they also have been shown to target multiple connected cellular pathways involved 
in the pathogenesis of the inflammatory response such as the NF-κB (nuclear factor 
kappa B) pathway (Kopp and Ghosh 1994). The contribution of the potential targets 
to the mode-of-action of these drugs still remain undetermined (Yin, Yamamoto et 
al. 1998; Alpert and Vilcek 2000). Side effects also arise from a target-mediated 
effect, where the target(s) plays different roles in various cell types, such as the case 
of the immunosuppressant cyclosporine and its cellular targets, the cyclophilins. 
Cyclosporine interacts with cyclophilin A, where the resulting complex prevents 
production of pro-inflammatory molecules TNF-α and interleukin 2 (Serkova 2004). 
However, cyclosporine also interacts with cyclophilin D, a key componenet in the 
permeability transition pores within the mitochondrial matrix, the disruption of 
which results in mitochondrial swelling and dysfunction (Elrod, Wong et al. 2010). 
Drug target identification strategies allow for the distinction of promiscuous drugs, 
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as in the first example, from pleiotropic targets. In the latter case, it can reveal 
undesirable disease targets, and for the former, equally undesirable compounds for 
therapeutic use. 
 
Conversely, for non-therapeutic compounds, a well-defined mode-of-action may 
allow for their applications as biological probes, used to explore the functions and 
roles of their targets in cellular pathways and processes. For example, the protein 
synthesis inhibitor cycloheximide has been extensively used to assess the 
contribution of protein synthesis to a given biological phenomenon (Maia 1994; 
Funder 2005). Alternatively, the compound could be used to identify unknown 
functions of its target. The highly conserved heat shock protein 90 (HSP90) 
chaperone complex, for example, which is involved in steroid receptor function and 
the stability of oncogenic kinases is a known target for the natural product (NP) 
compound geldanamycin (Cardenas, Cruz et al. 1999). Genome-wide studies in the 
yeast Saccharomyces cerevisiae using geldanamycin as a biochemical probe allowed 
for the mapping of the genetic interactions of HSP90 through functional inhibition 
by geldanamycin. These findings revealed a vast number of genes that were 
dependent on HSP90 for normal cellular function, leading to the identification of 
the varied and essential physiological roles of HSP90 in the cell, and how its 
interactions influence global patterns of gene expression (Zhao, Davey et al. 2005). 
In the same way, genetic interactions of the TOR1C complex (the TOR complex 
8 
 
targeted by rapamycin) were identified by screening yeast deletion mutants for 
rapamycin sensitivity. This lead to the genome-wide characterization of not only 
known functions of TOR, but also the construction of additional cellular pathways 
and processes associated with TOR signalling (Chan, Carvalho et al. 2000). 
 
1.2 Natural products for drug discovery 
The advent of drug screening technologies and combinatorial synthetic chemistry 
allowed for the generation of large chemical libraries (Kumar, Kiuchi et al. 2005), 
from which biologically active compounds could be identified for development as 
potential drugs. Historically, NP libraries were more difficult to compile due to the 
need for compound isolation and purification. However, advancement in isolation 
and structure elucidation techniques (Newman and Cragg 2007) in the latter part of 
the last century paved the way for competition with synthetic compound libraries in 
rapidly and robustly identifying biologically active NPs for drug discovery. Most 
importantly, NPs, unlike synthetic compounds, offered greater structural and 
chemical diversity, characteristics seemingly intrinsic to biologically active 
compounds, making them highly desirable in drug discovery research. This, coupled 
with efficient and robust techniques to identify diverse biologically active NPs saw a 
marked increase in NP drug discovery, and this is evident in the number of NPs and 
NP-derived compounds  represented as sources of new drugs over the past 25 years 
(Newman and Cragg 2007). 
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To date, more than half of the current pharmacopeia is dominated by NPs or 
combinatorial compounds derived from natural sources (Figure 1.1). These are 
unequivocally wide-ranging in their application: for the treatment of bacterial, viral 
and fungal infections, as immunosuppressants (rapamycin, first isolated from soil 
bacterium Streptomyces hygroscopicus (Vezina, Kudelski et al. 1975)), as anti-
inflammatory agents (salicylic acid, from the bark of the willow tree (Raskin 1992)), 
as well as in treatment of atherosclerosis (lovastatin, a hypolipidemic agent, is 
produced by several mold species (Moore, Bigam et al. 1985)), and in cancer 
therapeutics (paclitaxel, a well-established anti-cancer agent, was originally isolated 
from the bark of the pacific yew tree (Wani, Taylor et al. 1971; Hood, West et al. 
2002)). 
 
Figure 1.1. All small molecule new entities launched between 1981–2006. (S) indicates purely 
synthetic compounds, (NM) are synthetic compounds whose pharmacophore were of natural product 
origin, (ND) are compounds derived from natural products with semi-synthetic modifications, and 
(NP) indicates pure natural product molecules (Newman and Cragg 2007). 
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In comparison to synthetic compounds, NPs possess many pharmacologically 
attractive properties. Overall, NPs have a greater number of chiral centers and 
macrocycles, greater structural rigidity, and diverse ring systems (Figure 1.2). 
Skeletal diversity provides the basis for higher target selectivity and uptake 
efficiency, and stronger binding properties (Baker, Prior et al. 2002; Feher and 
Schmidt 2003; Clardy and Walsh 2004; Koehn and Carter 2005). Most importantly, 
biologically active NPs have evolved alongside their targets, as these molecules are 
often produced by the host organism to serve some sort of biological function. All 
these properties of NPs make them highly valuable in drug discovery. 
 
Figure 1.2. Structural diversity and biological specificity of NPs. Overall, NPs have greater number of 
chiral centers and low freely rotatable bonds, making NPs structurally diverse and possessing higher 
specificity for target-binding (Blunt, Copp et al. 2008). 
 
The remarkable diversity encompassed by NPs is indisputable in terms of their 
relevance to drug discovery research, and a number of approaches have been 
developed to capture their intrinsic value (Gullo, McAlpine et al. 2006). Most 
importantly, these attributes of NPs have provided modern medicine with a plethora 
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of novel drugs in a variety of disease settings, particularly in therapeutic areas with a 
dearth in leading drugs (Butler 2004; Simmons, Andrianasolo et al. 2005). 
 
1.3 Yeast in drug discovery 
The yeast Saccharomyces cerevisiae possesses many attributes that distinguish it as 
an ideal model eukaryotic system for diverse biological studies: it is small and 
inexpensive to grow, its entire genome has been sequenced, and its ~6300 open 
reading frames (ORFs) have been made readily usable for genome-wide analyses 
(Hudson, Dawson et al. 1997; Winzeler, Shoemaker et al. 1999). Yeast as a screening 
system suffers a drawback for drug discovery due to the extensive drug-efflux pump 
network (referred to as pleiotropic drug resistance (PDR) pumps) they possess. The 
presence of these inducible efflux pumps can be challenging, as they lower the 
effectiveness of a large proportion of drugs (Balzi and Goffeau 1995). For drug 
candidates that are substrates for this drug-efflux system, the use of sensitized yeast 
strains wherein drug-efflux is genetically compromised circumvents this problem. 
Under these circumstances, effective drug concentrations become comparable to 
those observed in cultured mammalian cell lines (Woo, Kato et al. 1999; Miyamoto, 
Machida et al. 2002). 
 
Notably, there is high cross-species conservation of genetic components between 
yeast and humans; 30% of known genes implicated in human diseases have yeast 
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orthologues (Foury 1997; Luesch, Wu et al. 2005), and fundamental cellular 
processes and metabolic pathways in S. cerevisiae are very similar to that of humans 
(Auerbach, Arnoldo et al. 2005). Thus this cross-species conservation enables the 
utilization of yeast to discover and characterize the biological activity of compounds 
that may be of therapeutic relevance in humans. Additionally, the close genetic 
relations S. cerevisiae has to pathogenic fungi such as Candida albicans makes this 
microorganism an ideal ready-made model system for anti-fungal drug discovery 
and mode-of-action studies (Hughes 2002). 
 
Many studies have employed S. cerevisiae to discover novel small molecule 
inhibitors (or less frequently, activators) and to characterize their mode-of-action 
within the microorganism itself. In this way, cincreasin, a small molecule inhibitor 
of the spindle-checkpoint was identified, and through the use of genome-wide tools 
available for S. cerevisiae, the target of cincreasin, MPS1, a protein kinase required 
for spindle-checkpoint function was characterized (Dorer, Zhong et al. 2005). 
Likewise, a class of sirtuin inhibitors were discovered through phenotypic-based 
chemical-genetic screening in S. cerevisiae. Sirtuins are a family of conserved 
enzymes involved in transcriptional silencing of telomeric loci (Grozinger 2001). 
These novel compounds were found to selectively inhibit yeast Sir2p activity in vivo 
and yeast Sir2p and human SIRT2 activity in vitro (Grozinger 2001). These studies 
demonstrate the utility and robustness of S. cerevisiae for drug discovery and drug 
13 
 
mode-of-action studies. In addition, the findings identified potential targets for 
therapeutic intervention, molecules that inhibit these targets, and further 
refinement in understanding these target functions within the cell – this is 
especially in the case of the sirtuins, wherein all seven human sirtuins remain 
largely uncharacterized. 
 
The foremost advantage of using S. cerevisiae for drug discovery is the availability of 
tools superlative for drug mode-of-action studies not available in aggregate in any 
other eukaryote species. The S. cerevisiae genome is easily manipulated, and most 
importantly, genetically tractable. The ease of which yeast undergo homologous 
recombination, coupled with advanced molecular biology such as robotic nucleotide 
synthesis has allowed the development of numerous powerful genomic tools. 
Various yeast libraries have been made available, including a genome-wide set of 
single deletion knock-outs each identifiable with unique DNA barcodes (Winzeler, 
Shoemaker et al. 1999), a yeast library of ORFs fused to TAP-tags (tandem affinity 
purification tags) (Rigaut, Shevchenko et al. 1999; Puig, Caspary et al. 2001) or GFP 
(green fluorescent protein) (Huh, Falvo et al. 2003), allowing systematic genome-
wide analyses of protein-protein interactions (Ross-Macdonald, Coelho et al. 1999) 
and protein localization (Niedenthal, Riles et al. 1996; Huh, Falvo et al. 2003) 
respectively. Furthermore, the characterization of homozygous and heterozygous 
gene disruption phenotypes (Tong, Evangelista et al. 2001; Giaever, Chu et al. 2002) 
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has been made possible with the yeast deletion mutant libraries (Winzeler, 
Shoemaker et al. 1999). Many studies have since used these approaches to build a 
comprehensive understanding of protein regulation, expression, function, and 
interaction.  
 
In contrast to mammalian-cell drug-target identification which relies heavily upon 
affinity-based methods to identify potential targets, the long and rich history of 
yeast molecular genetics methodologies affords the application of many additional 
approaches to identify drug targets. One of the most successful approaches to 
identifying drug targets in yeast has been the generation and characterization of 
drug-resistant mutants. Many studies have employed this approach for drug-target 
identification; Aureobasidin A is an anti-fungal agent with activity against both 
Candida sp. and S. cerevisiae (Heidler and Radding 1995). A resistant mutant strain 
was generated in S. cerevisiae to study the mechanism of aureobasidin A. The 
resistance was linked to a dominant mutation in a single gene, AUR1, a gene 
encoding phosphatidylinositol:ceramide phosphoinositol transferase (IPC synthase), 
an enzyme required in sphyngolipid biosynthesis and is essential for the viability of 
S. cerevisiae (Heidler and Radding 1995). 
 
Often, dominant mutations occur in the target of the compound of interest, and as it 
was in this case, aureobasidin A potently inhibited IPC synthase activity (Nagiec, 
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Nagiec et al. 1997). Moreover, phosphoinositol-containing sphingolipids are unique 
to fungi, making the sphingolipid biosynthesis pathway an attractive target for anti-
fungal agents (Nagiec, Nagiec et al. 1997; Yuichi S. 2004). Similarly, Thomas et. al. 
isolated 173 yeast mutants conferring resistance to anti-mitotic agent benomyl. 
Subsequent mutant characterization revealed all of the resistance conferring 
mutations had occurred in the same gene, TUB2, which encodes the β-tubulin 
subunit of yeast microtubules. Additionally, nine of the mutants conferred 
temperature-dependent growth, wherein these mutants showed characteristic cell-
division-cycle defects at their growth-restrictive temperatures, indicating the 
importance of tubulin function in cell division. Mapping of TUB2 further described 
it as the first cell-division-cycle gene that encodes for a cytoskeletal protein with 
central roles in the cell cycle (Thomas, Neff et al. 1985). 
 
The use of small molecule inhibitors in combination with the readily available 
genome-wide tools such as the yeast gene deletion sets has also greatly facilitated 
genetic analyses of a myriad of cellular processes. The discovery of the mitotic 
spindle checkpoint (Stearns, Hoyt et al. 1990; Chan, Carvalho et al. 2000) and 
identification of  genes required for the correct folding of β-tubulin (Stearns, Hoyt 
et. al. 1990), for example, were found through studying the relative sensitivity of 
yeast mutants to benomyl. In this case, benomyl hyper-sensitive rather than 
resistant mutants were identified. These studies, in combination with the generation 
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of the yeast deletion libraries have paved the way for the recently devised method of 
chemo-genomic profiling for drug mode-of-action, which will be further discussed 
in chapter two.  
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2. TETRAMIC ACID 289 AND EQUISETIN________________ 
 
2.1 Introduction: Natural products from terrestrial microbes 
Microbial natural products have played a pivotal role in drug discovery during the 
last century (Larsen, Smedsgaard et al. 2005). Since the discovery of penicillin G 
from Penicillium sp., interest in fungi, actinomycetes, and other microorganisms 
soared, and these became a hunting ground for novel drug leads (Larsen, Smedsgaard 
et al. 2005). Fungi in particular, have provided a plethora of biologically active 
compounds, many of which were subsequently actively developed and applied as 
pharmaceuticals and for industrial use (Sims, Fillmore et al. 2005). Compounds are 
deemed biologically active if they cause a specific response in a biological system. 
Specific responses detail physical interactions between the compound and a 
biological structure. More often than not, these responses lead to inhibition of a 
biological system by the compound; however stimulatory compounds have also been 
applied. Novel compounds displaying interesting biological activity thus become 
playgrounds for drug discovery and development. 
 
In this study, a small, focused natural product library of pure compounds isolated 
from soil fungi provided by our collaborator Dr Stephen Bloor (Biodiscovery NZ, 
Auckland), were screened for biological activity in yeast, from which two 
compounds were chosen for further drug-target identification studies; Tetramic acid 
289 (TA-289), a novel compound, and a known, structurally-related compound with 
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an uncharacterized mode-of-action, equisetin (Figure 2.1). TA-289 and equisetin 
belong to the tetramic acid class of compounds. Naturally occurring tetramic acids 
and tetramic acid derivatives constitute a substantial class of compounds; almost all 
compounds discovered bearing the tetramic acid moiety display some sort of 
biological activity, the spectrum of which is remarkable in its diversity, ranging 
from antifungal, to antibacterial, antiviral, to anticancer properties (Royles 1995; 
Singh, Bisht et al. 2006) – a number of tetramic acid compounds have been screened 
for biological activity against HIV-1 integrase (Singh, Zink et al. 1998; Hazuda, Blau 
et al. 1999), gram-positive and –negative bacteria (Vesonder, Tjarks et al. 1979), 
plants (Wheeler, Stipanovic et al. 1999), fungi (Schobert and Schlenk 2008), and 
cancer cell lines (Akita 1991; Sugie, al et al. 2002) in vivo and in vitro. This family 
holds a distinctive structural feature, the 2,4-pyrrolidinedione ring system, a key 
motif found in many natural products from which biological activity is derived 
(Singh, Bisht et al. 2006). 
 
Figure 2.1. Structures of TA-289 and equisetin. Circled in green is the tetramic acid moiety. 
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Equisetin, first isolated from Fusarium equiseti (Burmeister, Bennett et al. 1974), has 
since been shown to be produced by other fungi of the genus Fusarium (Hazuda, 
Blau et al. 1999; Sims, Fillmore et al. 2005), and has been successfully synthesized 
(Yuki, Shindo et al. 2001; Burke, Dixon et al. 2005). Equisetin displayed potent 
inhibitory activity against certain gram positive bacteria, including mycobacteria 
(Burmeister, Bennett et al. 1974). The compound was also shown to inhibit 
recombinant HIV-1 integrase in vitro, with reported IC50 values between 7-20 µM 
(Singh, Zink et al. 1998). Recently, a study on trypanosomal post-translation protein 
import showed that equisetin displayed inhibitory activity against translocation of 
post-translational proteins to the endoplasmic reticulum (IC50 3.3 µM) in 
Trypanosoma brucei (Patham, Duffy et al. 2009). 
 
Studies conducted by König et. al. in isolated rat mitochondria found equisetin 
potently inhibited the uptake of succinate, ATP (adenosine triphosphate), Pi 
(inorganic phosphate), and succinate in a dose-dependent manner. ATPase activity 
and Pi exchange were also significantly decreased in the presence of equisetin. In 
this study, equisetin was proposed to specifically inhibit the substrate anion carriers 
of the inner mitochondrial membrane, however the exact mechanism by which 
equisetin inhibits these carriers has not been established (König, Kapus et al. 1993). 
Lundin et. al. showed an increase in inorganic mitochondrial pyrophosphatase 
(PPase) activity by equisetin in S. cerevisiae (Lundin, Deopujari et al. 1992). To date, 
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the study conducted by Lundin et. al. is the only one to provide evidence of 
equisetin biological activity in S. cerevisiae. Another study examined the effects of 
equisetin on energy-linked reactions of chromatophores of the gram negative 
proteobacterium Rhodospirillum rubrum, and concluded a nonspecific action of 
equisetin on membranes and hydrophobic domains of proteins (Nyren and Strid 
1989). Currently, the mechanism-of-action of equisetin remains uncharacterized. 
 
Numerous compounds containing tetramic acid moieties have been isolated from 
various fungi, however there appears to be a distinct sub-class of equisetin-like 
compounds (Figure 2.2), all of which displayed potent antimicrobial activity against 
a number of gram positive bacteria (Staphylococcus sp., Pseudomonas sp., 
Enterococcus sp., Bacilli sp., and Streptococcus sp.), certain pathogenic fungi 
including Candida albicans (coniosetin), Cladosporium resinae and Trytophyton 
mentagrophytes (paecilosetin), and HeLa (CJ-17-572, CJ-21-058) and P388 
(paecilosetin) tumorgenic cell lines (Schobert and Schlenk 2008). Trichosetin was 
found to be phytotoxic, inhibiting the growth of roots and shoots in various 
seedlings, as was equisetin (Wheeler, Stipanovic et al. 1999). Moreover, a dose-
dependent increase in electrolyte leakage and lipid peroxidation caused by 
trichosetin, resulting in damaged mitochondria has been observed (Marfori, 
Kajiyama et al. 2003). As with equisetin, CJ-17-572 and CJ-21-058 inhibit SecA 
activity in vitro. SecA is part of the eubacterial translocase pathway, involved in 
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translocating pre-proteins and mature proteins across membranes within the cell 
(Bieker 1990; Sugie, al et al. 2002). The reported activities of these structurally 
related compounds may indicate possible similar mechanisms-of-action between 
TA-289 and equisetin, where often, structurally similar compounds have been 
shown to be comparable in their mechanisms (Ghannoum and Rice 1999). 
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Figure 2.2. Chemical structures of structurally-related tetramic acid compounds. A) TA-289, B) 
Equisetin (Burmeister, Bennett et al. 1974; Vesonder, Tjarks et al. 1979), 1) Trichosetin (Marfori 
2002), 2) Altersetin (Hellwig, Grothe et al. 2003), 3) Phomasetin (Cabelli 1991), 4) CJ-21-058 
(Sugie, al et al. 2002), 5) CJ-17-572 (Akita 1991), 6) LL-49F233α (Singh, Zaccardi et al. 1998), 7) 
Coniosetin (Schobert and Schlenk 2008), 8) Paecilosetin (Schobert and Schlenk 2008). 
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2.2 The yeast genome deletion set 
Following the complete genome sequencing of S. cerevisiae was the generation of a 
comprehensive set of yeast deletion strains, that is, the creation of a deletion strain 
for each open reading frame (ORF) in the yeast genome. As part of the deletion 
process, every ORF was replaced with a kanamycin-resistance cassette. In addition, 
each deletion was uniquely identified by the addition of a pair of 20 bp nucleotide 
sequence “barcodes”. Moreover, universal primer sequences flanking the unique 
“barcodes” allowed for mass PCR amplification and quantification of abundance of 
an individual mutant in a mixed population of mutant strains i.e. microarray-based 
phenotypic analyses (Boone, Bussey et al. 2007). From this, four yeast deletion 
libraries were produced: the homozygous deletion set wherein each strain is either 
mating type MATa, MATα, or as a diploid, has a non-essential gene replaced with 
the kanamycin-resistance cassette; the heterozygous deletion set comprising strains 
where one copy of each essential gene has been replaced with the kanamycin-
resistance cassette. 
 
To date, each of these collections, highly valued in the yeast community as key 
resource tools used for large scale and systematic genetics analyses, have been 
employed for drug target identification and/or mode-of-action studies. In general, 
the expression levels of a protein can be decreased by approximately half through 
the deletion of a copy of a gene in a diploid yeast strain, leading to hypersensitivity 
to an inhibitory compound (Giaever, Shoemaker et al. 1999); conversely, the 
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opposite can be achieved, where gene target overexpression confers drug resistance 
(Rine, Hansen et al. 1983; Launhardt, Hinnen et al. 1998). This approach exploits the 
concept that the gene target of a compound of interest can be determined through 
analysis of mutants that are hyper-sensitive to the compound compared to that of 
wild-type cells (Giaever, Shoemaker et al. 1999). While the use of the heterozygous 
deletion library takes into account nearly every gene in drug sensitivity, there is 
variability in the success of unambiguously determining drug targets, and that the 
most drug-sensitive strain does not always reveal the direct drug target (Sturgeon, 
Kemmer et al. 2006). 
 
Studies involving the use of the homozygous deletion library in determining the 
mode-of-action of a compound of interest are based on the fact that the deletion of a 
gene results in a complete lack of expression of associated nonessential gene 
products. In principle, changes in drug sensitivity are a result of deletions in 
nonessential genes whose products functionally interact with the drug target 
(Sturgeon, Kemmer et al. 2006). In this way, Chan et al. screened 2, 226 non-
essential deletion mutants with target-of-rapamycin (TOR) inhibitor rapamycin, and 
identified 106 mutants that displayed an increased sensitivity (Chan, Carvalho et al. 
2000). Within these identified mutants were those previously shown to have 
rapamycin sensitivity; however the additional mutants found in this study 
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broadened the knowledge of the cellular functions and components of the TOR 
pathway. 
 
While homozygous genetic profiling rarely identifies drug targets directly – essential 
genes are not represented in this library, and many small molecule inhibitors target 
essential genes in yeast, this approach provides an unprecedented and 
comprehensive view of cellular pathways and processes that are functionally 
affected by the small molecule (Sturgeon, Kemmer et al. 2006). Parsons et al. 
compared the chemical genomic screen profiles of 12 different compounds, to a 
collection of synthetic-lethal interaction profiles in order to decipher more precisely 
potential target pathways. For example, the profile of camptothecin, one of the 12 
drugs screened, was similar to the profiles obtained for DNA synthesis genes, 
allowing for identification of the compound’s probable mode-of-action even when 
the direct target was not represented in the gene cluster (Parsons, Brost et al. 2004). 
 
As more comprehensive databases and knowledge on genetic interaction networks 
grow and more cellular pathways are uncovered, the utility of both the 
heterozygous and the homozygous deletion library, screened in concert against a 
compound of interest will result in very powerful and informative tools for drug-
target identification in yeast (Sturgeon, Kemmer et al. 2006).  
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2.3 Aims and objectives 
The aim of this chapter was to establish basic biological activities of TA-289 and 
equisetin in yeast, and to ascertain a possible mechanism and/or site-of-action for 
both compounds. These included: 
 Determining MIC of TA-289 and equisetin in liquid and solid media under 
different pH and media conditions 
 Cell morphology and cell cycle analysis 
 Chemical genomic profiling of TA-289 utilizing the heterozygous diploid and 
the homozygous diploid yeast genome deletion sets 
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2.4 Materials and methods 
 
2.4.1 Yeast strains 
All S. cerevisiae strains used in this study are as follows: 
Strain Genotype 
YCG100 (BY4743) MATa/α his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 
YCG104 (BY4742, wt) MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 
YCG289 (yeGFP) 
MATα can1Δ::STE2p_LEU2; lyp1Δ; his3Δ1 leu2Δ0 
ura3Δ0 met15Δ0 
YCG326 (pdrΔ) 
MATα pdr1Δ::NAT pdr3Δ::URA3 can1Δ::STE2pr-
Sp_his5; lyp1Δ; his3Δ1 leu2Δ0 ura3Δ0 met15Δ0 
LYS2+ 
tub2Δ 
Heterozygous diploid TUB2/tub2Δ::kanR; his3Δ1 
leu2Δ0 ura3Δ0 met15Δ0 
 
 
2.4.2 Growth media 
All yeast cultures were performed in one of the following media below 
supplemented with either geneticin ((G418) 200 µg/mL final concentration), 
nourseothricin ((NAT) 100 µg/mL final concentration), or canavanine ((Can) 50 
µg/mL) and thialysine (S-aminoethyl-L-cysteine hydrochloride (Thia); 50 µg/mL) 
(Sigma-Aldrich, MO, USA), unless otherwise stated. For solid media preparation, 2% 
(w/v) agar was added (denoted as “-agar”): 
Yeast peptone dextrose (YPD): 1% (w/v) yeast extract, 2% (w/v) bacto-peptone, 2% 
(w/v) glucose. 
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Synthetic complete (SC): 0.17% (w/v) bacto-yeast nitrogen base (without amino 
acids or ammonium sulphate), 0.1% (w/v) monosodium glutamate, 0.2% (w/v) 
“amino acid mix” (Amberg 2005), 2% (w/v) glucose. 
Synthetic drop-out (SD) –Ura: as with SC but without uracil in the “amino acid 
mix”. 
SD –His/Arg/Lys: as with SC but without histidine, arginine, and lysine in the 
“amino acid mix”. 
Pre-sporulation (GNA): 1% (w/v) yeast extract, 3.8% (w/v) bacto-peptone, 12.5% 
(w/v) glucose. 
Enriched sporulation (SPO): 1% (w/v) potassium acetate, 0.1% (w/v) yeast extract, 
0.05% (w/v) glucose, 0.01% (w/v) “SPO amino acid mix” (Amberg 2005). 
 
2.4.3 Compounds and chemicals 
Received from Dr. Stephen Bloor (Biodiscovery New Zealand, Industrial Research 
Limited, Wellington); 88 natural product isolates derived from soil fungi Fusarium 
sp. The 88 compounds, approximated at 400 µg each in mass, were provided in a 96-
well tissue culture plate, into which 100% dimethyl sulfoxide (DMSO) was added to 
make ≈10 mM working stocks of each compound. The compounds were stored at –
20 °C until further use. Additional fractions of tetramic acid 289 (TA-289) and 
equisetin were provided (9.6 mg and 14.4 mg, respectively), and 10 mM working 
stocks of both compounds were prepared by dissolving in DMSO and then stored at 
–20 °C until further use. 
Mollisoside, kindly provided by Dr Peter Northcote (School of Chemical and 
Physical Sciences, Victoria University of Wellington), was prepared at a 1 mM 
working stock in DMSO and stored at –20 °C. 
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Purchased from Sigma-Aldrich Life Science and Biochemicals: cycloheximide, 
10 mg/mL working stock stored at –20 °C, benomyl, 10 mg/mL working stock stored 
at –20 °C, and DMSO, stored at room temperature. 
 
2.4.4 Growth inhibition in liquid media 
Two yeast strains, wild-type BY4742 (wt) and YCG326, a mutant strain deficient in 
the two main transcription factors of the yeast drug efflux pump network, PDR1 and 
PDR3 (pdrΔ) were grown in 2 mL SC broth overnight at 30 °C on a rotating drum. 
The cultures were subsequently counted on a haemocytometer, further diluted to 
5 x 105 cells/mL in fresh SC, after which 100 µL aliquots were dispensed into a 96-
well tissue culture plate to give a final concentration of 5 x 104 cells/mL. A 1 µL 
aliquot of each of the 88 compounds (10 mM working stock concentration) was 
added to the culture plate to give a final concentration of 100 µM of each compound. 
The plate was mixed by vortexing, then incubated at 30 °C for 18 h, after which cell 
growth was quantified by measuring optical density (OD) at 590 nm using a Wallac 
EnVision 2102 Multilabel Plate Reader (Perkin Elmer™, Waltham, MA, USA.). 
 
2.4.5 Liquid dose-response growth assays 
For all liquid dose-response assays, yeast cultures of BY4742 (wt) and pdrΔ were 
grown overnight in 2.5 mL SC media at 30 °C on a rotating drum. The cell 
concentrations of each culture were determined by haemocytometer and diluted to 
30 
 
5 x 105 cells/mL in one of four different media solutions: 1) SC (normal pH ~4.0), 2) 
pH 8.0 SC, buffered with 25mM HEPES (SC-H), 3) YPD (normal pH ~7.0), and 
4) pH 4.0 YPD, adjusted with 18.6 M hydrochloric acid (YPD-HCl). Then, 100 µL 
aliquots of each media solution were dispensed into 96-well tissue culture plates to 
give a final concentration of 5 x 104 cells/mL. 
An eight-point serial dilution of TA-289 and equisetin were prepared from the 
10 mM working stocks, from which a 1 µL aliquot of each dilution point was added 
in triplicate to the wells containing 100 µL SC or SC-H or YPD or YPD-HCl media 
with yeast, to achieve a final concentration range of 100 µM, 50 µM, 30 µM, 25 µM, 
10 µM, 5 µM, 3 µM, and 1 µM TA-289 and equisetin. DMSO (1% final 
concentration) served as a solvent control. 
 
For liquid dose-responses using the tub2Δ::KanR heterozygous diploid strain 
(tub2Δ), a mutant strain deficient in one gene copy of TUB2, the yeast homologue of 
β-tubulin, overnight cultures of BY4743 and tub2Δ were diluted in fresh SC media 
and dispensed into 96-well tissue culture plates as above. Eight-point serial dilutions 
of TA-289 and equisetin were prepared as described in the previous method and 
1 µL aliquots were added to the wells as per above, with 1% DMSO serving as a 
solvent control. Eight-point serial dilutions of benomyl was prepared from a 
10 mg/mL working stock, giving a final concentration range of 100 µg/mL, 50 µg/mL, 
30 µg/mL, 25 µg/mL, 10 µg/mL, 5 µg/mL, 3 µg/mL, and 1 µg/mL. As with TA-289 and 
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equisetin, 1 µL aliquots of benomyl diluents were added to wells containing BY4743 
and tub2Δ. Benomyl served as a positive control.  
Plates were mixed by vortexing and incubated at 30 °C for 18 h. Cell growth was 
quantified by measuring optical density (OD) at 590 nm. 
 
2.4.6 Solid dose-response growth assays 
Eight-point serial dilutions of TA-289 and equisetin were prepared from 10 mM 
working stocks dissolved in DMSO as in the liquid dose response assays. A 10 μL 
volume of drug diluent was added to 24-well tissue culture plates containing 1 mL of 
SC-agar, giving a final concentration range of 100 µM – 1 μM. DMSO (1% final 
concentration) served as a carrier control. Yeast cultures of BY4742 and pdrΔ were 
grown in 2 mL SC media overnight at 30 °C, after which the cultures were counted 
using a haemocytometer and then further diluted to 5 x 105 cells/mL in ddH2O. To 
each agar well, 2 μL aliquots of the cell suspension were added, giving a total 
concentration of 200 cells per well. The plates were incubated at 30 °C for 2 days, 
after which they were photographed using a Canon Powershot S3-IS camera and 
ZoomBrowser EX remote shooting software (Canon Inc., NY, USA). Cell growth was 
determined by visual inspection. 
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2.4.7 Colony forming unit assay 
Briefly, BY4742 and pdrΔ yeast cultures were grown overnight in 2 mL SC media at 
30 °C on a rotating drum, counted using a haemocytometer and further diluted to 
5 x 105 cells/mL in fresh SC, after which 100 µL aliquots were dispensed in triplicate 
into 96-well tissue culture plates. A 1 µL aliquot of either 10 mM TA-289, 10 mM 
equisetin, 0.1 mM cycloheximide, and 1 mM mollisoside, were added to the culture 
plates, giving final concentrations of 100 µM, 100 µM, 1 µM, and 10 µM, 
respectively. In addition, 1% DMSO served as a second positive carrier control. 
The plates were mixed by vortexing, and then incubated at 30 °C for 18 h. Following 
this, 100 µL aliquots from each drug-treatment were transferred to sterile 1.5 mL 
microcentrifuge tubes and cells were collected by centrifugation and the cell pellets 
thrice-washed with ddH2O. The washed cells were then counted using a 
haemocytometer and diluted to 5 x 103 cells/mL, and 10 μL from each sample tube 
was plated onto petri plates containing YPD-agar, to give 50 cells per plate. The 
plates were incubated at 30 °C for 2 days, after which they were photographed, and 
cell recovery assessed by the presence of colonies on each plate. 
 
2.4.8 Cell morphology 
Cells from the end-point liquid dose-response assays were assessed for 
morphological changes using an inverted phase contrast microscope at 60X 
magnification (Olympus NZ PTY Ltd, Auckland, NZ) and then photographed 
(Nikon TA Macalister Ltd, Auckland, NZ). Both BY4742 and pdrΔ cells treated at 
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100 µM and 30 µM of TA-289, as well as the DMSO control were photographed. 
Control cells were diluted 100 fold prior to photographing for ease of manual cell 
counting. Cell diameter of a random sample of 50 cells from each treatment were 
measured on ImageJ (Image Processing and Analysis in Java, National Institutes of 
Health). A two-tailed t-test assuming equal variances was performed, and 
differences in cell size of treated vs. untreated were calculated. 
 
2.4.9 Cell cycle analysis by flow cytometry 
Overnight cultures of BY4742 and pdrΔ strains were diluted and grown to mid-log 
phase (cell concentration as determined on a haemocytometer; approximately 
2 x 107 cells/mL) in 50 mL SC media, after which 0.5 mL aliquots were dispensed 
into sterile 15 mL falcon tubes. A 5 μL aliquot of TA-289 and equisetin taken from 
working stocks of 10 mM was added per tube to give a final concentration of 
100 μM. DMSO (1% final concentration) served as a carrier control. The treated and 
untreated cultures were mixed by vortexing and incubated for 6 h at 30 °C. Cells 
were collected by centrifugation for 5 min at 900x g at room temperature, then 
washed and resuspended in 1 mL ddH2O, of which 500 µL were fixed with 3.5 mL 
95% ethanol. Fresh tubes containing 2 mL SC media were inoculated with the 
remaining 500 µL of washed cells, and incubated at 30 °C on a rotating drum. A 
500 µL aliquot of cells were harvested and fixed in ethanol every 30 mins for 1.5 h. 
After the last harvest, all cell cultures were incubated overnight at 4 °C. 
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Cells were collected by centrifugation and washed twice with ddH2O. After a second 
centrifugation at 10 000x g, cells were resuspended in 1 mL fresh 1X RNase solution 
(10X solution; 0.05 g RNase A, 166.5 μL 3 M NaOAc, 4.85 mL ddH2O) and incubated 
for 3 h at 37 °C. Cells were recovered by centrifugation, supernatant discarded, and 
pellets resuspended in 500 µL fresh pepsin solution (1 mL solution; 5 mg pepsin, 
55 μL 1 N HCl, 945 µL ddH2O) an incubated for 5 mins at room temperature. Cells 
were collected by centrifugation, resuspended in 500 μL 50 mM Tris (pH 7.5), and 
stored overnight at 4 °C. 
Cells were stained with SYTOX Green nucleic acid stain (for each sample, 400 μL 
50 mM Tris (pH 7.5) containing 2 μM SYTOX Green) (Haase 2001; Amberg 2005). A 
400 μL aliquot of cells were stained with 400 μL SYTOX Green, and cell samples 
were sorted through the FACScan flow cytometer (BD Biosciences). Cell cycle stages 
were gated, analysed, and histogram plots were generated for each treatment 
condition with CellQuest Pro software (BD Biosciences). 
 
2.4.10 Determining the presence of cell populations by flow cytometry 
Cell concentrations of overnight cultures of the yeGFP strain were determined by 
measuring OD at 600 nm using a spectrophotometer (Genova Life Science, Bibby 
Scientific Ltd, Staffordshire, UK). These were then diluted to 5 x 105 cells/mL in 
fresh SC media. A 100 µL aliquot was taken from both BY4742 and pdrΔ cells treated 
at the highest concentration of TA-289 and equisetin after 18 h treatment as 
described in the liquid dose-response assays. Into this, a 100 µL aliquot of the diluted 
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yeGFP culture was added, and then 400 µL ddH2O. Cells were visualized on the 
FACScan flow cytometer (BD Biosciences, MD, USA) and contour plots were 
generated for each sample with CellQuest Pro software (BD Biosciences). 
 
2.4.11 Haplo-insufficiency and homozygous profiling 
Two chemical genomic profiling techniques utilizing the heterozygous diploid 
deletion set and the homozygous diploid deletion set were carried out with TA-289. 
These were performed according to the yeast tag microarray protocol (Rosemary 
Heathcott, personal communication, ESR Wellington) adapted from  (Parsons, Lopez 
et al. 2006). A repeat microarray was performed using the homozygous diploid 
deletion set for TA-289.  
 
2.4.12 Microarray analysis 
The microarray chips were read on an Axon Microarray Scanner, where 
fluorescently labeled control tags were scanned at 532 nm and experimental samples 
(drug-treated) scanned at 635 nm (Genomics Facility, Biochemistry Department, 
Otago University). 
The intensities of the up (UP) and down (DN) tags were normalized and log2 ratios 
of drug-treated/DMSO control data were obtained using Standardization and 
Normalization of Microarray Data (SNOMAD) software (http://pevsnerlab. 
kennedykrieger.org/snomadinput.html). Gene tags with a low fluorescent control 
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signal (less than 500) were removed, the remaining log ratios of tag replicates were 
averaged, and deviation (D) scores calculated (D score = (average of log ratios – mean 
of average of log ratios)/standard deviation of average of log ratios). Genetic and 
physical interactions and gene descriptions of selected gene “hits” (D score = < -3, 
and > -1) were batch-downloaded from the yeast genome database 
(http://www.yeastgenome.org). Interaction networks were created in Cytoscape 
open source platform for complex network analysis and visualization, v 2.8.1 
((Shannon, Markiel et al. 2003), Cytoscape Consortium). Hierarchical cluster 
analyses were carried out following Hillenmeyer et. al. 2008. Gene tags were 
grouped according to intracellular localization and compared to the yeast genome by 
taking random subsets of genes and statistically determining the significance of each 
localization, assuming a normal distribution of sampling. 
 
2.4.13 Cell death assays 
Cultures of BY4742, pdrΔ, and TA8 were prepared by inoculating either 2 mL SC, or 
2 mL SC-gly-EtOH (SC with 2% glycerol and 2% ethanol, instead of glucose) and 
grown overnight at 30 °C on a rotating drum. Cell concentrations of each culture 
were determined by measuring OD at 600 nm and subsequently diluted in either SC 
or SC-gly-EtOH to give a final cell concentration of 1 x 106 cells/mL.  
For the BY4742 and pdrΔ cell death assays with TA-289 and equisetin in SC-gly-
EtOH, a 100 µL aliquot of diluted cells in SC-gly-EtOH were dispensed into 96-well 
tissue culture plates, after which 1 µL aliquots of the previously described eight-
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point serial dilutions of either TA-289 or equisetin were added, giving a final 
concentration range of 100 µM to 0.03 µM. After addition of the compounds, the 
plates were mixed by vortexing, and a 1.5 µL aliquot of the treated cells were 
removed and spotted onto a Singer© plate containing SC. The plates were then 
incubated at 30 °C. A 1.5 µL aliquot of cells were harvested and spotted onto the SC 
plate every 15 mins for the first 30 mins, and then every 30 mins for 2 h.  
For BY4742 and pdrΔ cell death assays in H2O2 with SC-gly-EtOH, a 100 µL aliquot 
of diluted cells in SC-gly-EtOH were dispensed into 96-well tissue culture plates, 
after which 1 µL aliquots of the previously described eight-point serial dilution of 
H2O2 was added, giving a final concentration range of 9 mM to 3 mM. The assay was 
performed as per cell death assays described above, however cells were harvested 
every hour for 4 h. 
After the final harvest, plates were allowed to dry, and then incubated for two days 
at 30 °C. Photographs of the plates were taken on both day one and day two of 
incubation, and growth of colonies were assessed manually. 
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2.5 Results 
 
2.5.1 Initial screening of natural product isolates 
Biological activities of the soil microbial metabolites (88 compounds in total) were 
assessed by liquid growth inhibition assays, where observation of growth inhibition 
indicated biological activity and therefore cellular targets in yeast. Of the 88 
compounds screened, 22 were identified as biologically active in BY4742 (wt) cells 
(>70% growth inhibition compared to DMSO carrier controls) (Figure 2.3). 
 
Figure 2.3. Bioactive natural product isolates display differential activity depending on the PDR 
state of the yeast cell. Liquid growth inhibition assays were performed using two yeast strains, 
wt and pdrΔ, tested against 88 natural product isolates at 100 µM. Bioactivity of each compound 
was determined by calculating residual growth (experiment/control) (y-axis). The graph shows 
the 32 small molecules deemed as bioactive. Of these, 22 displayed no apparent difference in 
potency against the two yeast strains tested (402 pyrone – viridicatum toxin). On the contrary, 
ten compounds (angucyclinone – calbistrin; far right compounds) showed significant difference 
in potency levels between the two strains. 
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Ten of the 32 compounds observed to be active in the pdrΔ mutant strain were not 
active in the BY4742 (wt) strain (Figure 2.3; angucyclinone – calbistrin), suggesting 
these compounds are substrates for the yeast PDR efflux network pumps. A table of 
reported activities and/or mechanisms-of-action for the 32 biologically active 
compounds can be found in appendix 1.1 of this thesis. Two compounds from this 
screen, tetramic acid 289 (TA-289), a novel biologically active metabolite isolated by 
Dr Stephen Bloor, and equisetin, a known, structurally-related tetramic-acid 
compound with an uncharacterized mode-of-action, were chosen for further drug-
target identification studies. For this project, both compounds were chosen due to 
their unknown modes-of-action, and also because greater quantities were more 
readily available for study. 
 
2.5.2 TA-289 and equisetin display pH-dependent cytotoxic activities 
To determine the MIC concentrations of TA-289 and equisetin, dose-response assays 
in both liquid and solid media were performed. It was first observed that both TA-
289 and equisetin varied in potency under different media conditions. To determine 
whether the bioactivities of both compounds displayed media-dependent or pH-
dependent growth inhibitory activities, liquid dose-response assays were performed 
in two standard media types at low and high pH levels; SC (normal pH 4.0), SC-H 
(buffered to pH 8.0), YPD (normal pH ~7.0), and YPD-HCl (buffered to pH 4.0). 
 
40 
 
Under unbuffered conditions (SC, pH 4.0), TA-289 and equisetin displayed potent 
growth inhibitory activities in both yeast strains tested at micromolar 
concentrations. When the compounds were tested in media at higher pH (pH 8.0 
SC-H, and pH 7.0 YPD), this activity was abrogated completely for TA-289, and 
partially for equisetin (Figure 2.4, appendix 1.2). Interestingly, activities of TA-289 
and equisetin were observed in pH 4.0 YPD-HCl, strongly indicating that TA-289 
and equisetin display pH-dependent growth inhibitory activities, and not because of 
the media type used (i.e. synthetic amino acid mix vs. yeast extract).  
 
Figure 2.4. Growth-inhibitory effects of TA-289 are pH-dependent. wt (circles) and pdrΔ 
(squares) cells were treated with varying concentrations of TA-289 (x-axes) for 18 h in SC at two 
different pH conditions; pH 4.0 (A) and pH 8.0 (B). Cell density was measured by absorbance at 
OD 590 nm (y-axes). See appendix 1.2 for all dose-response assays. 
 
MIC values were calculated for each compound on the two yeast strains tested, as 
well as under the four different media conditions (Table 2.1). TA-289 and equisetin 
also displayed differential activity against BY4742 and pdrΔ strains, where a three-
fold difference in potency of both compounds was observed between BY4742 and 
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the pdrΔ strain. This suggests that both TA-289 and equisetin are substrates for the 
drug-efflux pump system in yeast. Notably, these differential growth inhibitory 
activities were not observed in the initial growth inhibition assays (Figure 2.3), 
where both compounds potently inhibited growth of both the BY4742 and pdrΔ 
strain at 100 µM. 
Table 2.1. MIC values of TA-289 and equisetin in wt and pdrΔ strains under different media 
conditions. 
Media 
MIC (µM) TA-289 MIC (µM) Equisetin 
wt pdrΔ wt pdrΔ 
SC (pH 4.0) 50 10 30 25 
SC-H (pH 8.0) >100 >100 50 50 
YPD-HCl (pH 4.0) 50 25 30 25 
YPD (pH ~7.0) >100 >100 >100 50 
 
 
Solid media dose-response assays were conducted in pH 4.0 SC, the pH condition 
where TA-289 and equisetin displayed strongest potency in yeast. The assays 
revealed the minimum inhibitory concentration (MIC) value for both compounds 
for future experiments conducted using solid media. The wt strain was not growth 
inhibited by either TA-289 or equisetin at any concentration tested. The pdrΔ strain 
however, did not grow in 50 µM TA-289 and equisetin, thus determining the MIC in 
solid media for both TA-289 and equisetin to be 50 µM in the pdrΔ strain 
(Figure 2.5). 
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Figure 2.5. Solid dose-response assay of TA-289 and equisetin. SC media containing varying 
concentrations of TA-289 and equisetin were inoculated with 5 x 104 cells per well and 
incubated for 2 days at 30 °C. Bioactivities of TA-289 (A) and equisetin (B) were assessed by 
observing colony growth of wt (BY4742) and pdrΔ compared to the respective untreated 
controls. 
 
 
Additionally, to determine whether the bioactivities exhibited by these compounds 
were cytotoxic i.e. cause cell death or irreversible growth inhibition, or cytostatic 
(reversible), a colony forming assay was performed and the ability of cells to recover 
from drug treatment was assessed. Interestingly, both TA-289 and equisetin 
displayed cytotoxic, or at least irreversible growth inhibitory effects in only the 
pdrΔ cells, where the cells washed of the compounds were unable to recover after 
two days of incubation, compared to both DMSO- and cycloheximide-treated cells 
(Figure 2.6). This was not observed in BY4742 (wt) cells, and especially in wt cells 
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treated with TA-289 which recovered just as well as the negative controls for cell 
death (DMSO and cycloheximide, which do not kill yeast). In wt cells that were 
treated with equisetin, cell recovery was slower and much less, however still 
present. This may be attributed to equisetin being more potent in yeast than TA-
289. 
 
Figure 2.6. TA-289 and equisetin are cytotoxic to pdrΔ yeast cells. Cells (wt and pdrΔ) treated 
overnight with either 100 µM TA-289, equisetin, 3 µM cycloheximide (cyh), or 10 µM 
mollisoside, were washed twice with ddH2O, diluted, and aliquots were plated onto rich media 
petri plates to give a final concentration of 30 cells per plate, after which plates were incubated 
for 2 days at 30 °C and then cell growth observed. Cell growth was also compared to untreated 
cells (DMSO), and mollisoside, a positive control for cell death. 
 
 
2.5.3 Cell morphology 
To determine whether TA-289 caused gross morphological changes in yeast, TA-
289-treated cells were observed under a microscope and cell morphology manually 
examined. At the highest concentration of TA-289 (100 µM), both wt and pdrΔ cells 
were statistically significantly smaller in size compared to untreated controls (Table 
2.2, Figure 2.7), with the average cell size being 1.67 fold smaller than untreated 
cells. Cells treated with a lower concentration, 30 µM, were also smaller, at 1.27 fold 
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smaller than untreated control cells. After treatment, similar phenotypes were 
observed in pdrΔ cells. See appendix 1.3 for photographs of pdrΔ cells. Aside from 
cell size, no gross morphological changes were observed. 
 
Table 2.2. Cell sizes of wt and pdrΔ cells treated with TA-289. Cells were treated with either 
30 µM or 100 µM TA-289 for 18 h and size of cells were measured. An un-paired student t-test 
was performed, and each value represents the fold decrease in cell size compared to untreated 
control cells. The corresponding p-values are indicated for each treatment. 
Treatment  
                             Strain 
wt pdrΔ 
30 µM TA-289 1.27 (p = 2.16 x 10-6) 1.15 (p = 1.15 x 10-4) 
100 µM TA-289 1.67 (p = 3.24 x 10-26) 1.41 (p = 2.67 x 10-16) 
 
 
Figure 2.7. TA-289 causes a small-size phenotype in yeast. TA-289-treated (100 µM) (B) wt cells 
display a small-size phenotype after 18 h treatment compared to DMSO control cells (A). See 
appendix 1.3 for all photographs. 
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The presence of cells at the highest concentration of TA-289 and equisetin tested 
indicate that cells may be irreversibly growth inhibited (if yeast cells do not bleb 
and “disappear” during apoptosis (as that observed in mammalian apoptosis 
(Madeo, Carmona-Gutierrez et al. 2009)), it is difficult to distinguish between dead 
cells and irreversibly growth inhibited cells), especially in the case of pdrΔ cells, 
where the colony forming unit assay showed pdrΔ cells were unable to recover 
from treatment with TA-289 or equisetin. Likewise, flow cytometric analysis of 
treated cells taken from the end point of liquid dose-response assays compared 
with a control yeGFP population of the same starting cell concentration used for a 
liquid dose-response assay also showed the presence of cells (Figure 2.8). A higher 
percentage of non-yeGFP cells in the BY4742-treated samples may indicate that 
BY4742 cells were slowly recovering from treatment with TA-289 and equisetin. 
This may just be a sub-population of cells that were able to survive treatment with 
TA-289 and equisetin and are thus slowly growing. The larger percentage of 
recovering wt cells compared to pdrΔ cells is further evidence for TA-289 and 
equisetin being substrates for the yeast efflux pumps, where wt cells are able to 
actively expel TA-289 and equisetin from within the cell to aid in the recovery 
process. 
46 
 
 
Figure 2.8. Cells are present after 18 h treatment with TA-289 or equisetin. BY4742 (wt) cells 
treated with 100 µM TA-289 (A), equisetin (B), and pdrΔ cells treated with TA-289 (C), and 
equisetin (D), taken from the end point of a liquid dose-response assay were mixed with a 
population of yeGFP cells and visualized by flow cytometry. 
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2.5.4 TA-289 and equisetin cause late phase cell cycle block 
Flow cytometric analysis of yeast DNA content was performed to determine 
whether TA-289 and equisetin caused a cell cycle block at a given cell cycle stage. 
Cells treated with either TA-289 and equisetin revealed a decrease in the population 
of cells at in G1 phase, and an accumulation of cells at the later phases of the cell 
cycle, namely at S-G2/M phase, compared to untreated controls – this was especially 
so for pdrΔ cells treated with TA-289 and equisetin (Figure 2.9, Table 2.3). The 
observed accumulation of treated cells indicates TA-289 and equisetin inhibit 
growth of yeast by causing a cell cycle block at S-G2/M phase. 
Figure 2.9. TA-289 and equisetin cause late-phase cell cycle block. BY4742 (wt) and pdrΔ cells 
treated with 100 µM TA-289 or equisetin for 4 h were fixed and stained with SYTOX green, and 
subsequently visualized by flow cytometry. Histogram overlays show wt and pdrΔ untreated 
controls (black) compared with cells treated with equisetin (blue) and TA-289 (pink). Untreated 
control G1 and G2/M (G2) phases are indicated in black. Changes in S and G2/M phase of treated 
cells are indicated in red. 
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Table 2.3. Percentage of both wt and pdrΔ cells in G1, S, and G2/M phase of the cell cycle 
when treated with 100 µM TA-289 or equisetin compared to untreated controls. Time 
(mins) indicate the time after washing cells after a 4 h treatment with TA-289 and 
equisetin. All values represented as percentages of the total gated population. Highlighted 
in blue are observed accumulation of S and G2/M phase in TA-289- and equisetin-treated 
cells. 
 
 
A time-course analysis showed that pdrΔ cells were unable to recover to a normal 
cell cycle distribution following withdrawal of both TA-289 and equisetin after 1.5 
h, while wt cells recovered from treatment with TA-289 within 30 mins after 
washing, and slower recovery in equisetin (over 1 h after washing). These cell 
recovery results replicate what was observed in the colony forming unit assay 
(Figure 2.6), wherein wt cells treated in equisetin displayed slower recovery rates 
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than wt cells treated with TA-289, while pdrΔ cells did not recover from treatment 
of either compounds (Figure 2.10). See appendix 1.4 for equisetin time-course 
histograms. 
 
Figure 2.10. TA-289 causes irreversible cell cycle block in pdrΔ cells. Cells treated with either 
TA-289 or equisetin were washed after a 4 h incubation period. Cells were then harvested every 
30 mins for 1.5 h and visualised by flow cytometry. Above shows an example of a time course 
histogram overlay of pdrΔ cells treated with TA-289 compared to their corresponding controls. 
Red arrow highlights the increase in G2/M phase from untreated cells growing normally, 
however this was not observed in cells treated with 100 µM TA-289, which were were unable to 
recover from treatment 90 mins after washing (green arrow). See appendix 1.4 for all time course 
histograms. 
 
 
Often, a cell cycle block at G2/M phase is indicative of a tubulin-targeting compound 
that prevents progression through mitosis (Hamel 1996). To determine whether TA-
289 or equisetin target tubulin, the tub2Δ::KanR heterozygous diploid was tested for 
sensitivity to both compounds. No differential sensitivity was observed between the 
tub2Δ strain and the diploid BY4743 strain when treated with TA-289 or equisetin, 
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as compared to hypersensitivity of the tub2Δ strain to the anti-mitotic agent 
benomyl (Thomas, Neff et al. 1985), suggesting that TA-289 and equisetin are not 
tubulin-targeting compounds (Figure 2.11). 
 
Figure 2.11. TA-289 and equisetin do not target tubulin. tub2Δ and wt diploid (BY4743) cells 
treated with a serial dilution of either TA-289 or equisetin, incubated for 18 h at 30 C and cell 
growth measured by determining OD at 590 nm.  
 
 
 
 
 
 
51 
 
2.5.5 Chemical genomic profiling of TA-289 
Chemical genomic profiles of TA-289 were generated by performing a yeast tag 
gDNA microarray utilizing two yeast deletion sets, the heterozygous diploid deletion 
set (HET) and the homozygous diploid deletion set (HOM). These deletion pools 
were treated with 10 µM TA-289 (a concentration that causes approximately 30% 
growth inhibition) used to probe affected biological pathways most likely required 
to buffer the inhibitory effects of TA-289. A total of 4466 genes (after filtering and 
normalization of data, including up and down tags, with replicates removed) were 
identified in the first HOM screen, and 4021 genes in the second HOM screen. An 
overlap of 4016 genes was identified between the two HOM screens. A total of 5236 
genes were identified in the HET screen, of which 4103 genes overlapped with the 
two HOM screens. A list of the top 40 sensitive gene hits from the HOM profiles 
(top 20 from each HOM screen), were categorized according to the biological 
processes from which they are involved (Table 2.4). These were selected by 
removing genes first identified to be multi-drug resistance genes according to a 
previously published large-scale chemical genomic screen data set (Hillenmeyer, 
Fung et al. 2008), and then filtering by deviation scores, where a D (deviation)-score 
of < -3 is deemed dubious. 
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Table 2.4. List of top 40 hypersensitive hits from HOM screens. Genes were grouped according 
to biological processes, and ordered according to sensitivity to TA-289, where the most negative 
D-score value indicates greatest sensitivity. Highlighted in blue are genes shown to be localized 
to the mitochondrion or the ER, and/or are involved in mitochondrial-associated processes. See 
supplementary file 1 for the complete list of genes identified as sensitive or resistant, their 
assigned sensitivity scores and associated biological processes. Key: Nuc = Nucleus, Cyt = 
Cytoplasm, Mito = Mitochondrion, Vac = Vacuole, Endo = Endosome, ER = Endoplasmic 
reticulum, Golgi = Golgi apparatus. 
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Of these, 11 were either involved in ER and mitochondrial processes or were 
localized to the mitochondrion or the ER. Previously described studies on equisetin 
showed the compound having effects on isolated mitochondria (König, Kapus et al. 
1993) and the ER (Patham, Duffy et al. 2009). Due to their structural similarities, 
and the enrichment of mitochondria and ER genes identified in these chemical 
genomic screens for TA-289, TA-289 may share the same mechanism-of-action with 
equisetin. Genes associated with oxidative stress responses and DNA repair, and cell 
cycle-related genes were also identified, most of which were shown to be involved 
in mitosis and cytokinesis (CIN8, RPN4, and BUD3) which reflects on the late phase 
cell cycle block observed in the cell cycle analyses performed using flow cytometry 
(Figure 2.9). 
 
A list of the top 15 sensitive gene hits from the HET screen is displayed below. 
These were selected again by removing the multi-drug resistance genes as described 
previously, however the most sensitive genes were selected, following the idea of 
haplo-insufficiency where the heterozygote strain containing the target protein will 
be hypersensitive (Table 2.5).  
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Table 2.5. List of top 15 hypersensitive hits from the HET screen. Genes were grouped according 
to biological processes, and ordered according to sensitivity to TA-289, where the most negative 
D-score value indicates greatest sensitivity. Essential genes are indicated with a value of 1, non-
essentials with a value of 0. Highlighted in blue are genes of interest, previously described to be 
involved in mitochondrial-related processes. See supplementary file 1 for the complete list of 
genes identified as sensitive or resistant, their assigned sensitivity scores and associated biological 
processes. Key: Nuc = Nucleus, Cyt = Cytoplasm, Mito = Mitochondrion, Vac = Vacuole, Endo = 
Endosome, ER = endoplasmic reticulum. 
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Of these 15, four were identified as essential genes, including TOM22, which plays 
regulatory roles in mitochondrial protein import. AUT7 has also been previously 
implicated in mitochondrial maintenance and degradation (i.e. mitophagy), of which 
the null mutant displayed abnormal mitochondrial function (Zhang, Qi et al. 2007). 
 
Moreover, mitochondrial electron transport chain (ETC) associated genes 
(complexes I through V) were also identified as sensitive in both HET and HOM 
screens. These included NADH dehydrogenase and NADH ubiquinone oxireductase 
NDE1 and 2, and NDI1, succinate dehydrogenase SDH2, 3, and 4, bc1 complex 
(cytochrome c reductase) QCR2, 6, 7, 9, 10, and CYT1 and 2, ubiquinone/coenzyme 
Q COQ1, 3, 6, and 9 (identified in the top 40 hypersensitive genes as YLR201C in 
List 2.1) cytochrome c oxidase COX5A, 5B, 7, 8, 9, 11, 14, 15, 16, 18, 19 and 20, PET 
(required for respiratory growth; ADP/ATP carrier, mitochondria ribosomal subunit, 
mitochondrial translational activator) 9, 10, 18, 54, 56, 100, 111, 112, 123, 127, 130, 
191, and 309, and F0-F1 ATP synthase ATP2, 3, 5, 10, 11, 16, 18, and 20 (see 
supplementary file 1). These results are consistent with previous indications of 
equisetin eliciting effects with mitochondria- and ER-related processes, and is also 
evidence for TA-289 exhibiting a similar mechanism. 
 
Hierarchical cluster analyses performed on datasets from both HOM screens with a 
previously published large-scale chemical genomic screen dataset (Hillenmeyer, 
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Fung et al. 2008) revealed similarity between the profile of TA-289 and those of L-
dopa and MPP+, i.e. L-dopa and MPP+ branched off from the same subset as that of 
the TA-289 screens (Figure 2.12).  
 
Figure 2.12. Close up clustergram of both TA-289 HOM screens (blue arrows). L-dopa and MPP+ 
are denoted with the orange arrow. See appendix 1.5 for the full clustergram. 
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Chronic exposure to L-dopa, a drug clinically used for the treatment of Parkinson’s 
disease, has been thought to enhance degeneration by causing oxidative stress 
through impairing mitochondrial respiratory capacity (Przedborski 1993). MPP+ (1-
methyl 4-phenylpyridinium) is a neurotoxin that acts on the electron transport 
chain in the mitochondria (Langston 1999). A total of 231 genes out of the combined 
633 genes identified as hits (both sensitive and resistant) in both HOM screens (see 
supplementary file 1 for complete list and also the threshold set to determine 
sensitive and resistant genes) overlapped with genes identified as hits in the profile 
screens of L-Dopa and MPP+ (see appendix 1.6). Of these, 41 genes overlapping 
between the TA-289 HOM screens and the L-Dopa and MPP+ screens were 
identified as genes localized to the mitochondrion or the ER, and a further 16 genes 
were identified as those involved in DNA damage and repair and/or oxidative stress 
(see appendix 1.6). These, coupled with the list of sensitive genes obtained from the 
HET and HOM screens, suggest that TA-289 may act on the mitochondria in S. 
cerevisiae. 
 
Protein localization data from a large-scale protein localization study (Huh, Falvo et 
al. 2003) of the gene hits from the second HOM screen were compared to that of the 
whole genome to identify enrichment or overrepresentation of any one cellular 
compartment. Gene hits identified in the HOM screen were primarily localized to 
the cytoplasm, however enrichment in the mitochondrion showed greatest 
significance (p < 0.01), followed by the ER and Golgi (p < 0.01) (Figure 2.13). 
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Moreover, these biological processes, in particular the mitochondrion- and the ER-
related processes, are consistent with the previously described mechanisms of 
equisetin (Lundin, Deopujari et al. 1992; König, Kapus et al. 1993; Patham, Duffy et 
al. 2009). This is also further evidence that TA-289 and equisetin may share similar 
mechanisms-of-action. 
 
 
Figure 2.13. Gene localizations of HOM screen compared to whole genome. Gene hits from 
the second HOM screen (inner circle) were grouped according to their cellular component 
and compared to the whole genome localization (outer circle). 
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2.5.6 TA-289 and equisetin: Glucose vs. Glycerol as a carbon source 
In light of the previous studies which identified the mitochondria as a possible site 
of action for equisetin (König, Kapus et al. 1993), in combination with the evidence 
that TA-289 may be acting at the mitochondria from the chemical genomic profiling 
screens, the effects of TA-289 and equisetin on yeast cells were tested on 
fermentable (glucose) and non-fermentable (glycerol-ethanol) carbon sources. 
Firstly, liquid dose-responses were conducted using either glucose as a carbon 
source, or glycerol-ethanol. These determine dependency of mitochondrial 
respiration in the presence of TA-289 and equisetin. Prolonged treatment (three-day 
incubation for glucose) with TA-289 and equisetin showed that wt cells were able to 
adapt to growth in the presence of TA-289 and equisetin (Table 2.6). However, 
when glycerol-ethanol was used as the carbon source (six-day incubation for 
glycerol-ethanol), even after six days of incubation, cells treated with TA-289 and 
equisetin did not display the adapted resistance as that observed in glucose. 
 
Table 2.6. MIC values of TA-289 and equisetin in wt and pdrΔ strains under different carbon 
sources. MIC values from the standard 18 h liquid dose-response assays are provided for 
comparison. 
Carbon source 
MIC (µM) TA-289 MIC (µM) Equisetin 
wt pdrΔ wt pdrΔ 
Glucose (standard 
18 h assay) 
50 10 30 25 
Glucose (day 3) >100 10 50 25 
Gly-EtOH (day 6) 50 25 50 25 
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Cell death assays used to determine the time at which it takes for TA-289 and 
equisetin to kill yeast cells were also compared between the two different carbon 
sources. When glucose is the carbon source, TA-289 does not kill BY4742 (wt) yeast, 
but kills pdrΔ cells at the highest concentration within the first 30 mins of 
treatment, and this potency increases within 2 h of treatment (Figure 2.14). The loss 
of potency observed when removing cells from a high concentration of TA-289 to a 
low concentration, i.e. from liquid and spotting onto solid, replicates the results 
observed in the CFU assay in chapter two (result 2.4), where BY4742 cells were able 
to recover. 
 
 
Figure 2.14. TA-289 kills pdrΔ cells within 2 h of treatment when glucose is used as a carbon 
source. wt (A) and pdrΔ (B) cells were treated with varying concentrations of TA-289 (y-axis), 
incubated at 30 °C in SC, where cells were spotted onto agar at the time of treatment (0 mins), 
and then every 30 mins for 2 h (x-axis). 
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In contrast, while cells did not gain resistance over time in glycerol-ethanol, they 
also do not die, as seen in pdrΔ cells where growth is observed even after 2 h of 
treatment, and where wt is inhibited only at the highest concentration at 2 h (Figure 
2.15). Similar observations were noted for equisetin cell death assays conducted with 
pdrΔ cells. See appendix 1.7 for cell death assays with equisetin. An important 
observation to note is that TA-289 seems to kill wt cells after 2 h of treatment in 
glycerol-ethanol. This was not observed in glucose, where wt cells recovered 
strongly.  
 
Figure 2.15. TA-289 does not kill pdrΔ cells when glycerol-ethanol is used as a carbon source. wt 
(A) and pdrΔ (B) cells were treated with varying concentrations of TA-289 (y-axis), incubated at 
30 °C in SC + gly-EtOH, where cells were spotted onto agar at the time of treatment (0 mins), 
and then every 30 mins for 2 h (x-axis). Highlighted in the red box are wt cells that seem to be 
dead after 2 h treatment with TA-289 in glycerol-ethanol, which was not observed in glucose 
(Figure 2.14). 
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2.6 Discussion 
 
2.6.1 Biologically active compounds from terrestrial fungi 
Fungal metabolites are diverse in biological activity, many of which possess 
favourable pharmacokinetic properties. A small library of natural products isolated 
from soil fungi was provided for drug mode-of-action study in yeast. Biological 
activities of the library of compounds (88 in total) were determined by treating two 
yeast strains and measuring the ability to grow in the presence of the compounds. 
For these initial screens, a compound was deemed biologically active where it caused 
greater than 70% growth inhibition compared to the solvent carrier control. Of the 
88 compounds tested, 32 were identified as biologically active in BY4742 (wt) yeast, 
and an additional 10 compounds were identified as active only in the pdrΔ yeast 
strain at 100 µM (Figure 2.1). Seven of the 32 compounds were novel and previously 
unreported, including TA-289, which was chosen for further study alongside 
equisetin, a known, structurally related compound (Burmeister, Bennett et al. 1974). 
Both compounds were isolated from terrestrial fungi of the genus Fusarium, and 
both displayed potent growth inhibitory effects on the two yeast strains tested. For 
the purpose of this study, TA-289 and equisetin were chosen due to their 
uncharacterized modes-of-action as well as their availability for study. 
 
TA-289 is a novel bioactive metabolite, while the structurally related equisetin has 
been previously shown to exert its inhibitory activities through the mitochondrial 
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substrate anion carriers in isolated rat mitochondria, and observed stimulatory 
effects on inorganic mitochondrial pyrophosphatase (Lundin, Deopujari et al. 1992; 
König, Kapus et al. 1993), in addition to inhibition of translocation of post-
translation proteins to the ER (Patham, Duffy et al. 2009). 
 
TA-289 and equisetin display pH-dependent growth inhibitory activities. This pH-
dependency strongly suggests a requirement for the protonation of both compounds 
at low pH for more efficient penetrance through the cellular membrane before 
reaching their site of action (Cui, Hirata et al. 1996). It is speculated that once TA-
289 and equisetin cross permeate the cell membrane, the compounds become de-
protonated as a result of higher intracellular pH levels (Valli, Sauer et al. 2005; Orij, 
Postmus et al. 2009) compared to that of the extracellular media, and thus become 
“trapped” in the cells unless they are actively removed. In yeast, the complex 
pleiotropic drug resistance network of efflux pumps allows efficient expulsion of 
xenobiotics from within the cell (Balzi, Chen et al. 1987). The generation of yeast 
strains deficient in the main transcription factors of these efflux pumps (PDR1 and 
its homologue, PDR3) circumvents this problem. In this study, experiments were 
conducted using two yeast strains (BY4742 (wt) and pdrΔ – a strain deficient in 
PDR1 and PDR3). Liquid and solid dose-responses revealed significant difference in 
the potency of both compounds between BY4742, and the pdrΔ strain. The potency 
of TA-289 and equisetin was significantly greater in the pdrΔ strain compared to 
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BY4742. This efflux pump-sensitivity was not observed in the initial screening of the 
natural products library. Therefore, while growth inhibition assays performed at a 
single concentration serve to indicate biologically active molecules in yeast, they do 
not necessarily determine whether a given molecule is a substrate for yeast drug-
efflux pumps. This is especially so in the case where the molecule is potent in yeast, 
overcoming the PDR network at higher concentrations and inhibiting growth of 
BY4742, as observed with TA-289 and equisetin. The differential sensitivity between 
BY4742 and pdrΔ cells to TA-289 and equisetin in the dose-response assays 
illustrates the effectiveness of making the cell more susceptible to xenobiotics 
through deletion of PDR1 and PDR3. Moreover, the increased potency observed in 
pdrΔ cells strongly indicates both compounds as substrates for (at least one of) the 
yeast efflux pumps.  
 
2.6.2 Effects of TA-289 and equisetin on cell morphology and cell cycle 
Saccharomyces cerevisiae cells divide by a process known as budding, where a cell 
exiting G1 phase produces a small bud, which then continues to grow as the cell 
progresses through the stages of the cell cycle. As such, the size of the bud is 
indicative of the stage of the cell cycle in which any given cell is currently 
undergoing. Most importantly, cell cycle analyses and morphological studies provide 
leads to possible mechanisms-of-action of biologically active compounds of interest. 
For instance, actin inhibitor latrunctulin A causes a cell cycle block at G1 phase 
(small-budded phenotype) (Ayscough, Stryker et al. 1997), where perturbance of 
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actin results in dysfunctional bud emergence as transport of cellular components and 
nutrients along actin cables are disrupted (Wen and Rubenstein 2009). 
 
Cell cycle analysis by flow cytometry revealed cells treated with TA-289 and 
equisetin displayed a decrease in G1 phase and an increase in S-G2/M phase 4 h after 
treatment. Notably, it is difficult to distinguish between S and G2/M phase in the 
yeast cell cycle, and the increase area observed as “S phase” could be for the most 
part, G2/M. The increase of G2/M phase observed in yeast cells is often associated 
with tubulin-targeting compounds (Iwasaki 1992; Hamel 1996), where microtubule 
stabilization and/or destabilization lead to mitotic arrest. This results in a 
characteristic cell cycle block at G2/M. A heterozygous diploid strain lacking TUB2 
(tub2Δ::KanR), which encodes for the β-tubulin subunit of yeast microtubules, was 
tested for sensitivity to TA-289 and equisetin. In the case where microtubules are 
the target, a heterozygous diploid with only one wild-type copy of the target gene 
will be hypersensitive, as the reduced number of protein product is overwhelmed by 
the compound that binds to it at a lower concentration than in wild-type, a 
phenomenon known as drug-induced haploinsufficiency (Giaever, Shoemaker et al. 
1999). The tub2Δ strain was no more sensitive to TA-289 or equisetin than the wt 
diploid, while it is hypersensitive to anti-mitotic agent, benomyl. This strongly 
suggests that neither TA-289 nor equisetin are tubulin-targeting compounds. 
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Prolonged treatment (18 h) of TA-289 and equisetin cause both wt and pdrΔ cells to 
display a small-size phenotype, known as pyknosis, a characteristic associated with 
yeast apoptosis. Yeast have been shown to exhibit several key morphological 
features of apoptosis, and in pyknosis, reduction in cell size, chromatin condensation 
and subsequently DNA fragmentation indicates a dying cell (Chen, Dunigan et al. 
2003). A positive correlation between reduction in cell size and the concentration of 
TA-289 and equisetin was tested. At the highest concentration of 100 µM, cells are 
1.4 fold smaller than untreated controls (P = 2.67 x 10-16). For cells treated at a lower 
concentration, 30 µM, size reduction is not as severe. These observations indicate 
that TA-289 and equisetin cause a dose-dependent apoptotic-like phenotype in 
yeast. 
 
A decrease in potency of both TA-289 and equisetin was observed in BY4743 diploid 
wt yeast cells (used as a control strain when testing the tub2Δ diploid mutant) 
compared to that of haploid BY4742 wt yeast cells (used in normal dose-response 
assays), with an approximated MIC of 50 µM for TA-289 in haploid BY4742 cells, 
compared to >100 µM in diploid BY4743 cells, and 30 µM for equisetin in haploid 
BY4742 cells, compared to 50 µM in diploids. Arguably, a haploid cell would contain 
half the number of target protein that would otherwise be present in a diploid cell, 
thus requiring less drug-target interactions to cause growth inhibitory effects. This 
situation leads to an apparent higher potency observed in haploid cells. Moreover, 
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the decreased potency can also be attributed to the presence of two gene copies of 
the transcription factors (PDR1 and PDR3) and drug efflux pumps that drive most of 
the yeast pleiotropic drug resistance genes in the diploid BY4743 cell, leading to a 
more efficient efflux pump system compared to the haploid BY4742 cell. In saying 
that however, diploid yeast cells tend to be twice the volume compared to haploid 
yeast cells (Amberg, Burke et al. 2005), and therefore the effective PDR protein 
concentration may be similar between a diploid and a haploid ell.  
 
Cell growth inhibition is indicative of a biologically active molecule. To determine 
whether these inhibitory effects are irreversible, cells treated with TA-289 and 
equisetin were washed and allowed to recover on rich media. Interestingly, BY4742 
cells treated with TA-289 and equisetin were able to recover after washing, while 
pdrΔ cells did not recover. This was also observed in the time-course cell cycle 
analysis of treated cells by flow cytometry, where BY4742 cells recovered within 1.5 
h after washing off TA-289 and equisetin, as indicated by a return of the G1 peak in 
TA-289-treated BY4742 cells, and a slower return in equisetin-treated BY4742 cells. 
The slower recovery of BY4742 cells treated with equisetin may be attributed to the 
fact that equisetin is more potent to yeast than TA-289, and this increased potency is 
postulated as a result of the compounds ability to either more effectively enter the 
cell and/or bind to its target(s) with higher affinity. As TA-289 and equisetin are 
substrates of the yeast efflux pumps, it is possible that BY4742 wt cells were able to 
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remove TA-289 and equisetin from within the cell at a sufficient rate before the 
compounds were able to elicit their irreversible inhibitory effects. This allowed 
BY4742 cells to recover from treatment with TA-289 and equisetin, in contrast to 
the more sensitive pdrΔ cells. As such, it can be suggested that TA-289 and equisetin 
cause either cell death or irreversible growth inhibition in yeast, however the effect 
is only reflected in pdrΔ cells lacking in an efficient efflux pump network. However, 
cell death assays observed in result 2.5.6 indicate the ability of TA-289 and equisetin 
to kill wt yeast cells in respiratory conditions (in glycerol-ethanol). This will be 
further discussed in section 2.5.4 of this discussion. 
 
2.5.3 Chemical genomic profiling of TA-289 
The advent of yeast genomics technologies have allowed for genome-wide study of 
the mechanisms of a biologically active compound. Chemical genomic profiling in 
particular utilises an inhibitory compound as a chemical probe, hand-in-hand with 
the yeast genome deletion sets to reveal affected biological processes. These in turn 
provide leads into further understanding the mechanism of a compound. In this 
study, two yeast genome deletion sets were screened against TA-289; the 
homozygous diploid deletion set (HOM), comprising of the complete homozygous 
deletion of nonessential genes from the S. cerevisiae genome, and the heterozygous 
diploid deletion set (HET), which are heterozygous deletions that thus include the 
essential genes of the yeast genome. While haplo-insufficiency profiling (as 
performed in the HET screen) is based on identifying the most sensitive hit as the 
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drug target, often this may not be so straight forward. Nevertheless, the combination 
of both screens allows for greater understanding of the mechanisms of TA-289. 
 
To this end, a number of gene deletions identified as sensitizing to TA-289 from the 
HOM and HET screens (top 40 and top 15, respectively) were associated with 
oxidative stress and DNA damage (RTT107, RPN4, STB5, CNB1, DPB3, and YBP1), 
mitochondria (ARC18, ILM1, ILM2, MSW1, CIN8, NPL4, YJR100C, MTG1, 
YLR201C (COQ9), YDR438W, MIP1, SNL1, AUT7, APJ1, and TOM22), translation 
and/or transcription, and regulation of transcription from RNA polymerase II 
promoter (RPS27B, INO2, PHO2, PHO23, SNF4, FZF1, GAL11, ARR1, LSM4, and 
MED4), endocytosis, vacuolar transport, and ER (VPS35, YKR007W, RAV1, GTR1, 
MON2, YIP4, GDA1, PRB1, and SIN3). Hierarchical cluster analyses showed both 
HOM screens displayed similarities (wherein they branched from the same subset in 
the cluster analyses) with L-Dopa and MPP+, a therapeutic drug and a neurotoxin 
thought to exert at least some of their biological effects by acting at the 
mitochondria and causing oxidative stress (Przedborski 1993; Langston 1999). 
Additionally, when localizations of gene hits from one of the HOM screens were 
compared to whole genome localization, a significant overrepresentation was found 
in genes localized to actin, the nucleus, Golgi, ER, and most significantly at the 
mitochondrion.  
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One of the top ten sensitive heterozygous deletion strains from the profiling screens 
was aut7Δ, an autophagy-related gene involved in autophagic removal of 
mitochondria induced by apoptotic factors. The aut7 null mutant displays reduced 
mitochondrial potential, reduced electron transport chain activity, cell cycle delay, 
and elevated ROS (Zhang, Qi et al. 2007). Haplo-insufficiency profiling has 
previously been shown to identify the mode-of-action of a biologically active 
compound (Baetz, McHardy et al. 2004; Lum, Armour et al. 2004), however, success 
can be variable, and in many cases the most sensitive hits from HET screens are 
often those involved in the consequential cellular processing following blocking of 
the mechanism of the drug rather than the target itself (Sturgeon, Kemmer et al. 
2006). As such, it is possible that an aut7 null mutant strain displays significant 
sensitivity to TA-289 as it is unable to degrade dysfunctional mitochondria and 
other damaged proteins induced by TA-289. 
 
Other interesting gene deletions that sensitized cells to TA-289 included tom22Δ, a 
component of translocase complex responsible for mitochondrial protein import, of 
which the deletion mutant displays cell cycle progression delay (Sopko, Huang et al. 
2006) and abnormal mitochondrial morphology (Altmann and Westermann 2005). 
Likewise, while it was not represented as a top hypersensitive hit in the HET screen, 
the ppa2Δ heterozygote still displayed relative sensitivity. PPA2 is a mitochondrial 
inorganic pyrophosphatase required for mitochondrial function, the absence of 
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which results in abnormal mitochondrial morphology (Dimmer, Fritz et al. 2002); 
equisetin has been previously showed to stimulate PPA2 activity (Lundin, Deopujari 
et al. 1992). Mitochondrial porin POR1, a voltage-dependent anion channel is 
required for mitochondrial membrane osmotic stability and permeability. Por1p has 
been previously identified as a putative target for SFK1, a mitochondrial respiratory 
chain inhibitor. The por1Δ heterozygote was identified as sensitive to TA-289 in one 
of the HOM screens and in the HET screen. 
 
DNA damage repair and oxidative stress response genes identified in these screens 
included those that were previously identified as genes that sensitize most to DNA-
damaging and oxidative stress inducing agents such as H2O2; RAD1, RAD5, RAD9, 
RAD17, RAD18, RAD55, RAD57, RAD59, MMS4 (response to damage by alkylating 
agents) (Xiao, Chow et al. 1998), MEC3 (part of the rad7p complex) (Cardone, 
Revers et al. 2006), RPL20A (a ribosomal protein) (Planta and Mager 1998), and 
YIM1 (mitochondrial inner membrane protease) (Birrell, Brown et al. 2002). Most 
interestingly, and perhaps highlighting the potential of the mitochondrion being the 
site of action of TA-289 (and possibly equisetin, as previously described by König et. 
al.), is the large number of genes associated with the electron transport chain (ETC). 
This included genes involved in complexes I through V (NDE, SDH, COQ, COX, and 
QCR), and genes associated with ADP/ATP carriers (PET). In concert, many of the 
genes identified in the chemical genomic profiling of TA-289 suggest two factors, 
72 
 
firstly, that the ER and especially the mitochondrial processes (due to the significant 
enrichment of genes localized to the mitochondrion) identified in these screens 
were consistent with previous reports of inhibition of post-translational protein 
import to the ER (Patham, Duffy et al. 2009), and also the substrate anion carriers of 
the mitochondrial respiratory chain by equisetin (König, Kapus et al. 1993), and 
secondly, is further evidence that TA-289 and equisetin may share similar a similar 
mechanism-of-action. 
 
2.5.4 Glucose vs. Glycerol as a carbon source 
Yeast are able to ferment and respire. In the presence of glucose, yeast preferentially 
undergo fermentation, whereas in glycerol-ethanol, they actively respire. Yeast cells 
displayed differences in growth inhibition when treated with TA-289 or equisetin 
depending on the carbon source used; either fermentative (glucose) or respiratory 
(glycerol-ethanol). The ability for cells to adapt to treatment of the two compounds 
appeared to be dependent on carbon source, in that TA-289 and equisetin kill yeast 
in glucose, but yeast cell death occurs slower in glycerol. Often, compounds 
targeting the mitochondria, in particular the mitochondrial respiratory chain, 
display greater potency (or are only biologically active) in respiring conditions (Li, 
Mo et al. 2005). In the case of TA-289 and equisetin, both compounds were active in 
fermentative and respiratory conditions. Therefore, if the target(s) is involved in the 
mitochondrial respiratory chain (as indicated by gene hits associated with the 
mitochondria, the significant localization of gene hits at the mitochondrion, and the 
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mitochondrial respiratory chain i.e. ETC), then it is presumed that within a 
fermenting cell, there is some basal level of respiration, as TA-289 and equisetin are 
still growth inhibitory towards yeast.  
 
Interestingly, when glycerol-ethanol is used as a carbon source, cells are more 
resistant to the death caused by TA-289 and equisetin, as observed in the cell death 
assays where even at 100 µM, pdrΔ yeast cells were only severely inhibited after two 
hours, compared to the complete death of cells within an hour of treatment when 
glucose is used. In glucose, yeast respire very little, and assuming that due to the low 
basal level of respiration, the target (presumably a protein) is also expressed at low 
levels, requiring less amount of drug (in this case, TA-289 and equisetin) to bind to 
the target in order to cause an effect. This will then result in a seemingly more 
potent effect of both TA-289 and equisetin under fermentative conditions. 
 
However, when comparing the cell death results to the liquid growth dose-responses 
over an 18 h time period, cells are no less resistant to TA-289 and equisetin in 
glycerol-ethanol compared to glucose in liquid. Moreover, over prolonged exposure 
of wt cells to TA-289 and equisetin in liquid, cells are able to gain resistance in 
glucose, but not glycerol-ethanol. Therefore an alternative and a more probable 
scenario, is that when the cell is fermenting, the target of TA-289 and equisetin, 
though expressed, is non-essential, and overtime the cell is able to adapt by 
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upregulating some sort of multi-drug resistance mechanism. This suggests that when 
glycerol-ethanol is the carbon source and cells are actively respiring, the target thus 
becomes essential, possibly because it is required for respiration, and so TA-289 and 
equisetin seem to inhibit the growth of cells in liquid over a longer period of time 
(up to six days). 
 
Most importantly, while TA-289 kills pdrΔ cells within the first hour of treatment 
in glucose (as observed in the cell death assay figure 2.14), wt cells recovered. 
However, some wt cell death was observed in glycerol-ethanol (figure 2.15). This 
strongly indicates that the respiratory state of yeast is critical for the ability of TA-
289 to kill, and is further evidence that the mitochondria is heavily involved in the 
way which TA-289 causes yeast cell death. Interestingly, while pdrΔ cells were 
extremely susceptible to TA-289 in glucose, they showed resistance in glycerol-
ethanol. This is unexpected because TA-289 has been shown to be a substrate for the 
yeast efflux pumps, and thus should be more potent to pdrΔ cells than it is to wt 
cells. It is speculated that this resistance may be due to pdrΔ cells holding higher 
antioxidant capacity than wt cells, where it is observed that pdrΔ cells were more 
resistant to TA-289 in glycerol-ethanol (figure 2.15). It is therefore suggested that 
the antioxidant capacity of a cell plays a more key role in a cell’s ability to grow in 
the presence of TA-289 than that of the efflux pump capacity. Similar results were 
observed for cell death assays conducted with equisetin in different carbon sources. 
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Possibly, greater yeast cell death may be observed over a longer period of time, as 
cell death assays were only recorded for 2 h. 
 
S. cerevisiae display similar cell death characteristics to that of mammalian 
apoptosis, including caspase-initiated apoptosis, and apoptotic phenotypes such as 
pyknosis (as observed in morphological assessment of yeast cells treated with TA-
289 in result 2.5.3); a reduction in cell size, chromatin condensation and DNA 
fragmentation (Madeo, Carmona-Gutierrez et al. 2009). The apoptotic pathway in 
yeast is similar to the intrinsic apoptotic pathway in mammalian cells, and is 
regulated by several key mechanisms including mitochondrial release of apoptosis-
inducing factor AIF1 (Wissing, Ludovico et al. 2004), yeast suicide protein YSP1 
(Pozniakovsky, Knorre et al. 2005), cytochrome c (Skulachev 1996), and activation 
of yeast metacaspase MCA1 (Madeo, Herker et al. 2002). The mitochondrion has 
been shown to be an important regulator of programmed cell death (PCD) 
(Skulachev 1996; Madeo, Herker et al. 2004; Eisenberg, Büttner et al. 2007). The 
differential potency and time it takes for yeast to die in the presence of TA-289 and 
equisetin in different metabolic states (i.e. fermentative or respiratory) is indication 
that PCD upon treatment with TA-289 and equisetin may be due to impairment of 
mitochondrial function as a result of the binding of both compounds to a target(s) 
that is intimately associated with the mitochondrion. 
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The chemical genomic profiling screens of TA-289 allowed for the identification for 
potential mechanisms of the compound, with particular interest centred around the 
mitochondrial-related processes (König, Kapus et al. 1993). The previously described 
mechanisms of equisetin and the genes identified in the microarray screens for TA-
289 indicate that both compounds may share similar modes-of-action. The ability of 
TA-289 and equisetin to kill yeast appears to be dependent on carbon source, where 
the capacity for cells to respire may play a role in sensitizing to or giving resistance 
to TA-289 and equisetin, and that this strongly indicates a potential site-of-action at 
the mitochondria.  
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3. RESISTANT MUTANT GENERATION__________________ 
 
3.1 Introduction: Resistant mutant generation 
Drug resistant mutant generation and characterization as an approach to determine 
the modes-of-action of various biologically active compounds has been successfully 
applied in various model organisms. In S. cerevisiae, its ease of manipulation and 
genetic tractability makes it an ideal eukaryotic organism to generate drug resistant 
mutants and to determine the gene(s) conferring resistance. In this way, the targets 
of many biologically active small molecules have been successfully identified in S. 
cerevisiae, including nystatin (Ahmed and Woods 1967), oligomycin (Wakabaya.K 
and Gunge 1970), reveromycin (Miyamoto, Machida et al. 2002), and rapamycin 
(Singh, Sun et al. 1979). 
 
However, while the generation of mutants resistant to inhibitory compounds is 
fairly straightforward, the same cannot be said for identifying the gene in which the 
mutation has occurred, and determining the relationship of the mutation to the 
target of the compound of interest. Resistance to a growth inhibitory small molecule 
can occur in many ways, often depending on the consequence of the target-protein 
function and of the interaction of the target with the compound, as well as the 
nature of the mutation itself.  A mutation affecting resistance can arise from, 1) the 
up-regulation of an adaptive response such as the multidrug resistance pumps to 
more efficiently export xenobiotics (Balzi and Goffeau 1995), 2) alteration of a gene 
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that is required to activate and/or inactivate a compound, 3) alteration of a gene that 
affects the target(s) of a compound, or less usually but more simply 4) alteration of a 
gene that is the target of the compound. In the case of cycloheximide, which elicits 
its growth inhibitory effects by inhibiting protein synthesis through targeting the 
ribosome, a number of mutants found to confer resistance to cycloheximide ranged 
from recessive, to semi-dominant, and dominant mutations (Middlekauff, Hino et al. 
1957; Wilkie and Lee 1965; Sutton, Ares et al. 1978; Stocklein and Piepersberg 1980; 
Fried and Warner 1982; Kaaufer, Fried et al. 1983). 
 
For compounds that target large complexes with multiple subunits such as 
cycloheximide, it is not surprising that mutations in any one of the subunits within 
the ribosomal complex has been shown to provide resistance with such a spectrum 
of characteristics (Sutton, Ares et al. 1978; Stocklein and Piepersberg 1980; Fried and 
Warner 1982; Kaaufer, Fried et al. 1983). Likewise, resistance to small molecules 
that cause growth inhibition and/or death by the generation of reactive oxygen 
species, such as hydrogen peroxide, is a common example of an adaptive mechanism, 
wherein cells up-regulate, through a variety of means, intracellular anti-oxidant 
capacity to counteract the generation of reactive oxygen species (Dawes 2004; 
Thorpe, Fong et al. 2004). 
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Underpinning any of these possibilities in explaining and characterizing a drug 
resistant mutant is the necessity of first determining the mutant lesion. An approach 
commonly used to determine a site of mutation is to create a plasmid-borne genomic 
library of a resistant mutant and transform the library into the parental strain from 
which the resistant mutant was derived. The fragment that gives rise to resistance is 
selected by growing the transformed parental strain on drug-containing media, after 
which the fragment is sequenced and the point of mutation identified (Fried and 
Warner 1981). This was applied to identify the cellular targets of reveromycin A, 
where strains containing a high-copy plasmid overexpressing the ILS1 (encoding 
tRNA synthetase, IleRS) gene conferred resistance to reveromycin A. Inhibition of 
tRNA synthetase in vivo was also observed, further indicating IleRS as the target of 
reveromycin A (Miyamoto, Machida et al. 2002). 
 
Another approach takes advantage of a microarray-based growth assay combined 
with a commercially available plasmid library of molecular barcoded ORFs, to 
transform a drug resistant mutant. This approach allows identification of recessive 
mutations through mapping by complementation, as the transformant that receives 
the wild-type copy of the drug resistance gene will be unable to grow in the 
presence of the drug. As each ORF is uniquely barcoded, identification on an 
oligonucleotide microarray is possible, and the mutant gene may be subsequently 
cloned and sequenced (Ho, Magtanong et al. 2009). 
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To date, while many approaches are used to determine drug resistance-conferring 
mutations, the challenge remains in identifying the true target of a small molecule of 
interest – lest we forget that some biologically active compounds have multiple 
targets, a classic example being salicylate and aspirin (Kopp and Ghosh 1994; Vane 
1994). As mentioned earlier, there are many ways a cell can become resistant to a 
drug. Moreover, there is no correlation between the dominant-recessive nature of a 
resistant mutant, and the nature of the gene as a drug target. Nevertheless, the 
characterization of the nature of a drug resistant allele undoubtedly provides 
valuable information, both in mapping the mutation itself, and towards 
understanding the mechanism of the drug. 
 
3.2 Synthetic genetic array mapping 
SGA (Synthetic Genetic Array) analysis (Tong, Evangelista et al. 2001), is an assay 
that explores phenotypic enhancement between gene pairs. SGA analysis, in short, 
involves crossing a query strain comprising the deletion mutant of interest carrying 
a nourseothricin (NAT) antibiotic resistance marker to the genome-wide 
homozygous deletion set carrying the kanamycin (G418) resistance marker in an 
ordered array, en masse. Double mutants are thus able to grow in the presence of 
both antibiotics (Boone and Tong, 2005). These basic attributes of SGA have also 
proven to be a powerful tool for a high-throughput mapping of mutations 
(Jorgensen, Nelson et al. 2002) in a procedure called SGA mapping (SGAM). This 
methodology relies on a key fact, where if the query allele, in this case an unknown 
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mutation, and the deletion mutant array (DMA) allele are the same, only one 
antibiotic marker will be present, causing cells to die when selected on both 
antibiotics. This appears as a visible no-growth hole in SGA culture plates. 
 
Linkage disequilibrium is a phenomenon whereby an allele occupying a locus at any 
given site on a chromosome does not segregate independently from another allele 
occupying a second nearby locus because of low meiotic recombination frequency of 
the adjacent or nearly adjacent alleles. In the case just described, the characteristic 
no-growth/growth of query/array genes occupying the same locus will spread to 
approximately half-dozen or so genes on either side of that locus, forming a clear 
visual display or linkage group of no-growth. This effectively maps the location of 
the query mutation on the SGA array. A novel application of the SGAM method in 
our laboratory has been to map drug resistant mutations, such that essentially, the 
drug/drug resistant mutant pair replaces the query antibiotic/antibiotic marker pair 
described above; a procedure called C-SGAM (chemical-synthetic genetic array 
mapping) (Ploi Yibmantasiri, manuscript in preparation). 
 
The C-SGAM method of mutation mapping utilizes the generation of a mutant yeast 
strain resistant to a bioactive molecule of interest that is crossed with the yeast 
deletion set following the SGA methodology. As described, taking advantage of drug 
82 
 
resistance as a selectable marker, the final pinning procedure in the SGA therefore 
involves double mutant selection on drug-containing (to select for the presence of 
the resistant mutation) and G418 (geneticin)-containing media (to ensure the 
presence of the original xxxΔ genes from the DMA) (Figure 3.1). In the event where 
the mutation allele occupies the same locus as a particular gene in the deletion array 
(xxxΔ), recombination cannot occur as both resistant alleles cannot occupy the same 
locus, resulting in inviable progeny when grown in the presence of both G418 and 
the drug of interest. A symmetrical linkage pattern is therefore often observed 
where growth defect is inversely proportional to the probability of meiotic 
recombination between neighbouring genes of the gene target (Figure 3.2) i.e. 
linkage disequilibrium. This pattern identifies the position of the locus of resistance, 
thus narrowing the area of the genome which may contain the drug target (or at the 
very least, the resistance-conferring gene mutation) of the compound of interest. 
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Figure 3.1. A simplified flow diagram of the C-SGAM methodology. (a) A MATα strain carrying 
the drug-resistant mutation of interest (drugR - aptly named, the “query strain”), is crossed with 
the haploid yeast deletion set, all of which are of mating type MATa, and in place of every gene 
deletion (xxxΔ) is a dominant kanamycin-resistance (kanR) selectable marker to produce a 
diploid strain (b). The resulting heterozygous diploids are induced to sporulate (c), after which 
only the MATa meiotic progeny that express certain SGA reporters are selected (d). (e) Selecting 
for kanR ensures original deletion array mutants are present (xxxΔ), and the final double mutant 
selection step in drug- and G418-containing media (f), selects for double mutants containing the 
mutation of interest (drugR) and the deletion mutant from the array (kanR).  
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Figure 3.2. Visual representation of linkage disequilibrium. The chromosomal location of a 
resistant allele can be identified by observing the growth patterns of yeast colonies on an arrayed 
plate containing double selection media (a). An example of a linkage pattern is shown in (b), 
where the target gene ADH2 is highlighted in yellow and linkage genes are in red. Figure (b) 
obtained from Bede P. Busby 2007 final project report. 
 
A major flaw in the SGA methodology – this is especially so when utilizing SGA 
methods to map drug resistant mutations i.e. the C-SGAM – lies in the quantity of 
biologically active compounds required to perform the final selection on a large 
volume of solid media. In the case where a compound of interest is limited in 
quantity, as it is often with purified natural products, and it is so for the novel 
compound, TA-289, the application of a microarray-based growth assay may be used 
as a mapping tool, i.e. measuring the amount of barcode present for each gene 
deletion from a genome-wide pool of “array mutants” grown in a small volume in 
the presence of the compound. Fluorescence intensities are then used to identify 
linkage disequilibrium patterns on a microarray chip, paralleling the colony growth 
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used to identify patterns on agar plates in a standard SGAM method. This novel 
method of mapping by microarray will allow the assessment of gene fitness through 
pooled competitive growth, and as such requires much less drug than what is needed 
for SGA.  
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3.4 Aims and objectives 
The aim of this chapter was to explore the mechanisms-of-action of TA-289 and 
equisetin through the generation of mutants resistant to TA-289 and equisetin, and 
then by mapping the resistance-conferring gene(s) by combining two established 
yeast methodologies: 
 Resistance mapping 
 Microarray growth assay 
Part of this study also involved a proof-of-principle for the novel method of 
combining the C-SGAM methodology with mapping by microarray at the final SGA 
selection step by using a characterized mutant and the compound to which it is 
resistant as a pilot study. 
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3.5 Materials and methods 
 
3.5.1 Yeast strains 
All S. cerevisiae strains used in this study are as follows: 
Strain Genotype 
YCG191 (CYHr) 
MATα can1Δ::STE2p_LEU2; lyp1Δ; his3Δ1 leu2Δ0 
ura3Δ0 met15Δ0 
YCG326 (pdrΔ) 
MATα pdr1Δ::NAT pdr3Δ::URA3 can1Δ::STE2pr-
Sp_his5; lyp1Δ; his3Δ1 leu2Δ0 ura3Δ0 met15Δ0 
LYS2+ 
YCG387 
MATa pdr1Δ::kanR pdr3Δ::URA3; his3Δ1 leu2Δ0 
URA3Δ0 met15Δ0 
pdr1Δ (pdr1Δ-p) Derived from BY4741; pdr1Δ::kanR 
 
3.5.2 Growth media 
All yeast cultures were performed in one of the following media as prescribed 
previously, supplemented with either G418 (200 µg/mL final concentration), NAT 
(100 µg/mL final concentration), or Can (50 µg/mL) and Thia (50 µg/mL) (Sigma-
Aldrich), unless otherwise stated. 
 
3.5.3 Compounds and chemicals 
Purchased from Sigma-Aldrich Life Science and Biochemicals: Ethane methyl 
sulfonate (EMS) stored at room temperature, sodium thiosulfate (Na2S2O3) at 50% 
and 5% working concentrations prepared in ddH2O and stored at room temperature, 
dibasic and monobasic sodium phosphate (Na2HPO4, NaH2PO4, respectively) at 
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0.2 M working stocks prepared in ddH2O and stored at room temperature, 
cycloheximide, 10 mg/mL working stock prepared in DMSO and stored at –20 °C, 
dithiothreitol (DTT), 1 M working stock prepared in ddH2O and stored at –20 °C, 
hydrogen peroxide (H2O2), 3% working stock prepared in ddH2O and stored in the 
dark at 4 °C. 
 
3.5.4 Resistant mutant generation by ethane methyl sulfonate mutagenesis 
Liquid cultures of YCG326 (pdrΔ) were grown overnight in 2 mL SC media at 30 °C 
on a rotating drum. Mutagenesis was adapted from a standard protocol (Amberg 
2005). Cells were collected by centrifugation, washed once with 1 mL ddH2O, and 
pellets resuspended in 1 mL 0.1 M sodium phosphate buffer (pH 7.0). To one culture, 
30 µL of ethane methyl sulfonate (EMS) was added, giving a final concentration of 
3% EMS, while the other culture remained as an unmutagenized control. 
Cells were lightly vortexed and incubated at 30 °C for 1 h on a rotating wheel, after 
which the cells were collected by centrifugation, supernatant discarded into a 
beaker containing 50% sodium thiosulfate, and pellets gently washed twice with 
200 µL 5% sodium thiosulfate. Cells were gently resuspended in 1 mL ddH2O. The 
cultures were transferred to fresh, sterilized 15 mL falcon tubes, further centrifuged, 
and cell pellets resuspended in 2 mL YPD, after which the tubes were incubated at 
30 °C for 2 h on a rotating wheel.  
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A 20 µL aliquot of the mutagenized and unmutagenized cultures were inoculated on 
to petri plates containing 20 mL SC, or SC with either 60 µM TA-289, or 60 µM 
equisetin, giving a final concentration of 20 000 cells per plate. The plates were 
incubated at 30 °C for three to four days, and a selection of mutants, both 
spontaneous and EMS-generated, and of various sizes, were picked off and re-
streaked onto SD –Ura +NAT petri plates, to attain single colonies with the 
appropriate selection markers. 
 
3.5.5 Confirmation of resistance by serial spot dilution 
Single colonies from each mutant (so named from here on as TA1–TA22 and EQ1–
EQ21), as well as the parental strain used to generate resistant mutants, pdrΔ, were 
inoculated into 2 mL SC liquid media and grown overnight at 30 °C. Cells were then 
collected by brief centrifugation, washed twice, and resuspended in ddH2O. A 
100 µL aliquot from each culture was dispensed to a 96-well plate, and the OD at 
590 nm was measured to gauge the cell concentration of each culture. Where 
appropriate, cell cultures were diluted to give 1 x 108 cells/mL. These were then 
serially diluted ten-fold, thrice, in 96-well plates, from which 1.5 µL of each cell 
diluent was inoculated on to SC +NAT containing either 60 µM TA-289 or 60 µM 
equisetin, giving final cell concentrations of 150 000, 15 000, and 1 500 cells per 
well, respectively. 
All mutant strains and the parental strain (pdrΔ) were tested against both 
compounds to not only confirm resistance, but also to identify the possibility of 
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cross-resistance. Non-drug containing plates (SC +NAT only) served as carrier 
controls. Excess moisture was removed by drying the plates in a laminar flow hood, 
and then incubated at 30 °C for three days, after which they were photographed and 
colony sizes scored according to the level of resistance compared to controls; a score 
of 1 = little growth (weak resistance), 2 = fair growth, 3 = good growth, 4 = very 
good growth (strong resistance, grows like parental strain (pdrΔ) in untreated 
conditions). 
 
3.5.6 Identifying mutant phenotypes under differing stress conditions 
Briefly, cell concentrations of overnight cultures of all confirmed resistant mutants 
(TA1-22, EQ1-21), as well as the parental strain used to generate the mutants, pdrΔ, 
were determined and where necessary diluted to give 1 x 108 cells/mL. These 
mutants were transferred to a 96-well tissue culture plate and arrayed in 
quadruplicates in 384 format on a Singer© plate using a Singer RoToR© HDA (Singer 
Instruments Co. Ltd., Somerset, UK), with the parental strain bordering the arrayed 
mutants. The mutant and parental cultures were then further arrayed onto Singer© 
plates containing either SC, SC-Gly-EtOH (SC containing 2% glycerol and 2% 
ethanol, instead of glucose), SC-Gal (SC containing 2% galactose, instead of glucose), 
SC + 50 nM cycloheximide, or SC + 0.4 mM DTT. The plates were then incubated at 
three different temperatures; 25 °C, 30 °C, and 37 °C for two days. Photographs of 
the plates were taken using ZoomBrowser EX remote shooting software (Canon) 
after two days and analysed by Colony HT (Collins, Schuldiner et al. 2006). 
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3.5.7 Creating an isogenic wild-type for mating with resistant mutants 
 
3.5.7.1 PCR amplification of the URA3 deletion cassette 
Primers used for this PCR were as follows: 
Primer # Primer spec Primer Sequence 
353 PDR3 forward deletion ACTGCATCAGCAGTTTTATTAATTTTT
TCTTATTGCGTGACCGCAACATGGAG
GCCCAGAATACCCT 
354 PDR3 reverse deletion CCATTTACTATGGTTATGCTCTGCTTC
CCTATTTCTTTTGCGTTTCAGTATAGC
GACCAGCATTCAC 
 
Briefly, 5 µL of purified pAG60 plasmid (containing the URA3 gene) was added to a 
PCR tube containing 20 µL of PCR reagent mix (14.15 µL ddH2O, 5 µL Q buffer 
(Qiagen), 2.5 µL 10x PCR buffer, 1 µL 20 mM dNTPs (5 mM each dNTP), 0.75 µL 
50 mM MgCl2, 0.25 µL 100 mM forward deletion primer, 0.25 µL 100 mM reverse 
deletion primer, 0.1 µL Hot Star taq). A second tube containing no template served 
as a negative control. Reaction controls for the PCR were: 94 °C for 15 mins for 
enzyme activation and template denaturation, 35 cycles of 95 °C for 45 s for 
template denaturation, 54 °C for 40 s for primer annealing, 68 °C for 1 min for 
primer extension, and 68 °C for 10 mins to complete any partially extended primers. 
PCR products were kept at 10 °C to prevent heat denaturation. A 5 µL aliquot of the 
PCR product and an aliquot of the purified pAG60 plasmid were run on a 1% 
agarose gel stained with ethidium bromide at 100 V for 25 mins, after which the gel 
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was visualized under UV, a photo taken of the gel and expected PCR product band 
sizes determined according to the 1kb plus ladder (Invitrogen NZ ltd). Expected 
band size for the pAG60 plasmid was 3 944 bp, and for the URA3 deletion cassette 
PCR product, ~1 600 bp. 
 
3.5.7.2 High efficiency transformation with URA3 deletion cassette 
An overnight culture of a MATa pdr1Δ::kanR (pdr1Δ-p) strain was grown in 2 mL 
SC media at 30 °C, after which the cell concentration of the culture was determined 
by measuring OD at 600 nm using a spectrophotometer (Genova Life Science), and 
subsequently diluted to give 1 x 107 cells/mL in a 15 mL volume. The culture was 
then incubated in a shaking incubator at 30 °C for a further 7 h to ensure a cell 
culture at mid-log phase (as determined by counting on a haemocytometer). 
Following the high-efficiency transformation protocol (Gietz and Schiestl 2007), the 
cells were transformed with the URA3 deletion cassette amplified with deletion 
primers with homology to both the URA3 cassette and to the flanking regions of the 
PDR3 open reading frame to generate a MATa pdr1Δ::kanR pdr3∆::URA3 strain 
(referred here on as YCG387). 
 
Transformants were streaked onto SD –Ura +G418 plates to obtain single colonies 
for PCR confirmation. The same colony used for PCR confirmation was used to 
inoculate 10 mL YPD media and grown overnight at 30 °C in a shaking incubator to 
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stationary phase, after which the cells were collection by centrifugation, washed, 
and resuspended in 1 mL YP with 15% glycerol. The 1 mL culture was then 
transferred to a cryotube and stored in -80 °C until further use. 
 
3.5.7.3 Confirmation of transformants by colony PCR 
Two transformant colonies and the pdr1Δ-p parental strain used for this 
transformation (to serve as a negative control) were incubated in 50 µL 1 mg/mL 
zymolase in ddH2O at 30 °C for 30 mins. A 5 µL aliquot from each of the cell-
zymolase suspension was added to the PCR tubes; pair tubes were made for each 
cell-zymolase suspension. Into each tube 20 µL PCR reagent mix (containing 162 µL 
ddH2O, 25 µL 10x PCR buffer, 8 µL 20 mM dNTPs (5 mM each dNTP), 2 µL 100 mM 
forward deletion primer, 2 µL 100 mM reverse deletion primer, 1 µL Hot Star taq) 
containing the appropriate primers were added. Primers used were: 
Primer Primer spec Primer Sequence Expected 
size 
368 URA3 forward internal GACACCTGGAGTTGGATT 
880 bp 
369 URA3 reverse external TTATGAACACGCACAGGC 
370 URA3 forward external AATTCAACGCGTCTGTGAGG 
761 bp 
371 URA3 reverse internal TACCGCCTAGGTAACCAT 
 
Reaction controls for the PCR were: 94 °C for 15 mins for enzyme activation and 
template denaturation, 35 cycles of 95 °C for 45 s for template denaturation, 54 °C 
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for 40 s for primer annealing, 68 °C for 1 min for primer extension, and 68 °C for 10 
mins to complete any partially extended primers. PCR products were kept at 10 °C 
to prevent heat denaturation. A 5 µL aliquot of each PCR product were run on a 1% 
agarose gel stained with ethidium bromide at 100 V for 25 mins, after which the gel 
was visualized under UV, a photo taken of the gel and expected PCR product band 
sizes determined according to the 1kb plus ladder (Invitrogen). 
 
3.5.8 Determining dominance and/or recessiveness of resistant mutants 
 
3.5.8.1 Generating heterozygous diploid mutants 
Briefly, the strongest confirmed resistant mutant, TA8, as well as the parental strain 
used to generate the resistant mutants (YCG326, pdrΔ) were mated with the isogenic 
MATa wild-type strain (YCG387) and then replica-plated onto SD –Ura +NAT 
+G418 to select for diploids, namely, the mutants that have successfully mated with 
the isogenic wt strain. The desired diploids were re-streaked onto fresh SD –Ura 
+NAT +G418 petri plates and grown for two days at 30 °C to attain single colonies. 
These heterozygous diploids were used to determine dominance and recessiveness of 
the mutations. 
 
Cell concentrations of overnight cultures of TA8, pdrΔ parental, along with the 
corresponding heterozygous diploids were determined by measuring OD at 600 nm 
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on a spectrophotometer (Genova Life Science), and subsequently diluted to 
5 x 105 cells/mL. Each yeast culture was then serially diluted ten-fold, four times, 
after which a 10 µL aliquot from each dilution was spotted onto petri plates 
containing 60 µM TA-289, as well as the corresponding untreated control plates 
containing only SC media. Excess moisture was removed by drying the plates in a 
laminar flow hood, incubated for two days at 30 °C, and then photographed. The 
level of resistance was determined by colony growth of heterozygous diploids 
mutants to original haploid resistant mutants on drug-containing plates. 
 
3.5.9 Growth rate assays 
Overnight cultures of pdrΔ and of the TA8 resistant mutant were prepared by 
inoculating into 2 mL SC media and subsequently incubated overnight at 30 °C. Cell 
concentrations were determined by measuring OD at 600 nm on a 
spectrophotometer (Genova Life Science), and the cultures diluted to 
2 x 107 cells/mL in fresh SC media. A 500 µL aliquot of each diluted culture was 
dispensed in triplicate into the centre wells of a 48-well tissue culture plate, and 
surrounding these, wells containing 500 µL of ddH2O throughout the entire plate. 
The plate was then placed in the Wallac EnVision 2102 Multilabel Plate Reader 
(Perkin Elmer™, Waltham, Mass.) at 30 °C. The plate was mixed and absorbance read 
at OD 590 nm every 15 mins for 18 h. Raw OD data obtained were natural log (ln) 
transformed and fitted with the LINEST function in Microscoft Excel (2007) to a 
straight line, which gave estimates of the gradient and y-intercept. These were used 
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to calculate growth rates of both strains. See appendix 2.3 for full calculations of 
doubling-time for each strain. 
 
3.5.10 Proof-of-principle C-SGAM with microarray: Using cycloheximide as a pilot 
A 10 mL overnight culture of YCG191, a cycloheximide resistant mutant (CYHr), 
was divided and 100 µL aliquots transferred to a 96-well tissue culture plate and 
arrayed in 384 format onto YPD +NAT Singer© plates. Quadruplicate plates were 
arrayed and incubated at 30 °C for two days in preparation for mating with the 
homozygous haploid MATa deletion set. SGA analysis was carried out using the 
Singer RoToR© HDA (Singer Instruments Co. Ltd., Somerset, UK) following the 
protocol set out by Tong and Boone 2006. 
Duplicate sets of the second-to-last selection stage of the SGA (SD –His/Arg/Lys 
+Can +Thia +G418) were generated, one set of which was subsequently pinned onto 
SD –His/Arg/Lys +Can +Thia +G418 +10 µg/mL cycloheximide. 
For the proof-of-principle mapping by microarray, the border colonies of the second 
set of plates were removed and the remaining colonies from each plate were pooled 
and 15 mL aliquots were freeze dried and stored at –80 °C (Mike Cook, School of 
Biological Sciences, University of Edinburgh, UK, personal communication). A 500 
µL aliquot of the pooled cells was used to inoculate 10 mL fresh SC +G418 and 
incubated overnight at 30 °C on a rotating drum. Cell concentrations of the 
overnight cultures were determined by measuring OD at 600 nm on a 
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spectrophotometer (Genova Life Science), and subsequently diluted to 
1 x 107 cells/mL in 10 mL fresh SC +G418. A 100 µL aliquot of 1 mg/mL 
cycloheximide was added to the yeast culture, giving a final concentration of 10 
µg/mL cycloheximide. DMSO (1% final concentration) served as a carrier control. 
The cultures were mixed by brief vortexing, and incubated at 30 °C on a rotating 
drum for 15 h. 
 
Following the first overnight incubation, the cultures were further diluted to 
1 x 107 cells/mL in 10 mL fresh SC +G418, and treated with the same concentration 
of cycloheximide or DMSO, then incubated for another 15 h at 30 °C. Genomic 
DNA of both treated and untreated cultures were precipitated, purified, quantified, 
amplified, and hybridized onto arrays following the MasterPure DNA Purification 
Kit (Epicentre Biosciences) and the yeast tag microarray protocol (Rosemary 
Heathcott, personal communication, ESR Wellington) adapted from Parsons 2006.  
 
3.5.11 Microarray analysis 
The microarray chips were read on an Axon Microarray Scanner, where 
fluorescently labeled control tags were scanned at 532 nm and experimental samples 
(drug-treated) scanned at 635 nm (Genomics Facility, Biochemistry Department, 
Otago University). 
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The intensities of the up and down tags were normalized and log2 ratios of drug-
treated/DMSO control data were obtained using Standardization and Normalization 
of Microarray Data (SNOMAD) software (http://www.pevsnerlab. 
kennedykrieger.org/snomadinput.html). Gene tags with a low fluorescent control 
signal (less than 500) were removed, the remaining log ratios of tag replicates were 
averaged, and deviation (D) scores calculated (D score = (average of log ratios – mean 
of average of log ratios)/standard deviation of average of log ratios). Gene tags were 
ordered according to chromosome position and the region surrounding the RPL28 
locus of resistance was plotted against the respective log2 ratios. 
 
3.5.12 Reactive oxygen species detection by flow cytometry 
Cell concentrations of overnight cultures of pdrΔ and the haploid TA-289 resistant 
mutant, TA8, were determined by measuring OD at 600 nm, and subsequently 
diluted to 1 x 107 cells/mL in fresh SC media. pdrΔ cells were treated with H2O2 
(1 mM final concentration) and incubated for 30 mins at 30 °C. Following each 
incubation period, cells were treated with DCF (50 µM final concentration) and 
further incubated at 30 °C for 15 mins. Cells were then placed on ice, diluted with 
400 µL ddH2O, and co-stained with 6 µg/mL propidium iodide prior to visualizing. 
The flow cytometry data obtained were analysed on FlowJo version 7.6.1 flow 
cytometry analysis software (Tree Star Inc., Ashland, OR, USA). Cell populations 
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were manually gated according to the untreated control and recorded as percentage 
of total population within the sample. 
 
3.5.13 Cell death assays 
Overnight cultures of pdrΔ and TA8 were prepared by inoculating either 2 mL SC, 
or 2 mL SC +gly-EtOH, and grown overnight at 30 °C on a rotating drum. Cell 
concentrations of each culture were determined by measuring OD at 600 nm and 
subsequently diluted in either fresh SC or SC +gly-EtOH to give a final cell 
concentration of 1 x 106 cells/mL. 
For the TA8 and pdrΔ cell death assays in H2O2, an eight-point serial dilution of 
H2O2 was prepared in ddH2O to give a concentration range from 0.9 M to 0.3 M. A 
100 µL aliquot of diluted cells in either SC or SC +gly-EtOH were dispensed into 96-
well tissue culture plates, into which 1 µL aliquots of each H2O2 diluent were added, 
giving final concentrations of 9 mM to 3 mM. After addition of H2O2, the plates 
were mixed by vortexing, and a 1.5 µL aliquot of the treated cells were removed and 
spotted onto a Singer© plate containing SC. DMSO (1% final concentration) served 
as a carrier control for both assays. The plates were then incubated at 30 °C. A 1.5 µL 
aliquot of cells were harvested and spotted onto the SC plate every 30 mins for 3 h 
for cells in SC, and every 30 mins after the first hour for 2.5 h for cells in SC +gly-
EtOH. 
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3.5.14 C-SGAM of TA-289 resistant mutant by hydrogen peroxide 
A 10 mL overnight culture of the TA-289 resistant mutant, TA8, was transferred to a 
96-well tissue culture plate (100 µL aliquots per well), and then arrayed in 384 
format onto SC Singer© plates. Triplicate plates were arrayed and incubated at 30 °C 
for two days in preparation for mating with the homozygous haploid MATa deletion 
set. SGA analysis was carried out using the Singer RoToR© HDA (Singer Instruments 
Co. Ltd., Somerset, UK) following the protocol set out by Tong and Boone 2006 with 
slight modifications; After the haploid selection step, cells were twice treated with 
6 mM H2O2 prior to the final selection with G418.    
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3.6 Results 
 
3.6.1 Resistant mutant generation 
Mutants resistant to TA-289 and equisetin were generated by exposure to EMS and 
also by spontaneous mutations. A total of 22 spontaneous and EMS-generated 
mutants resistant to TA-289 (TA1-TA22), and 21 resistant to equisetin (EQ1-EQ21) 
were collected. These mutants were confirmed by a serial-spot dilution with 60 µM 
TA-289 or equisetin. In addition, the mutants were also tested for cross-resistance by 
testing TA mutants on 60 µM equisetin, and EQ mutants on 60 µM TA-289. All 43 
mutants were also grown in the presence of xenobiotics (1 mg/mL cycloheximide 
(CYH), 0.4 mM DTT), or in different carbon sources (2% galactose and 2% gly-
EtOH), and all were subjected to normal (30 °C,) high (37 °C), and sub-optimum 
(25 °C) temperature conditions. Identifying conditional mutants provides an insight 
into the mutation itself, in addition, it may provide a growth-restrictive condition to 
be used in the mapping procedure instead of using a small molecule inhibitor (i.e. 
TA-289 and equisetin) as a probe. 
 
Of the 22 TA-289 resistant mutants, five were cross-resistant to equisetin. Of the 21 
equisetin resistant mutants, six were cross-resistant to TA-289 (a score of >2 was 
deemed resistant, where a score of 4 was considered strong resistance. See appendix 
2.1 for table of scores and figure of mutants) (Figure 3.3). When tested under 
different stress conditions, six of the 43 mutants displayed differential sensitivity 
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compared to the parental strain pdrΔ when galactose (Gal) or glycerol-ethanol (Gly-
EtOH) was used as a carbon source. One mutant, EQ2, did not grow in Gal or Gly-
EtOH at 25 °C and 37 °C, but was sensitive only to Gly-EtOH at 30 °C. No mutants 
displayed altered sensitivity to CYH or DTT at any tested temperatures (Table 3.1).    
 
Figure 3.3. TA-289 and equisetin resistant mutants. This Venn diagram illustrates the number of 
mutants generated from either spontaneous mutations or from EMS-induced mutations resistant 
to TA-289 and equisetin, as well as the cross-resistant mutants. 
 
 
Table 3.1. Table describing resistant mutants that display differential sensitivity under varying 
stress conditions compared to the parental strain. Growth/no growth in each condition was 
determined by scoring either a 0 (normal growth), or 1 (no growth) for each mutant. Each score 
of 1 indicates sensitivity to the particular condition compared to parental growth. An overall 
score indicates sensitivity of each mutant to the conditions tested. 
103 
 
3.6.2 Mutation in TA8 is dominant 
Almost all but 4 mutants displayed only transient resistance, and so lost resistance to 
TA-289 and/or equisetin over time. One mutant, TA8, was chosen for further study 
as it displayed strongest resistance and was not as slow-growing as the other 
mutants. TA8 did not display cross-resistance to equisetin, nor was it sensitive in any 
of the conditions tested. To determine whether the mutation in TA8 is dominant or 
recessive, TA8 was mated to an isogenic wild-type strain YCG387 (see appendix 2.2), 
and both haploid and heterozygous diploid strains were tested with 60 µM TA-289, 
the concentration that was originally used for resistant mutant generation. The 
heterozygous diploid mutant was not growth inhibited by TA-289, suggesting that 
the mutation in TA8 is dominant (Figure 3.4). 
 
Figure 3.4. Mutation in TA8 is dominant. TA8 (A), the corresponding heterozygous diploid (B), 
the parental wt haploid strain used to generate the resistant mutant (C), the isogenic wt haploid 
strain used to mate with TA8 (D), and the corresponding wt heterozygous diploid (E) were 
serially diluted four-fold and spotted onto 60 µM TA-289. 
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3.6.3 Proof-of-principle C-SGAM with microarray 
A pilot C-SGAM with a microarray step at the final was conducted using a CYHr 
mutant. C-SGAM with this mutant was successfully performed by Ploi Yibmantasiri 
(School of Biological Sciences, Victoria University of Wellington), however 
measuring growth alterations from pooled deletion mutants in competitive growth 
assays using the microarray method at the end of the SGA procedure is novel. The 
CYHr mutant was chosen because the locus of resistance is known (rpl28Q208L), 
allowing us to identify it both on the agar plates as well as in the microarray. A 
linkage disequilibrium pattern was indeed visible on the expected location in the 
SGA, where non-essential genes in linkage disequilibrium with RPL28 (YGL103W) 
show a pattern of growth defect, with the greatest growth defects occurring in genes 
directly adjacent to the locus of RPL28. (Figure 3.5).  
 
Figure 3.5. Linkage disequilibrium pattern around RPL28 locus. Yellow circles show linkage 
pattern, where the genes adjacent to RPL28 (red squares), YGL104C and YGL101W showed the 
greatest growth defect. 
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This linkage pattern was not observed in the microarray growth assay. Strains 
deleted for genes in linkage disequilibrium with RPL28 were expected to be under-
represented (the more negative the log2 ratio value, the more under-represented a 
given gene) compared to the control, however the log2 ratio of the fluorescence 
intensities of both up (UP) and down (DN) tags of the open reading frames (ORF) of 
genes adjacent to RPL28 (YGL104C and YGL101W) showed no difference in 
intensity compared to the rest of the deletion strains identified in the microarray 
(figure 3.6). 
 
Figure 3.6. A close-up view of neighbouring genes to RPL28. Log2 ratios of both UP and DN tags 
of the chromosome region corresponding to RPL28 and its neighbouring genes are plotted. 
Genes adjacent to RPL28, YGL101W and YGL104C (green boxes) are as noted. Neighbouring 
genes along the chromosome are also noted in black. 
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3.6.4 TA8 mutant displays resistance by upregulating anti-oxidant production 
In combination with the results from chapter two indicating a possible target at the 
mitochondria for TA-289 and equisetin, and also from previously reported activities 
suggesting that equisetin acts on the mitochondrial respiratory chain (König, Kapus 
et al. 1993), an involvement of reactive oxygen species (ROS) was thought to be a 
likely possibility. Thus, the TA8 mutant was tested for its ability to grow in the 
presence of TA-289 and equisetin under different carbon sources, as well as the level 
of intracellular ROS production of the mutant. The oxidant-sensitive fluorescent dye 
2,7-dichlorofluoroscein diacetate (DCF) was used to quantitatively measure ROS 
production within a cell. Propidium iodide was used as a counter stain to detect cells 
with compromised cell membranes, often indicated as dead cells. H2O2 treatment 
served as a positive control for ROS production. Interestingly, untreated TA8 
mutant cells displayed a higher basal level of ROS production than the untreated 
pdrΔ parental cells, and also displaying more ROS production in an untreated state 
compared to when pdrΔ cells were treated with H2O2 (Figure 3.7). 
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Figure 3.7. TA8 mutant displays a higher basal level of ROS production. pdrΔ cells were either 
treated with 1 mM H2O2 (top right: pdrΔ 1 mM H2O2), or left untreated (Top left: pdrΔ 
untreated), and the TA8 mutant untreated (Bottom left: TA8), were stained with DCF (x-axis) to 
detect ROS, and co-stained with propidium iodide (y-axis) to detect dead cells. Cell populations 
were gated according to the untreated pdrΔ control. The pink arrow highlights the increase in 
ROS level observed in the TA8 mutant under normal untreated conditions. 
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As it was suggested that the resistance of the TA8 mutant to TA-289 was due to its 
higher basal level of ROS production, and thus presumably an overall greater 
antioxidant capacity, a cell death assay of the TA8 mutant treated with varying 
concentrations of a known oxidant H2O2 was performed to truly determine whether 
this was a specific mutation or a non-specific mutation that allows for the mutant to 
be resistant to different oxidants. Figure 3.8 shows that TA8 is resistant to H2O2 even 
at the highest concentration (9 mM), while the parental pdrΔ cells were much more 
sensitive.  
 
Figure 3.8. TA8 is resistant to H2O2. TA8 (A) and pdrΔ (B) cells were treated with varying 
concentrations of H2O2 (y-axis) with glucose as a carbon source and incubated at 30 °C for 3 h. 
An aliquot of cells treated at each concentration were spotted onto SC plate every 30 mins (x-
axis) and incubated for 2 days at 30 °C. 
 
 
This suggests that the mechanism of resistance of the TA8 mutant to TA-289 is a 
result of a non-oxidant specific mutation that caused an overall higher production of 
ROS, and thus an overall upregulation of anti-oxidants to adapt to the ROS 
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production within the cell, and more importantly, ROS induced by TA-289 or other 
oxidants such as H2O2. Interestingly, TA8 was more sensitive to H2O2 when glycerol-
ethanol was used as a carbon source compared to the pdrΔ parental strain (Figure 
3.9), suggesting a possible threshold of antioxidant capacity that may be a result of 
the resistance-conferring mutation. 
 
Figure 3.9. TA8 is more sensitive to H2O2 under respiratory conditions. TA8 (A) and pdrΔ (B) 
cells were treated with varying concentrations of H2O2 (y-axis) with glycerol-ethanol as a carbon 
source and incubated at 30 °C for 2.5 h. An aliquot of cells were spotted every 30 mins (x-axis) 
after an hour into H2O2 treatment and incubated for 2 days at 30 °C.  
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3.7 Discussion 
 
3.7.1 Resistant mutant generation 
The generation of resistant mutants for drug target identification has been 
successfully established in S. cerevisiae due to its genetic tractability and ease of 
manipulation. In many drug mode-of-action studies, resistant mutant generation has 
been an integral part in determining the target of a compound of interest. In this 
study resistant mutant generation was chosen as a method to aid in determining the 
modes-of-action of TA-289 and equisetin. Resistant mutants were generated by both 
spontaneous mutations and by treatment with a mutagen, EMS. Out of 43 resistant 
mutants isolated (22 TA-289-resistant and 21 equisetin-resistant mutants), only four 
displayed true resistance, while all other mutants displayed transient resistance to 
TA-289 and equisetin. The strongest resistant mutant, TA8, was chosen for further 
characterization. The resistance-conferring mutation in TA8 was found to be 
dominant. Dominant mutations suggest a gain-of-function in the protein product, 
such as where a cell is resistant as a result of an upregulation in multi drug resistance 
pumps. 
 
Subsequently, TA8 also displayed a higher basal level of ROS compared to the 
parental strain (pdrΔ) used to generate the resistant mutants. Moreover, when tested 
against a known oxidant, H2O2, TA8 displayed resistance at the highest 
concentration tested (9 mM). This indicated a possible mechanism by which TA8 
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displays resistance to TA-289 was by upregulating its antioxidant capacities, as the 
mutant produces a higher basal level of ROS. The mitochondrion is a major source 
of ROS production. ROS are generated as a consequence of the mitochondrial 
respiratory chain, i.e. the ETC (electron transport chain), where these free radicals 
cause extensive damage to proteins, DNA, and other cellular components. For a cell 
that is unable to detoxify the ROS induced, prolonged exposure will ultimately lead 
to cell death (Sies 1985; Salmon, Evert et al. 2004). Moreover, abnormal 
mitochondrial function has been shown to cause an elevation of endogenous ROS 
(Perrone, Tan et al. 2008)(this will be further discussed in chapter 4). If the target of 
TA-289 and equisetin is at the mitochondria, it is possible that treatment with both 
compounds cause disruption to mitochondrial function, leading to elevated ROS, 
and cell growth inhibition. As such, a mutant resistant to TA-289 can be resistant 
simply by up-regulating its ability to detoxify the ROS induced by the compound. 
This is observed in the ROS-detection assay where the TA8 resistant mutant displays 
a higher level of ROS, and thus presumably, a higher level of antioxidant capacity 
also. This allows the mutant to become resistant to TA-289, and other oxidants, such 
as H2O2. 
 
Additionally, the gain-of-function mutation provides an explanation to the 
dominant characteristics of the resistance-conferring mutation of TA8, and also 
possibly why the majority of the resistant mutants isolated only displayed transient 
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resistance. Interestingly, when glycerol-ethanol is used as a carbon source for the 
cell death assays, TA8 was more sensitive to H2O2 treatment compared to the pdrΔ 
parental strain. It is possible that while TA8 produces more ROS naturally when 
glucose is the carbon source (i.e. under fermentative conditions), and therefore has 
higher antioxidant capacities. However under respiratory conditions, where ROS 
production is often elevated due to respiration, the resistance-conferring mutation 
in TA8 may prevent the normal adaptive response that would otherwise be observed 
in wild-type cells, wherein a threshold for upregulation of antioxidant capacities is 
reached in the case of the TA8 mutant. 
 
3.7.2 Mapping the resistance-conferring mutation 
One of the many advantages that studies using S. cerevisiae benefit from is the 
availability of tools that are available for high-throughput genome-wide analysis. 
The yeast genome deletion sets are exploited in a variety of ways to discover genetic 
and physical interactions, and for this study in particular, to probe for drug mode-of-
action. One feature of the deletion set is the addition of a unique barcode to every 
gene deletion, thus allowing identification by PCR amplification and hybridization 
to DNA microarrays. The development of DNA microarrays enables genome-wide 
analysis offered by the SGA methodology, but the assessment of fitness levels of 
thousands of genes may be performed in parallel. This method monitors whole gene 
expression pooled into a single tube, compared to the 14-plate array format in SGA 
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analysis, thus this method requires much less drug to determine competitive fitness 
and functional networks. This approach takes advantage of the unique barcodes 
generated for each yeast ORF to analyse the barcode representation in each 
population. This provides a measure of relative fitness and identifies any synthetic 
interactions (Boone, Bussey et al. 2007). 
 
Moreover, as the data obtained from microarray analysis can be arrayed according to 
chromosomal location (as they are so arrayed on plates for the SGA), it may 
therefore be possible to identify linkage patterns on a microarray chip. By 
combining the C-SGAM method as described in the introduction of this chapter, 
with the microarray method to analyse drug-target interactions wherein all mutants 
are pooled at the haploid selection step of the C-SGAM and drug-treating them in 
parallel (Figure 3.10), en masse, there is a significant reduction on the amount of 
drug needed. This is a considerable advantage, and is exemplified in the case where 
there is limited amount of drug to study first hand; often with natural product 
compounds, quantity is heavily limited. Figure 3.10 (adapted from (Boone, Bussey et 
al. 2007)) illustrates the main principle of the method. 
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Figure 3.10. Parallel analysis by DNA microarray for resistance mapping. Populations of pooled 
mutant cells from the haploid xxxΔ selection in the C-SGAM methodology, each marked with 
unique molecular barcodes, are grown in the presence or absence of both G418 and the drug of 
interest (in this case, TA-289). Genomic DNA is purified, and barcodes that represent each strain 
are amplified by PCR using common primers labelled with fluorescent markers Cy3 (control 
marker) or Cy5 (drug treatment marker). Competitive hybridization of the barcode PCR 
products on to a microarray chip that contains corresponding oligonucleotides determines drug 
sensitivity of each mutant strain. This gives a quantitative read-out of the representation of each 
mutant in a mixed population, wherein a linkage disequilibrium pattern is identified by 
fluorescence intensity on the microarray chip. 
 
Unfortunately, while the microarray method requires less drug, a major 
disadvantage is that by pooling of a large number of mutants and relying on 
fluorescence intensities, background noise within the system can result in an assay 
that is too insensitive to discern enough relative growth differences required to 
identify the mutant series comprising the linkage group. Additionally, 
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methodologies used in the microarray protocol, such as genomic DNA purification 
and PCR amplification of the gene tags are sources of variation, all of which will 
undoubtedly affect the outcome of the microarray data. The loss of some data as a 
result of this is compensated to some extent, (to standard chemical genomic profiling 
screens) as most likely there will always be functionally related genes that will be 
identified. However, in the case where the identification of a specific pattern relies 
on a handful of genes located on a particular chromosome, strong signalling from the 
fluorescent oligonucleotide tags become increasingly important. 
 
Unlike the pilot C-SGAM study where this method was employed to map a known 
resistance-conferring mutation (rpl28Q208L), a distinct linkage disequilibrium 
pattern was unidentifiable when mapping using the DNA microarray method (this 
pattern was identified in the C-SGAM on plate format, indicating that a pattern of 
linkage around the locus of resistance was achieved). In the microarray growth 
assay, the expected under-representation of neighbouring genes to RPL28 was not 
observed (as highlighted by figure 3.6.). Nevertheless, further optimization of the 
microarray method may allow for a more successful approach to mapping by 
microarray. 
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Since the C-SGAM procedure requires a substantial amount of drug to map the 
resistance-conferring mutation (a problem that the unsuccessful mapping by 
microarray method was designed to skirt-around), and as the quantity of TA-289 
was limited, another approach of identifying growth conditions in lieu of sufficient 
quantities of drug can be employed to map the resistance-conferring mutation of the 
TA8 mutant. As the TA8 mutant also displayed resistance to H2O2, H2O2 was selected 
as a condition to map the resistance-conferring mutation of TA8 by the normal C-
SGAM method. Unfortunately, the TA8 mutant seems to either lack the ability to 
sporulate, or is poor at sporulating under the necessary SGA conditions. Thus the 
“conditions” approach for mapping of the resistance-conferring mutation of the TA8 
mutant may be more successful with further optimization to aid in the sporulation 
step of the SGA. 
 
Evidently, given the differences in the ability to kill or irreversibly inhibit growth in 
glucose and in glycerol, i.e. TA-289 and equisetin seem to kill yeast quickly in 
glucose, but cells do not die with treatment of these compounds in glycerol (as 
observed in figures 2.14 and 2.15), it is not surprising that the resistant mutant 
generated in this study displayed resistance most likely by preventing the triggering 
of cell death, rather than resistance at the actual drug target. The TA8 mutant 
exhibited a higher level of basal ROS compared to the parental strain, which 
indicates that its level of antioxidant capacity is also elevated under normal 
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physiological conditions. This suggests that up-regulation of antioxidant capacity 
allows the TA8 mutant to prevent the induction of cell death by TA-289. A more 
successful approach at finding a resistance-conferring mutation may be through 
selecting resistant mutants in glycerol. In glucose, TA-289 and equisetin potently 
kill pdrΔ cells, presumably because of a combination of two factors; 1) pdrΔ cells 
lack an efficient efflux pump network to expel the compounds, and 2) in glucose, 
there is low level of respiration, and as such, low level of antioxidant capacity. 
However as observed in chapter two (figure 2.15), in glycerol, pdrΔ cells were more 
resistant, again, presumably because when cells are actively fermenting, antioxidant 
capacities are up-regulated, which are enough to counteract the effects of TA-289 
and equisetin even when they are efflux pump-compromised. This suggests that 
respiring cells are more resistant to killing by TA-289 and equisetin due to the up-
regulation of antioxidant capacity, and are able to adapt to the stress caused by these 
compounds. Additionally, in the case where TA-289 and equisetin do target the 
mitochondria, the target(s) will become more essential under respiratory conditions, 
and it is assumed that mutation in the target(s) will provide strongest resistance to 
the compounds. Therefore, under respiratory conditions, it is less likely that a 
mutant conferring resistance to the compounds will be resistant simply by 
preventing apoptosis (as observed in the TA8 mutant isolated in this chapter), and as 
such the mutation may be more associated with the mechanism of TA-289 and 
equisetin, and upon further optimization of microarray techniques, the resistance-
conferring mutation may be mapped. 
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4. REACTIVE OXYGEN SPECIES IN Saccharomyces cerevisiae 
 
4.1 The role of mitochondria in the production of reactive oxygen 
species 
Reactive oxygen species (ROS) are reactive agents produced as a result of the 
respiratory and metabolic processes in all aerobically growing organisms and 
microorganisms. These reactive agents include free radicals and peroxides such as 
superoxide anions (·O2-), hydroxyl radicals (·OH), hydrogen peroxide (H2O2), alkoxy 
(RO·) and peroxy (ROO·) radicals, the accumulation of which results in oxidative 
stress (Sies 1985; Rice-Evans 1995). Oxidative damage caused by intracellular ROS 
leads to significant deleterious damage to cellular components such as proteins, 
lipids, and DNA (Salmon, Evert et al. 2004). 
 
Mitochondria are a major source of endogenous ROS, the production of which stems 
from leakage of electrons from within the mitochondrial respiratory electron 
transport chain (ETC), resulting in the generation of ROS. The ETC comprises four 
complexes (complex I–IV) and F0-F1 ATP-synthase (sometimes referred to as 
complex V) present in the inner mitochondrial membrane (IMM). Complexes I-IV 
transfer electrons from donors (such as NADH (reduced nicotinamide adenine 
dinucleotide)(complex I; NADH dehydrogenase) and succinate (complex II; 
succinate dehydrogenase)) to the terminal acceptor oxygen (O2), and the protons 
(H+) released into the intermembrane space by complexes I, III (bc1 complex, 
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cytochrome c reductases), and IV (cytochrome c oxidase), are used by ATP-synthase 
to convert ADP (adenosine diphosphate) to ATP (adenosine triphosphate). This 
charge distribution is known as the mitochondrial transmembrane potential (ΔΨm), 
and is required for the synthesis of ATP (Ricci, Waterhouse et al. 2003) (Figure 4.1). 
 
Figure 4.1. A simplified model of the mitochondrial ETC and ROS production. Electrons (e-) 
enter the ETC via complex I and II. Complex I uses the conversion of NADH to NAD+, while 
complex II, the conversion of succinate to fumarate to transfer e- from coenzyme Q (Q) to 
ubiquinone (UQ), which then passes e- to complex III. Cytochrome C (Cyt c) transfers e- from 
complex III (bc1 complex, cytochrome c reductase) to complex IV (cytochrome c oxidase), 
which on acceptance of the e-, converts H+ and O2 into H2O. All complexes except for complex 
II pump protons (H+) into the intermembrane space. This charge distribution (ΔΨm, the 
mitochondrial transmembrane potential) is used by ATP-synthase (complex V) to convert ADP 
into ATP. ROS is mainly produced by complexes I and III during this process (Ricci, Waterhouse 
et al. 2003). 
 
 
Complexes in the ETC thought to be responsible for most of the ROS production 
include the redox-cycling ubiquinone complex III, and complex I, where 
hyperpolarization of the mitochondrial transmembrane potential (ΔΨm) results in 
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reverse electron transfer (Turrens, Alexandre et al. 1985; Kushnareva, Murphy et al. 
2002; Ricci, Waterhouse et al. 2003), and complex II (succinate dehydrogenase) 
(Zhang, Yu et al. 1998) has also been previously shown to be a source of ROS. 
 
In the event of premature electron leakage to oxygen, the ROS superoxide anion  
·O2-, in particular is generated. The detoxification of superoxide by the antioxidant 
enzymes superoxide disumutases (Gralla, Kosman et al. 1992) produces H2O2, which 
can readily cross most biological membranes. The most deleterious effects arise 
when H2O2 is converted to the highly reactive hydroxyl radical, which in contrast to 
the superoxide anion reacts indiscriminately with most macromolecules within the 
cell, often producing more free radicals in the process (Perrone, Tan et al. 2008). 
Hydroxyl radicals are generated through the catalysis of superoxides and H2O2 by 
transition metal ions such as Fe2+ (via the Fenton-Haber Weiss reaction (Haber and 
Weiss 1932; Koppenol 2001)). This process is cyclic, reinitiated each time by the 
superoxide anion (Halliwell 1995; Temple, Perrone et al. 2005; Perrone, Tan et al. 
2008). For a cell that is unable to maintain its redox state and ion homeostasis, this 
detrimental event will eventually lead to cell death (Madeo, Carmona-Gutierrez et 
al. 2009; Tan, Teo et al. 2009). 
 
There are a few key factors that affect mitochondrial ROS production and oxidative 
damage to the cell as a result. It has been well established in a number of eukaryotic 
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organisms that mitochondrial respiratory capacity and mitochondrial inner 
membrane potential play significant roles in the degree of ROS generation (Perrone, 
Tan et al. 2008). Hyperpolarization of the mitochondrial inner membrane leads to 
disruption of the mitochondrial transmembrane potential (ΔΨm), and as a result of 
this, increased ROS production (Machida and Tanaka 1999). Mutations and/or small 
molecule inhibitors that impair the ETC in S. cerevisiae have been associated with 
elevated ROS production, of which the magnitude of ROS production is dependent 
on the nature of the disruption to the mitochondrial respiratory capacity (Barros, 
Netto et al. 2003).  
 
4.2 Mitochondrial ROS production and yeast apoptosis 
Mitochondria-mediated cell death often arises through loss of mitochondrial 
function; collapse of the ΔΨm, mitochondrial fragmentation and/or swelling, and 
release of cytochrome c from the inner mitochondrial membrane (IMM) to the 
cytosol. This is the case for drug-induced cell death by amiodarone, where the 
compound increases cytostolic Ca2+, causing hyperpolarization of the ΔΨm, and 
induction of ROS from complex III of the ETC leading to an eventual collapse of the 
ΔΨm, and cytochrome c release (Pozniakovsky, Knorre et al. 2005). Alternatively, 
cell death can occur through the translocation of mitochondrial endonucleases such 
as apoptosis-inducing factor AIF1 to the nucleus, where it mediates chromatin 
condensation and DNA degradation (Madeo, Carmona-Gutierrez et al. 2009). 
Exposure to oxidant H2O2 causes ROS generation, leading to the induction of AIF1 
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in programmed cell death (Madeo, Frohlich et al. 1999). In both cases, the induction 
of ROS has been implicated as an important up-stream component in mediating 
programmed cell death. In the case where cell death occurs through mitochondrial-
mediated apoptosis, ROS generation is almost always present. However, the 
mechanisms by which ROS generation mediate the triggering of apoptotic effectors 
is not fully understood, and additionally, the challenge also remains in defining the 
exact site of ROS production (Perrone, Tan et al. 2008).  
 
4.3 Inhibitors of the electron transport chain and the generation of 
reactive oxygen species 
Many biologically active compounds that cause cell death in yeast do so via 
mitochondrial pathways, including ETC inhibitors such as the complex I-inhibitor 
rotenone (Ramsay, Krueger et al. 1991), the complex II-inhibitors atpenins 
(Miyadera, Shiomi et al. 2003), the complex III-inhibitors antimycin A (Chen, 
Vazquez et al. 2003; Lai, Zhang et al. 2005) and myxothiazol (Thierbach and 
Reichenbach 1981; Thierbach and Michaelis 1982), the complex IV-inhibitor 
potassium cyanide (KCN) (Delhumeau, Cruzmendoza et al. 1994), and the complex 
V-inhibitor oligomycin (Bertina, Steenstra et al. 1974). Paraquat is a compound that 
acts as an alternative terminal acceptor at complex IV, becoming a free radical itself 
and causing damage in that way (Cocheme and Murphy 2008) (figure 4.2). 
Notably, while it may be presumed that inhibition of any one complex causes 
disruption to its function and thus ROS production at that site, it is not necessarily 
124 
 
the case. Complex I inhibitor rotenone for example, causes ROS production 
proximal to the rotenone binding site, thought to be located between flavin 
mononucleotide (a co-chaperone of NADH dehydrogenase (Rao, Mackler et al. 
1963)) and the binding site of rotenone. Additionally, ROS generation caused by 
certain ETC inhibitors can be alleviated by a compound that inhibits the ETC up-
stream of the binding site, as it was in the case of edelfosine (Zhang, Gajate et al. 
2007), and farnesol (Machida, Tanaka et al. 1998), whose inhibitory effects leading 
to the generation of ROS were perturbed by rotenone. Furthermore, inhibition at 
any complex of the ETC does not always result in stimulation of ROS production, 
namely superoxide anions, by the target complex. ROS accumulation and/or 
production are dependent upon the site at which the inhibitor targets. Take for 
example complex III inhibitors antimycin A, and myxothiazol. The production of 
unstable semiquinones at complex III during oxidation of coenzyme Q quinol 
molecules has been suggested to be the major source of superoxide anion production 
at this complex (figure 4.2). 
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Figure 4.2. A simplified model of the Q-cycle at complex III and the mechanism of superoxide 
production. Complex III oxidises coenzyme Q quinol (QH2), the cycle of which is known as the 
Q-cycle. The first step involves oxidation of QH2 at the Q0 site, in which an electron (e-) is 
transferred to the iron-sulfur protein (ISP), cytochrome c 1 (Cyt c 1), and cytochrome c (Cyt c), 
which then passes it along to the next complex in the ETC, cytochrome c oxidase (complex IV, 
not shown in this figure). This oxidation of QH2 to transfer an e- down the ETC creates an 
unstable semiquinone (Q0·-), which donates an e- through conducting pathways from the Q0 site 
to the Qi site. At the Qi site, a coenzyme Q molecule (Q) is reduced by the donated e- into QH2, 
and the cycle begins again. The sites of inhibition by antimycin A and myxothiazol are as 
illustrated (Andreyev 2005). 
 
Antimycin A inhibits the electron transfer of the unstable semiquinone to the site 
where it is reduced to a quinol molecule, causing an accumulation of unstable 
semiquinone molecules and thus promoting superoxide anion production (Lai, 
Zhang et al. 2005). On the other hand, myxothiazol acts at the Q0 site of complex III, 
preventing formation of the unstable semiquinone, and this inhibition at complex III 
of the ETC has indeed been shown to reduce superoxide production (Thierbach and 
Reichenbach 1981; Turrens, Alexandre et al. 1985; Korshunov, Skulachev et al. 
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1997). Notably, while myxothiazol inhibits superoxide production by complex III, it 
has been shown to stimulate H2O2 production at a site distal to its binding site in 
complex III (Starkov and Fiskum 2001). Hence, ROS production can still occur even 
when an ETC inhibitor such as myxothiazol prevents superoxide production. In the 
cases where ROS is produced, the challenge remains in determining the site of ROS 
production; as described previously, ROS production can occur up-stream or down-
stream of the binding site, and is also dependent on the type on inhibition. 
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4.2 Aims and objectives 
The aim of this chapter was to determine whether TA-289 and equisetin cause cell 
death by ROS production in yeast, and whether the production originates from 
within the mitochondria. This will include: 
 In vivo detection of ROS 
 Assessment of mitochondrial activity and morphology 
 
Part of this study involved testing a select number of gene deletions hypothesised to 
be potential targets of TA-289 and equisetin. 
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4.3 Materials and methods 
 
4.3.1 Yeast strains 
All S. cerevisiae strains used in this study are as follows: * this mutant and the 41 
following = mutants used in this study from the yeast gene deletion set. 
Strain Genotype 
YCG100 (BY4741) MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 
YCG289 (yeGFP) 
MATα can1Δ::STE2p_LEU2; lyp1Δ; his3Δ1 leu2Δ0 
ura3Δ0 met15Δ0 
YCG326 (pdrΔ) 
MATα pdr1Δ::NAT pdr3Δ::URA3 can1Δ::STE2pr-
Sp_his5; lyp1Δ; his3Δ1 leu2Δ0 ura3Δ0 met15Δ0 LYS2+ 
YCG387 
MATa pdr1Δ::kanR pdr3Δ::URA3; his3Δ1 leu2Δ0 
URA3Δ0 met15Δ0 
YOR356W (Cir2p-
GFP) 
Derived from BY4741 
*aac1Δ Derived from BY4741; aac1Δ::kanR 
aac3Δ Derived from BY4741; aac3Δ::kanR 
atp1Δ Derived from BY4741; atp1Δ::kanR 
atp5Δ Derived from BY4741; atp5Δ::kanR 
aco1Δ Derived from BY4741; aco1Δ::kanR 
aco2Δ Derived from BY4741; aco2Δ::kanR 
aif1Δ Derived from BY4741; aif1Δ::kanR 
ctt1Δ Derived from BY4741; ctt1Δ::kanR 
dic1Δ Derived from BY4741; dic1Δ::kanR 
mir1Δ Derived from BY4741; mir1Δ::kanR 
odc1Δ Derived from BY4741; odc1Δ::kanR 
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odc2Δ Derived from BY4741; odc2Δ::kanR 
pic2Δ Derived from BY4741; pic2Δ::kanR 
sfc1Δ Derived from BY4741; sfc1Δ::kanR 
por2Δ Derived from BY4741; por2Δ::kanR 
mca1Δ Derived from BY4741; mca1Δ::kanR 
rad9Δ Derived from BY4741; rad9Δ::kanR 
sod1Δ Derived from BY4741; sod1Δ::kanR 
sod2Δ Derived from BY4741; sod2Δ::kanR 
ura1Δ Derived from BY4741; ura1Δ::kanR 
gpd1Δ Derived from BY4741; gpd1Δ::kanR 
gpd2Δ Derived from BY4741; gpd2Δ::kanR 
gut2Δ Derived from BY4741; gut2Δ::kanR 
coq1Δ Derived from BY4741; coq1Δ::kanR 
coq2Δ Derived from BY4741; coq2Δ::kanR 
cor1Δ Derived from BY4741; cor1Δ::kanR 
cox5AΔ Derived from BY4741; cox5AΔ::kanR 
cox6Δ Derived from BY4741; cox6Δ::kanR 
cox7Δ Derived from BY4741; cox7Δ::kanR 
cox9Δ Derived from BY4741; cox9Δ::kanR 
cyt1Δ Derived from BY4741; cyt1Δ::kanR 
pet122Δ Derived from BY4741; pet122Δ::kanR 
pet494Δ Derived from BY4741; pet494Δ::kanR 
nde1Δ Derived from BY4741; nde1Δ::kanR 
qcr2Δ Derived from BY4741; qcr2Δ::kanR 
qcr6Δ Derived from BY4741; qcr6Δ::kanR 
qcr7Δ Derived from BY4741; qcr7Δ::kanR 
130 
 
qcr8Δ Derived from BY4741; qcr8Δ::kanR 
rip1Δ Derived from BY4741; rip1Δ::kanR 
sdh1Δ Derived from BY4741; sdh1Δ::kanR 
sdh2Δ Derived from BY4741; sdh2Δ::kanR 
emi5Δ Derived from BY4741; emi5Δ::kanR 
 
4.3.2 Growth media 
All yeast cultures were performed in one of the following media as prescribed 
previously, supplemented with either G418 (200 µg/mL final concentration) or NAT 
(100 µg/mL final concentration), unless otherwise stated. 
 
4.3.3 Compounds and chemicals 
Purchased from Invitrogen NZ Ltd (Auckland, NZ): MitoTracker® Green FM at a 
working stock of 20 mM prepared in DMSO and stored in the dark at –20 °C. 
Purchased from Sigma-Aldrich Life Science and Biochemicals: Propidium iodide at a 
working stock concentration of 10 mg/mL prepared in ddH2O and stored in the dark 
at 4 °C, 2,7-dichlorofluorescein diacetate (DCF) at a working stock of 1 mM prepared 
in DMSO and stored in the dark at –20 °C, rapamycin at a working stock 
concentration of 0.4 mg/mL prepared in DMSO and stored at –20 °C, hydrogen 
peroxide (H2O2) at a working stock concentration of 0.9 M prepared in ddH2O and 
stored in the dark at 4 °C. 
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4.3.4 Detecting reactive oxygen species by flow cytometry 
Cell concentrations of overnight cultures of pdrΔ were determined by measuring 
OD at 600 nm, and subsequently diluted to 1 x 107 cells/mL in fresh SC media. pdrΔ 
cells were treated with either TA-289 or equisetin (100 µM final concentration) and 
incubated for either 30 mins or 60 mins at 30 °C. H2O2 (1mM final concentration) 
served as a positive control. The procedure for DCF-staining and visualization were 
carried out as per chapter three method 3.4.11. 
 
4.3.5 Detecting mitochondrial activity by flow cytometry 
Briefly, cell concentrations of overnight cultures of wt and pdrΔ were determined 
by measuring OD at 600 nm and subsequently diluting in SC to given final cell 
concentrations of 1 x 107 cells/mL, and divided into 100 µL aliquots in sterile 
microcentrifuge tubes. Cells were treated with either 25 µM or 50 µM TA-289 and 
equisetin, mixed by brief vortexing, and incubated at 30 °C for 1 h. DMSO (1% final 
concentration) served as a carrier control. After 15 mins into treatment, cells were 
stained with MitoTracker® Green FM (200 nm final concentration) and then further 
incubated. Cells were then collected by centrifugation, washed, and resuspended in 
100 µL SC. 
For flow cytometry analysis of mitochondrial staining by MitoTracker of wt and 
pdrΔ, cells were diluted with 400 µL ddH2O, kept on ice and co-stained with 6 
µg/mL propidium iodide prior to visualizing. Flow cytometry data obtained was 
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analysed on FlowJo version 7.6.1 flow cytometry analysis software (Tree Star Inc., 
Ashland, OR 97520). 
 
4.3.6 High-throughput visualization of mitochondria 
Briefly, an overnight culture of YOR356W (a Cir2p-GFP fusion protein expressing 
strain; Cir2p-GFP has been previously shown to localize in the mitochondria and is 
highly expressed (Huh, Falvo et al. 2003).) was diluted to 1x107 cells/mL in either 
fresh SC media, or SC-gly-EtOH, from which 100 µL aliquots were transferred into 
sterile microcentrifuge tubes. Cells were then treated with either TA-289 (50 µM 
final concentration), or equisetin (50 µM final concentration). DMSO (1% final 
concentration) served as a carrier control. The cells were mixed by brief vortexing, 
and then incubated for 1 h at 30 °C. Photographs of the treated and untreated cells 
were taken 30 mins into the incubation, and again at the end of the incubation. In 
preparation for visualization of mitochondria morphology, 50 µL aliquots of treated 
and untreated cells were dispensed into microplates and visualized using the Opera® 
confocal microplate imaging reader (PerkinElmer Inc, CA, USA). 
 
4.3.7 Liquid dose-response assays 
All liquid dose-response assays were prepared as per methods previously described 
in chapter two (method 2.4.5) for dose-response of BY4742 (wt) and pdrΔ cells to 
TA-289 and equisetin. 
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For dose-response assays conducted using glucose as a carbon source, see chapter 
two (method 2.4.5). The plate was incubated for three days at 30 °C, and cell density 
was measured on day three. 
For dose-response assays conducted using glycerol-ethanol as a carbon source, 
glycerol (2% final concentration) and ethanol (2% final concentration) were added 
to fresh SC media instead of glucose. In addition, 100 µL of ddH2O was added to all 
other wells that did not contain experimental samples, to prevent the experimental 
wells from drying out. The plate was kept in a plastic sleeve and incubated for six 
days at 30 °C, taken out each day and mixed vigorously before placing back into the 
incubator. Optical density was measured (590 nm) on day six. 
For dose-response assays in the presence of 0.7 M NaCl, wells containing NaCl with 
no drug served as a solvent control. Plates were incubated at 30 °C for 24 h and cell 
density measured as per normal.  
 
4.3.8 Testing candidate gene targets 
A selection of deletion strains were grown overnight at 30 °C in YPD media in a 96-
well plate; aac1Δ, aac3Δ, atp1Δ, atp5Δ, aco1Δ, aco2Δ, aif1Δ, ctt1Δ, dic1Δ, mir1Δ, 
odc1Δ, odc2Δ, pic2Δ, sfc1Δ, por2Δ, mca1Δ, rad9Δ, sod1Δ, sod2Δ, ura1Δ, gpd1Δ, 
gpd2Δ, gut2Δ, coq1Δ, coq2Δ, cor1Δ, cox5AΔ, cox6Δ, cox7Δ, cox9Δ, cyt1Δ, pet122Δ, 
pet494Δ, nde1Δ, ndi1Δ, qcr2Δ, qcr6Δ, qcr7Δ, qcr8Δ, qcr10Δ, rip1Δ, sdh1Δ, sdh2Δ, 
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and emi5Δ. Cell concentration of each strain was determined by measuring OD at 
600 nm, and subsequently diluted to 1 x 107 cells/mL in fresh SC media. 
Deletion strains aac1Δ, aac3Δ, atp1Δ, atp5Δ, aco1Δ, aco2Δ, aif1Δ, ctt1Δ, dic1Δ, 
mir1Δ, odc1Δ, odc2Δ, pic2Δ, sfc1Δ, por2Δ, mca1Δ, rad9Δ, sod1Δ, sod2Δ, ura1Δ, 
gpd1Δ, gpd2Δ, and gut2Δ, and wt (BY4741) were treated with 50 µM TA-289 for 18 
h at 30 °C, after which cell density (OD 590 nm) was measured. Residual growth 
relative to wt was plotted and resistance/sensitivity of each strain was determined at 
1% significance. 
Deletion strains coq1Δ, coq2Δ, cor1Δ, cox5AΔ, cox6Δ, cox7Δ, cox9Δ, cyt1Δ, pet122Δ, 
pet494Δ, nde1Δ, ndi1Δ, qcr2Δ, qcr6Δ, qcr7Δ, qcr8Δ, qcr10Δ, rip1Δ, sdh1Δ, sdh2Δ, 
and emi5Δ, and BY4741 were treated with 15 µM, 30 µM, and 60 µM equisetin for 
18 h at 30 °C, after which cell density (OD 590 nm) was measured. Residual growth 
relative to wt was plotted and resistance/sensitivity of each strain was determined at 
1% significance.  
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4.4 Results 
 
4.4.1 TA-289 causes the production of reactive oxygen species 
Based on the mitochondrial hits attained from the chemical genomic profiling of 
TA-289 (chapter two, result 2.5.5), and as the resistant mutant generated in chapter 
three (result 3.6.4) displayed resistance by up-regulating antioxidant capacity, both 
TA-289 and equisetin were tested for their ability to increase the production of 
reactive oxygen species (ROS) in yeast. The oxidant sensitive fluorescent stain, DCF, 
was used to measure ROS production within cells. When DCF crosses the cell 
membrane, it is hydrolysed, and in the presence of ROS, oxidised to the highly 
fluorescent dichlorofluorescein (Wang and Joseph 1999). In this study, propidium 
iodide was also used as a counter stain to detect permeablized cells (which are 
presumably dead). The pdrΔ cells treated with TA-289 displayed a large increase in 
ROS production compared not only to the untreated control, but also to the positive 
control, H2O2, within 30 mins of treatment (Figure 4.3). 
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Figure 4.3. TA-289 causes production of ROS. pdrΔ cells were treated with TA-289 and 
equisetin, and stained with DCF (x-axis) to detect ROS and propidium iodide (y-axis) to detect 
dead cells. Cell populations were gated according to the untreated control. 
 
 
A large population of TA-289-treated cells were also positively stained for 
propidium iodide, suggesting that prolonged ROS production eventually leads to cell 
death; propidium iodide stains cells with damaged membranes, where cell wall 
permeability is an important characteristic for viable cells (Jones and Senft 1985). 
After 60 mins of TA-289 treatment, the population of cells producing ROS 
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decreased, while the percentage of propidium iodide-permeable cells increased, 
further indicating that cell wall permeablization occurs as a result of ROS 
production (Table 4.1). Almost all the cells treated with equisetin were propidium 
iodide-permeable within 30 mins, with only a very small population producing ROS. 
These observations indicate that TA-289 may cause cell death by inducing the 
production of ROS, and that both compounds display fast kinetics in that respect – 
this is especially so in the case for equisetin, mirroring the kinetics observed in the 
cell death assays (chapter two, result 2.5.6) (Figure 4.3, Table 4.1). 
Sample 
                         % Cell  
population 
Live ROS 
ROS and 
dying 
Dead 
Untreated 62.20 1.74 1.98 33.70 
100 µM TA-289, t30 16.30 2.82 35.90 42.30 
100 µM TA-289, t60 5.18 0.18 19.70 73.10 
100 µM EQ, t30 0.97 0.03 2.40 95.90 
100 µM EQ, t60 0.39 0.06 0.90 98.10 
Table 4.1. Table showing percentage of live, ROS, ROS and dying, and propidium iodide-
permeable cell populations. Untreated samples were compared to cells treated for 30 mins (t30) 
and 60 mins (t60) with TA-289 and equisetin. 
 
 
 
4.4.2 TA-289 and equisetin effect mitochondria and alter mitochondrial morphology 
Altered ROS production is often indicative of perturbed mitochondrial activity 
(Andreyev 2005; Sedensky and G. Morgan 2006). Cells treated with TA-289 and 
equisetin were stained with a fluorescent stain specific for mitochondria, and 
morphological changes assessed by flow cytometry. A leftward shift in fluorescence 
intensity of the mitochondrial stain, MitoTracker© Green FM, in wt cells treated 
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with TA-289 indicates a disruption in mitochondrial uptake of the stain, an effect 
that is more pronounced in pdrΔ cells. In cells treated with equisetin, stain uptake is 
significantly disrupted, with lower cell counts indicating a higher population of cell 
death in equisetin-treated cells compared to the less potent TA-289 (Figure 4.4).  
 
Figure 4.4. TA-289 and equisetin have an affect on mitochondria. wt (Top) and pdrΔ (Bottom) 
cells treated with 25 µM (orange line) and 50 µM (blue line) TA-289 and equisetin were stained 
with MitoTracker© Green FM and visualized. A shift in fluorescence intensity and a decrease in 
treated cell populations compared to the untreated controls (pink line) indicate that TA-289 and 
equisetin have an effect on the mitochondria. 
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Mitochondrial morphology was also assessed by confocal microscopy using a strain 
expressing a Cir2p-GFP fusion protein, which localizes to the mitochondria. 
Mitochondrial morphology was severely altered in equisetin-treated cells (Figure 
4.5.C) after 30 mins treatment compared to untreated controls (Figure 4.5.A). There 
was some morphological changes observed in TA-289-treated cells (Figure 4.5.B), 
though only slightly compared to that caused by equisetin. The slight peak observed 
in pdrΔ cells treated with equisetin (at 104 relative fluorescence unit, figure 4.4) 
displaying strong positive fluorescence intensity can be attributed to dying or dead 
cells readily taking up more MitoTracker stain and thus have on overall, higher 
fluorescent intensities. These results indicate that, in addition to the production of 
ROS, both TA-289 and equisetin are affecting mitochondria in a way that severely 
alters their morphology.  
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Figure 4.5.A. YOR356W (Cir2p-GFP) Untreated control cells. Normal mitochondrial 
morphology is displayed. Branched networks of mitochondria run along entire lengths of the 
cells. 
 
Figure 4.5.B. YOR356W (Cir2p-GFP) Cells treated with 50 µM TA-289. A slight difference in 
mitochondrial morphology is displayed. There are lesser amounts of normal branched networks 
of mitochondria, with more cells displaying diffused mitochondrial bodies across whole cells, 
and in some cells there are some slight punctate patterns (pink arrows) in a similar fashion to 
equisetin-treated cells. 
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Figure 4.5.C. YOR356W (Cir2p-GFP) Cells treated with 50 µM equisetin. Branched 
mitochondrial networks are completely obliterated. Mitochondrial formation is almost punctate-
like, diffused across whole cells. 
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4.4.3 High salt does not sequester potency of TA-289 and equisetin 
On the basis that a porin voltage-dependent channel might be involved in these 
mitochondrial effects, it was tested whether TA-289 and equisetin share a similar 
mechanism with SFK1, a putative Por1p (mitochondrial porin voltage-dependent 
anion channel) inhibitor (Butcher and Schreiber 2003). A dose response assay was 
performed with TA-289 and equisetin in the presence of high salt (0.7 M NaCl). As 
this concentration of NaCl slightly inhibits yeast cell growth, the assay was 
performed for 24 h instead of the standard 18 h. Unlike SKF1, which inhibits in the 
absence of salt but not in its presence, the potencies of neither TA-289 nor equisetin 
were sensitive to the presence of NaCl. In fact, the opposite was observed, where 
NaCl seemed to increase and/or prolong the potency of TA-289 and equisetin (Table 
4.2). See Appendix 3.1 for dose-response figures. 
 
Table 4.2. MIC values of TA-289 and equisetin in wt and pdrΔ strains in the presence or absence 
of NaCl. 
Condition 
MIC (µM) TA-289 MIC (µM) Equisetin 
wt pdrΔ wt pdrΔ 
No NaCl >100 25 50 25 
0.7 M NaCl 50 10 30 25 
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4.4.4 Testing candidate genes: Non-ETC genes 
A selection of strains with gene deletions that may be potential targets of TA-289 
and equisetin were tested for sensitivity and/or resistance to either TA-289 or 
equisetin. The selected panel included genes involved in the mitochondrial ETC (a 
potential source of reactive oxygen species (ROS), and non-ETC related genes; genes 
hypothesised to be sources of ROS, genes involved in oxidative stress response, genes 
identified as putative targets of equisetin (König, Kapus et al. 1993), and genes 
associated with apoptosis. Non-ETC related genes showed no significant resistance 
(>1, where 1 is indicated as wt growth) to TA-289 (Figure 4.6). 
 
Figure 4.6. Sensitivity of non-ETC genes to TA-289. Deletion strains associated with ROS (pink), 
response to oxidative stress (green), apoptosis (red), and putative targets of equisetin (blue) were 
tested for sensitivity/resistance against 50 µM TA-289, and residual growth relative to wt (y-axis) 
was plotted, where 1 on the y-axis indicates wt growth in 50 µM TA-289. Orange arrows 
indicate genes that displayed more than half-fold sensitivity to TA-289 compared to wt. 
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Genes encoding for proteins that may be a source of ROS production such as the 
aconitases ACO1 and ACO2, and dehydrogenases URA1, GPD1, GPD2, and GUT2, 
also displayed some sensitivity, where only aco2Δ and gut2Δ were a half-fold 
sensitive to TA-289. As such, it can be concluded that TA-289 does not cause the 
generation of ROS in cells through binding of putative non-ETC sources of ROS 
such as dehydrogenases, and that these genes do not encode the source for ROS. 
 
Apoptotis-inducing factor AIF1 is translocated from the mitochondrion to the 
nucleus upon oxidative stress, leading to chromatin condensation and DNA 
degradation, i.e. pyknosis (Wissing, Ludovico et al. 2004). If aif1p was required for 
the cell death caused by TA-289 and equisetin, the aif1Δ mutant strain will be 
resistant, however this was not observed, with the aif1Δ mutant showing the same 
sensitivity as BY4741 (wt). Yeast metacaspase MCA1 is another positive regulator of 
apoptosis upon H2O2 treatment (Madeo, Herker et al. 2002). Given that the TA-289 
resistant mutant generated in the previous study (chapter three, results 3.6.4) is also 
resistant to H2O2, it is possible that MCA1 may be required for the cell death caused 
by TA-289, however wt sensitivity of the mca1Δ mutant indicates otherwise. 
 
Genes encoding for proteins involved in oxidative stress response could also be 
potential targets of TA-289 and equisetin, wherein binding of the enzymes may 
result in decreased tolerance to ROS (Gralla, Kosman et al. 1992). Additionally, the 
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production of ROS observed upon TA-289 treatment may indicate that the 
compound may be targeting antioxidant functions that result in accumulation of 
ROS. These genes include catalase CTT1, superoxide dismutases SOD1 and SOD2, 
and RAD9, involved in DNA damage repair. In this instance, the sod1Δ  mutant was 
sensitive to TA-289, which suggests that 1) superoxide anions (·O2-) are being 
generated because 2) the sod1Δ mutant is unable to remove these free radicals and is 
thus more sensitive compared to wt. However, the sod2Δ mutant is not sensitive. 
Whether this is an artefact of the assay conducted, or because SOD2 is not as highly 
expressed as SOD1 under normal physiological conditions and so the sod2Δ mutant 
is not as compromised as the sod1Δ mutant, it is unclear. 
 
Yeast homologues of the putative gene targets of equisetin were also tested, 
including ATP-associated genes AAC1 and AAC3 (ADP/ATP translocators; AAC1 is 
expressed under aerobic conditions and AAC3 is expressed under anaerobic 
conditions), and ATP1 and ATP5 (subunits of F0-F1 ATP synthase), 
oxo/dicarboxylate carriers ODC1, ODC2, and DIC1, phosphate carriers MIR1 and 
PIC2, and succinate/fumarate carrier SFC1. The mitochondrial porin POR2 was 
included in this screen as Por1p was indicated as the target of  mitochondrial 
inhibitor SFK1 (Butcher and Schreiber 2003), and ATP5 has been shown to be the 
target of oligomycin (Bertina, Steenstra et al. 1974). These groups of genes showed 
no dramatic increased in sensitivity to TA-289 aside from AAC3 – the differing 
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sensitivites of aac3Δ and aac1Δ mutants to TA-289 can be explained by their 
expression levels under anaerobic conditions i.e. glucose, where the expression of 
AAC3 in glucose plays a role in maintaining cell viability and respiration, and thus 
the aac3Δ mutant is sensitive to TA-289. However AAC1 is not expressed in glucose 
(the conditions used in this assay), and as such the aac1Δ mutant will most probably 
not be as sensitive to TA-289 as that of the aac3Δ mutant, as it is observed in figure 
4.6. The lack of a pattern of sensitivity to TA-289 in these group of genes suggest 
that 1) neither TA-289 nor equisetin act in a similar way to SFK1, or oligomycin (as 
neither the por2Δ or atp5Δ strains displayed resistance) and 2) that possible targets 
of equisetin (and by association, TA-289) highlighted by König et. al. may not be the 
true targets of TA-289 and equisetin in yeast. 
 
4.4.5 Testing candidate genes: ETC genes 
The mitochondrion is a major source of ROS. The generation of ROS and altered 
mitochondrial morphology upon treatment of TA-289 and equisetin suggests a 
possible site of action at the ETC. As such, select genes from each ETC complex were 
tested with three different concentrations of equisetin and their 
sensitivity/resistance to the compound was measured. Figure 4.7 shows gene 
deletions associated with complex I of the ETC (NED1 and NDI1), and complex II 
(SDH1, SDH2, and EMI5). NDE1 and SDH2 showed significant sensitivity to lower 
concentrations of equisetin (1% significance). However, SDH2 displayed strong 
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resistance (two-fold resistance at the highest concentration). NDI1 and EMI5 were 
no different to wt growth in equisetin. 
 
 
Figure 4.7. Sensitivity of complex I and complex II genes to equisetin. Deletion strains of genes 
involved in complex I (nde1Δ, ndi1Δ) and complex II (sdh1Δ, sdh2Δ, and emi5Δ) were tested 
for sensitivity/resistance against 60 µM, 30 µM, and 15 µM equisetin, and residual growth 
relative to wt (y-axis) was plotted. Resistance (red asterisk) and sensitivity (green diamond) of 
1% significance are denoted. 
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Figure 4.8 below shows gene deletions associated with complex III, including genes 
required for ubiquinone (coenzyme Q) biosynthesis (COQ1 and COQ2).  
 
Figure 4.8. Sensitivity of complex III genes to equisetin. Deletion strains of genes involved in 
complex III were tested for sensitivity/resistance against 60 µM, 30 µM, and 15 µM equisetin, 
and residual growth relative to wt (y-axis) was plotted. Resistance (red asterisk) and sensitivity 
(green diamond) of 1% significance are denoted. 
 
 
COR1 (core subunit of complex III), and CYT1 (cytochrome c1), displayed 
significant resistance at all concentrations of equisetin tested. RIP1 (ubiquinol to 
cytochrome c electron transport) also displayed resistance at 60 and 30 µM equisetin. 
The QCR genes (subunits II of complex III) also displayed resistance at the 
concentrations of equisetin tested, however QCR10 showed significant sensitivity at 
30 and 15 µM, but normal growth at 60 µM equisetin. Notably, only QCR10 
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displayed significant sensitivity, with all other genes tested displaying either 
resistance or normal growth (≈1, wt growth). 
 
Figure 4.9 below shows gene deletions associated with complex IV, cytochrome c 
oxidase, and cytochrome c translation (PET122 and PET494). 
 
Figure 4.9. Sensitivity of complex IV genes to equisetin. Deletion strains of genes involved in 
complex IV were tested for sensitivity/resistance against 60 µM, 30 µM, and 15 µM equisetin, 
and residual growth relative to wt (y-axis) was plotted. Resistance (red asterisk) of 1% 
significance are denoted. 
 
 
COX7 and COX9 (subunits VII and VIIa of complex IV) displayed resistance at 30 
and 60 µM equisetin. COX6 (subunit VI), whose expression is regulated by oxygen 
levels (Wright, Simpson et al. 1995), also displayed resistance to equisetin, at the 
highest concentration tested. COX5A, predominantly expressed during aerobic 
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growth, is most resistant at the highest concentration of equisetin tested, displaying 
two-fold resistance. Mitochondrial translation activators PET122 and PET494 
displayed normal growth in all concentrations, with PET494 showing resistance to 
equisetin only at 60 µM. Here, all deletion strains of genes encoding for proteins 
involved in complex IV of the ETC displayed either normal growth (≈1, wt growth) 
or were strongly resistant.  
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4.5 Discussion 
 
4.5.1 Effects of TA-289 and equisetin on the redox state of yeast 
S. cerevisiae are free-living unicellular organisms, and as such the eukaryote must 
endure whatever stressors to which it is exposed. Endogenous stress can occur in 
many ways, one of them being the production of reactive oxygen species (ROS), 
natural by-products of respiration in all aerobic organisms. Oxidative stress as a 
result of ROS production will cause damage to major cellular components such as 
proteins, lipids, and DNA, and ultimately, where a cell is unable to maintain its 
redox state, cell death (Salmon, Evert et al. 2004). The work presented here shows 
that the novel fungal metabolite TA-289 and structurally related equisetin both 
significantly affect the redox state of yeast, likely so by the induction of oxidative 
stress.  
 
Oxidant sensitive probes such as 2,7-dichlorofluorescein diacetate (DCF) are often 
used to measure ROS levels within cells. In this instance, the cell permeable dye 
propidium iodide was also used as a counter stain to DCF. TA-289 caused a marked 
increase in ROS production in cells within 30 mins treatment, and by the hour, the 
majority of the cell population were either dead (stained positive for propidium 
iodide) or dying from elevated ROS production (stained positive for both DCF and 
propidium iodide). Equisetin treated cells displayed similar characteristics, however 
over 90% of the cell population were dead within 30 mins of treatment, with the 
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rest staining positive for ROS production. This could be attributed to the fact that 
equisetin is much more potent than TA-289, and so is more fast-acting on yeast cells. 
This evidence is supported by the cell death assays conducted in glucose as a carbon 
source, where TA-289 and equisetin kill within the first hour of treatment (wt and 
pdrΔ cells for equisetin, pdrΔ cells only for TA-289), while a known oxidant, H2O2, 
takes up to three hours before yeast are severely compromised. This in turn may 
explain why cells treated with H2O2 in the ROS-detection assays had only slight 
elevated ROS production, where the level of ROS produced will most likely increase 
given enough exposure time to H2O2. It is likely that if cells were visualized after 15 
mins exposure to equisetin instead of 30 or 60 mins, more ROS-producing cells may 
be detected with a lesser population of dead cells. Ultimately the best course of 
determining ROS production would be a time-course analysis with tighter intervals 
between each visualization to establish elevated production of ROS, and most 
importantly, that this event appears to precede yeast cell death, or at least precede 
the increase in cell wall permeability. 
 
Interestingly, a small percentage of cells in the untreated control were stained 
positive for ROS production. Additionally, there was also a population of dead cells 
as shown by positive-staining with propidium iodide. It is not uncommon however 
that in any given population of cells, there will always be a proportion of cells that 
are dead, or are dying and thus may produce more ROS naturally. The cell 
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membrane is a target of ROS, and a damaged membrane will most likely become 
more permeable. Propidium iodide is able to cross permeablized cell membranes 
(often an indication of dead cells) (Davey and Hexley 2010), therefore it is possible 
that cells treated with TA-289 and equisetin stain positive for propidium iodide due 
to compromised cell membranes, not because the cells are dead from the effects of 
the compounds. Moreover, cells that stain positive for propidium iodide have been 
shown to be able to repair the cell membrane if given enough incubation time to do 
so, and so subsequent exposure to propidium iodide post-repair do not stain positive 
(Davey and Hexley 2010). Nevertheless, the proportion of cells that are able to 
repair their membranes enough to exclude propidium iodide is relatively minor, and 
the inability of pdrΔ cells to recover from treatment with TA-289 and equisetin as 
observed in the CFU assays (chapter two, result 2.5.1) and the time course analyses 
(chapter two, result 2.5.4) is strong indication that pdrΔ cells are severely 
irreversibly growth inhibited in their inability to expel the compounds, not in their 
inability to repair the cell membrane (as wt cells were able to recover from 
treatment with TA-289 and slow recovery from equisetin). 
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4.5.2 The effects of TA-289 and equisetin on yeast mitochondria 
The mitochondrion is often known as the powerhouse within a cell, where ATP 
generated within this organelle is transported to various cellular components in the 
cell that rely on ATP to function. The mitochondrial transmembrane potential 
(ΔΨm) is essential not only for ATP production, but also the regulation of 
metabolite transport, and is required for mitochondrial protein import (Ricci, 
Waterhouse et al. 2003). Mitochondria are also a major source of ROS production, 
where premature electron leakage from the ETC during respiration results in the 
formation of free radicals such as the superoxide anion (·O2-), and the hydroxyl 
radical (·OH). The generation of ROS can lead to a collapse in the ΔΨm, where 
cellular damage caused by ROS and prolonged exposure will ultimately lead to cell 
death. To this end, the site of action of both TA-289 and equisetin has been 
indicated at the mitochondria. From results attained in these studies, it is strongly 
suggested that TA-289 and equisetin share the same mechanisms-of-action, wherein 
both compounds cause a deleterious production of ROS, leading to yeast cell death 
that is speculated to be mediated and or initiated by/in the mitochondrion. 
 
Following ROS-detection assays, studies into the effect of TA-289 and equisetin on 
the mitochondria by staining with whole mitochondria stain, MitoTracker© Green 
FM revealed that cells treated with either TA-289 or equisetin exhibited 
significantly reduced uptake of MitoTracker© Green FM. The MitoTracker probe is a 
mitochondrion-selective dye containing a thiol-reactive chloromethyl moiety. Once 
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inside the mitochondria, MitoTracker reacts with accessible thiol groups on peptides 
and proteins to form a fluorescent conjugate with proteins in the mitochondria 
(Molecular Probes, Invitrogen Corporation, CA, USA). Although a reduced staining 
of MitoTracker is observed in treated cells, this is not necessarily due to a disruption 
in the ΔΨm, as MitoTracker will stain mitochondria regardless of ΔΨm. 
 
Loss of MitoTracker staining in the mitochondria could be a result of oxidation of 
accessible thiol groups by ROS produced as a result of treatment with TA-289 or 
equisetin, and where there are less thiol groups for MitoTracker to react with and 
fluoresce; fluorescent intensity is lessened compared to untreated controls. ROS has 
been shown to alter mitochondrial membrane, a consequence of lipid peroxidation 
and thiol oxidation (Batandier, Fontaine et al. 2002). To determine whether this is 
indeed happening within the mitochondria, staining with MitoTracker prior to 
treatment with either TA-289 or equisetin should not result in the sequestering of 
fluorescence intensity as MitoTracker would have already bound to accessible thiol 
groups. Additional staining with mitochondria-selective probes that are sensitive to 
changes in the ΔΨm will establish whether effects of TA-289 and equisetin result in 
a collapse of the ΔΨm. 
 
Assessment of mitochondrial morphology using a Cir2p-GFP fusion protein 
expressing strain localized in the mitochondria showed that TA-289, and especially 
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equisetin, caused gross morphological changes in the yeast mitochondria. Under 
normal physiological conditions, yeast mitochondria form a network of tubular 
membranes located at the cell cortex, on the inner face of the plasma membrane 
(Hoffmann and Avers 1973) arising from a single, branched mitochondrion that is 
continuous between the mother cell and daughter cell and throughout a large 
portion of the cell cycle. The mitochondrion is actively transported by cytoskeletal 
components to the emerging bud during G1-S phase (Stevens 1981). 
 
The tubular networks observed in untreated cells were partially disrupted in TA-
289-treated cells, and completely disrupted in equisetin-treated cells within 1 h in 
what appears to be fragmentation or punctate patterns. Again, the significant effects 
induced by equisetin compared to that of TA-289 are most likely due to its greater 
potency in yeast; equisetin is more hydrophobic than TA-289 and thus will be more 
permeable. Currently, it is unclear whether elevated ROS production causing 
cellular damage is a result of the changes in mitochondrial morphology, or whether 
it is the production of ROS that causes morphological changes in the mitochondria. 
Nevertheless, these results clearly show TA-289 and equisetin are affecting yeast 
mitochondria, potentially collapsing the ΔΨm, where loss of ATP synthesis and ROS 
generation are both contributing factors in irreversible growth inhibition. 
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4.5.3 Potential molecular targets of TA-289 and equisetin: The ETC 
To date, a number of suggestions have been made as to the target of equisetin. 
Equisetin was shown to potently inhibit the activity of purified HIV-1 integrase 
(Singh, Zink et al. 1998), and SecA activity in vitro (Sugie, al et al. 2002), and the 
substrate anion carriers of the rat mitochondrial ETC (König, Kapus et al. 1993) have 
also been suggested. Patham et. al. also showed that equisetin inhibited the 
translocation of proteins to the ER. In S. cerevisiae, there is no homologue of HIV-1 
integrase, however observed biological activity in yeast suggests either a different 
mechanism-of-action of equisetin (and in relation, TA-289), or the likelihood of 
multiple targets by the compound. Yeast homologues of mammalian translocons 
include SBH1 and SBH2; sbh1Δ cells have been shown to be sensitive to oxidative 
stress-inducing compounds, CTBT (7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine) 
(Batova, Klobucnikova et al. 2010), and glycoaldehyde (Jayakody, Hayashi et al. 
2010). 
 
SBH1 and SBH2 are subunits of the SEC61 translocon complex, and as in bacteria, 
are involved in translocation of proteins across the ER lumen and into the 
mitochondria (Boisrame, Chasles et al. 2002). At present, it is unclear whether 
inhibition of SecA activity will cause ROS production, however, the process by 
which SecA carries out protein translocation is ATP-dependent (Sugie, al et al. 
2002), and it is possible that activity is diminished through interference of ATP by 
equisetin (notably, ATP uptake is inhibited in another study conducted by König et. 
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al.). The inhibition of substrate anion carriers (Pi, succinate, and ATP) of the isolated 
rat mitochondria, in combination with reports that show the ability of equisetin to 
activate inorganic pyrophosphatase (ppa2p) (Lundin, Deopujari et al. 1992), suggests 
that equisetin acts on the mitochondria in yeast also. 
 
All the deletion strains comprising genes involved in the ETC that showed 
significance resistance to equisetin, were identified as sensitive to compounds 
known to induce oxidative stress, including 2-phenyl-3-nitroso-imidazo[1,2-
a]pyridine (Yu, Lopez et al. 2008), DTT (1,4-dithiothreitol) (Rand and Grant 2006), 
3-amino-1,2,4-triazole (Alamgir, Erukova et al. 2010), and 2,4-
diacetylphloroglucinol (Kwak, Han et al. 2011). This suggests that the mechanism by 
which equisetin acts on the cell is different to the described compounds. In saying 
that however, several genes associated with the ETC that displayed resistance to 
equisetin as observed in figures 4.7-4.9, were sensitized to TA-289 in the chemical 
genomic profiling screens performed in chapter two. This may be a result of cellular 
tolerance, where at higher concentrations (i.e. 30 µM and 60 µM equisetin as 
conducted in this study) cells significantly increase their buffering capacity to 
counteract the effects of the drug. 
 
Putative genes identified as potential targets for equisetin as described by König et. 
al. were also tested in this study. König et. al. showed that equisetin inhibited uptake 
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of Pi, succinate, and ATP, therefore suggesting genes involved in the import/export 
of these molecules as targets. Yeast deletion strains of genes showing homology to 
the putative targets described by König et. al. were tested. These were phosphate 
carriers MIR1 and PIC2, succinate/fumarate carrier SFC1, and oxo/dicarboxylate 
carriers ODC1, ODC2, and DIC1. No one deletion strain of any of these genes 
described were significantly sensitive to equisetin at all concentrations tested, 
suggesting that these are not the targets of equisetin. 
 
AIF1 is a mitochondrial pro-apoptotic gene responsive to oxidative stress, the 
deletion of which increases resistance to oxidative stress (Wissing, Ludovico et al. 
2004); its deletion strain aifΔ showed no significant sensitivity. SOD1 and SOD2, 
superoxide dismutases regulated in response to oxidative stress, the deletion of 
which often result in increased sensitivity to ROS-inducing agents (Tan, Teo et al. 
2009)). As with AIF1, sod1Δ and sod2Δ showed little significant sensitivity or 
resistance, with only the sod1Δ mutant displaying a two-fold sensitivity compared 
to wt. These results indicate that equisetin may act somewhere in the mitochondrial 
ETC, or its target(s) associates with the ETC, as deletion strains of genes not 
associated with ETC displayed varying resistance and sensitivity, most likely as a 
result of indirect effects of equisetin binding to its target. 
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A selection of genes associated with complexes I through IV of the ETC were tested 
with equisetin. Among these, complex III- and complex IV-associated genes were 
the only group of genes to show either differential sensitivity compared to wt, or 
were resistant to equisetin (with the exception of QCR10 at complex III), indicating 
a possible site of action at either of these complexes in the ETC. It was also noted 
that deletion strains that were resistant to equisetin displayed strongest resistance at 
the highest concentration tested (60 µM) compared to 15 and 30 µM. This may be a 
result of cellular response to oxidant dose, where genes involved in detoxification 
have been shown to be down-regulated at low oxidant doses, but significantly up-
regulated at higher doses (Alic, Felder et al. 2004), leading to greater resistance. This 
possibility should be amenable to testing by expression microarrays to test for 
specific gene transcription. Likewise, what may seem as strong resistance could be a 
result of the wild-type strain being severely growth inhibited at higher 
concentrations, and thus compared to wild-type growth, resistance appears more 
significant. 
 
Currently, it is unclear whether complex IV is capable of producing ROS, however 
inhibition of complex IV by equisetin and TA-289 may cause premature leakage of 
reducing electrons from cytochrome c. Additionally, it is possible that the target of 
equisetin may be downstream of the ETC complexes tested, owing to the pattern of 
resistance across all four complexes. Similar to paraquat (Tan, Teo et al. 2009), 
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equisetin and TA-289 may act as alternative terminal receptors of the ETC, 
becoming a free radical in itself and generating more ROS. A more probable 
scenario, taking into consideration the observations of resistance displayed by genes 
associated with complex III and complex IV (figures 4.6-4.9), is that 1) resistance is 
observed at complex III because gene deletions involved in that complex  result in 
reduced ROS production rate, and 2) resistance is observed at complex IV because 
gene deletions involved in complex IV result in an electron flow “back-up” to 
complex III which, notably, has not been shown to cause a burst of ROS production 
(Andreyev 2005). There is no evidence for ROS production at complex IV, and in 
this case, the source of ROS production upon treatment with either TA-289 or 
equisetin may be generated from complex III of the ETC, a well-known producer of 
ROS. Notably, not all genes involved in the ETC were tested, and as such the 
sensitivity of these deletion strains may be worth testing against TA-289 and 
equisetin in the future. 
 
To this end, TA-289 and equisetin have been shown to elicit ROS production in 
yeast, wherein elevated ROS levels leads to either irreversible growth inhibition or 
cell death (as observed by the ROS-detection and propidium iodide staining assays). 
Treatment with TA-289 and equisetin also cause severe morphological changes in 
mitochondrial morphology, most probably as a result of ROS production. Currently, 
it can only be speculated that due to gross morphological changes in the 
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mitochondria, there is loss of ΔΨm, however equisetin has been previously 
demonstrated to not have significant effects on the ΔΨm (König, Kapus et al. 1993). 
The disparities between resistance and sensitivity of non-ETC genes tested in this 
study suggest that TA-289 and equisetin may act at the ETC, where the pattern of 
resistance observed between genes involved in complexes III and IV indicate a 
potential site-of-action at those complexes. However, evidence showing equisetin 
inhibits the translocation of post-translation proteins to the ER (Patham, Duffy et al. 
2009) further indicates a possible action outside of the ETC, or a target that is tightly 
involved in both the mitochondria and the ER. 
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5. FINAL DISCUSSION_________________________________ 
 
5.1 Mitochondrial-mediated ROS production in yeast 
The novel fungal metabolite TA-289, and a structurally related compound equisetin, 
display potent growth inhibitory effects against S. cerevisiae at micromolar 
concentrations. Further characterization of the mechanism by which these two 
compounds elicit their effects on yeast have been attempted in this study using 
various genome-wide tools available for S. cerevisiae. Evidently, the late-phase cell 
cycle block and chemical genomic profiling of TA-289 presented in chapter two, as 
well as previous reports indicating the effects of equisetin on the mitochondria, lead 
us to hypothesise that both compounds were eliciting their effects by causing 
elevated ROS production leading to oxidative stress, triggering either programmed 
yeast cell death or irreversible growth inhibition. 
 
Production of ROS was detected in cells after treatment with TA-289. Treatment 
with TA-289 also resulted in cells with significantly damaged and permeable cell 
membranes, a characteristic of dead cells. In this instance however, it is believed 
that cells treated with TA-289 and equisetin are susceptible to propidium idodide-
staining as a result of ROS generation which causes damage to cellular components, 
including the cell membrane. Thus, a more definite marker for cell death will need 
to be applied to determine whether cells die from treatment with TA-289 and 
equisetin, or are simply irreversibly growth inhibited as was noted with isolated rat 
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mitochondria (König, Kapus et al. 1993). Moreover, the reagent used to detect the 
presence of ROS in cells does not discriminate between different types of ROS. 
However, taking into consideration the late phase cell cycle block observed in the 
cell cycle analysis in chapter two, it is possible that the highly reactive hydroxyl 
radical, ·OH, is generated upon TA-289 and equisetin-treatment, as the production 
of these radicals have been known to cause a cell cycle block at G2 phase (Perrone, 
Tan et al. 2008). Whether the hydroxyl radical is generated as a direct result upon 
treatment with TA-289 and equisetin, or whether it is through the generation of 
other free radicals such as superoxides and peroxides (these three ROS are often 
linked by either spontaneous or enzymatic dismutation (Batandier, Fontaine et al. 
2002)), remains unclear. 
 
The growth inhibition of yeast cells by TA-289 and equisetin during fermentative 
growth indicate that the target(s) of TA-289 and equisetin must be present even 
under these conditions. If the target(s) is located or is associated with mitochondrial 
pathways, and if the source of ROS is indeed from the mitochondria, then it is 
presumed that there is the presence of some basal level of respiration, even when 
yeast are fermenting, since ROS is produced upon treatment with TA-289 and 
equisetin. Thus, upon target-binding, premature electron leakage from the ETC 
causes ROS, gross morphological changes in the mitochondria, and presumably a 
decrease in cellular ATP. Apoptosis is a process that requires ATP (Ricci, 
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Waterhouse et al. 2003). Although yeast display similar hallmarks of mammalian 
apoptosis such as pyknosis (as it is observed in cells treated with TA-289 and 
equisetin), it is unclear whether the requirement for yeast apoptosis is dependent 
upon ATP as it is in mammalian apoptosis (Madeo, Herker et al. 2004; Madeo, 
Carmona-Gutierrez et al. 2009). If ATP-synthesis is indeed compromised and/or 
depleted upon TA-289 and equisetin treatment, but yeast cells are still displaying 
apoptotic markers like pyknosis and also staining positive for cell death (propidium 
iodide), the requirement for yeast apoptosis in this instance may indeed be different 
to mammalian apoptosis. 
 
The difference in growth inhibition and/or adaptive resistance observed between 
treatment with TA-289 and equisetin in fermentable and non-fermentable carbon 
sources suggest either 1) when yeast are fermenting, the target(s) of TA-289 and 
equisetin are lowly expressed, requiring less drug to bind to the target(s) and thus 
the cell is overwhelmed; or 2)  under active respiration (non-fermenting conditions), 
the target(s) is presumably more expressed as it is required for respiration, and the 
increase in expression of drug target will require more drug to bind to the target and 
cause an effect. Moreover, when a cell is actively respiring, the cell will most likely 
produce more ROS compared to fermentative conditions, and thus antioxidant 
capacities are up-regulated (Drakulic, Temple et al. 2005). The combined effect of 
the presence of more drug target, and the increased antioxidant capacity may 
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explain the increased resistance to TA-289 and equisetin observed in the cell death 
assays performed in chapter two, where TA-289 and equisetin do not appear to kill 
pdrΔ yeast in glycerol-ethanol, but the compounds killed wt yeast (figures 2.14 and 
2.15). The seemingly increased sensitivity of wt to TA-289 and equisetin is evidence 
that respiration plays an important role in cell survival upon treatment with these 
two compounds. The resistance observed in the cell death assays by the pdrΔ cells 
can be explained by these mutants having higher basal level of ROS under normal 
respiratory conditions, and thus an overall greater antioxidant capacity to be able to 
buffer the inhibitory effects of TA-289 and equisetin. Longer exposure time 
performed for cell death assays in glycerol may determine whether the inhibitory 
effects of TA-289 and equisetin will eventually overcome the initial adaptive 
resistance mechanisms observed in the pdrΔ cells.  
 
Often, it can be difficult to ascertain whether the production of ROS precedes or is a 
result of cell death and/or growth inhibition. Notably, the resistant mutant 
generated in this study showed that resistance to TA-289 could be achieved by the 
mutant strain possessing greater antioxidant capacity due to its higher basal level of 
ROS production. This was determined where the mutant also displayed resistance to 
a known oxidant, H2O2. These findings also provide evidence that induction of ROS 
by TA-289 is a separate process and precedes cell death, as the mutant with up-
regulated antioxidant capacity has the ability to grow at concentrations of TA-289 at 
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which wild-type succumbs. This interpretation is supported by the time-course 
analyses of cells treated with TA-289 display elevated ROS production prior to cells 
becoming permeable to propidium iodide. Most importantly, while it has been 
established that ROS production caused by TA-289 and equisetin may lead to cell 
death and/or growth inhibition, it is more challenging to determine the source of 
ROS. In light of the assays performed with the selected genes involved in the ETC 
complexes, the pattern of resistance observed across the deletion strains of complex 
III suggest a possible source of ROS at that complex when treated with TA-289. It is 
important to note however, that the site of ROS production does not necessarily 
equate to the binding-site (i.e. the target) of TA-289 and equisetin. 
 
Many of the results concerning genetic interactions reported here can be explained 
by processes linked to the mitochondria or genes involved in mitochondrial 
inheritance. Gene groupings identified in the chemical genomic profiling (both 
homozygous profiling and haplo-insufficiency profiling) included mitochondrial-
related processes, DNA damage and oxidative stress, all of which are affected 
directly by the generation of ROS induced by TA-289, and most probably equisetin, 
as both compounds have displayed very similar mechanisms so far. In the case 
where the mitochondrion is the site of action for TA-289 and equisetin, it will be 
the first organelle to be affected by ROS as these will most likely be generated 
within the organelle itself. A large number of genes associated with RNA 
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polymerase II regulation (both negative and positive regulation), and transcription 
from RNA polymerase II promoter were also identified. Studies have shown that the 
regulation of RNA polymerase II plays a role in stress response and cell fate 
(Pelechano, Jimeno-Gonzalez et al. 2009; Jouvet, Poschmann et al. 2010). As RNA 
polymerase II is an integral complex in gene expression, for a cell that is unable to 
repair damaged proteins or DNA, or transcribe mRNA encoded for the response of 
cellular stress and damage, it will most likely be sensitive to TA-289 and equisetin. 
This observation does not argue so much for any particular specificity for both 
compounds as it does that cellular response to TA-289 and equisetin is a living cell 
response i.e. general up-regulation of gene expression. 
 
Additional processes affected also included those that occurred in the endoplasmic 
reticulum (ER) and endosome trafficking and vesicular transport, where the close 
contact sites between mitochondria and ER will most likely be exposed to ROS 
leakage from the mitochondria. As ROS can interact with many different proteins 
and lipids (especially so in the case of the hydroxyl radical ·OH), damage to these 
cellular components will cause an ER stress response, and in the event where stress 
is prolonged and the cell is unable to traffic or repair damaged proteins, the result is 
detrimental. Moreover, in the event where mitochondria-mediated ion signalling 
such as Ca2+ which plays a role in cellular fate, is affected by TA-289 and equisetin, 
the resulting dysfunction in ion dynamics between the mitochondria and ER can be 
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deleterious to the cell (Decuypere 2011). Equisetin was previously shown to inhibit 
Ca2+ uptake in isolated rat mitochondria (König, Kapus et al. 1993). This, combined 
with the identification of genes associated with Ca2+ signalling in the chemical 
genomic profiling of TA-289, is further evidence that TA-289 and equisetin may 
share the same mechanism-of-action. Additionally, it illustrates that the effects of 
TA-289 and equisetin on yeast mitochondria could also result in aberrant Ca2+ 
signalling. A dysfunction in ion dynamics and signalling, ATP depletion disrupting 
ATP-dependent processes, ROS generation leading to cellular damage, could all be 
explained by the effects of TA-289 and equisetin on mitochondria. 
 
A small number of genes involved in cell cycle progression, particularly in the 
mitotic phase, however a number of G1 cyclins were also identified. As mentioned 
previously, ROS production, in particular the production of hydroxyl radicals ·OH, 
has been shown to cause a cell cycle block at G2 (Perrone, Tan et al. 2008). Notably, 
yeast cells also respond to oxidative stress by delaying cell cycle progression 
(Flattery-O'Brien and Dawes 1998; Chiu, Tactacan et al. 2011), however, the delay 
would result in delayed entry at G1, whether this is relayed in cells not completing 
the cell cycle (thus a seemingly G2 block) prior to entry again at G1, it is unclear. 
Likewise, it could be a combined action, where ROS production induces cell cycle 
bock and subsequently a delay in entry into G1, which may explain both early and 
late phase cell cycle-related genes sensitizing to TA-289. 
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5.2 Role of cardiolipin 
Cardiolipin is a phospholipid primarily localized to the mitochondrial inner 
membrane, constituting about 20% of total lipid mitochondrial composition 
(Pangborn 1942; Houtkooper and Vaz 2008). It is an integral component in 
mitochondrial metabolism, where the lipid has been shown to be required for 
structural maintenance of the ETC complexes, in particularly complex IV and V 
which require cardiolipin molecules to maintain full enzymatic function (Eble, 
Coleman et al. 1990; Robinson, Zborowski et al. 1990). Depletion of cardiolipin 
significantly reduces complex IV and V activity and mitochondrial protein import, 
collapsing the mitochondrial transmembrane potential (ΔΨm) and disrupting 
mitochondrial function (Jiang, Ryan et al. 2000). Moreover, oxidation of cardiolipin 
leads to the formation of hydroperoxides, which can easily break down into the 
highly reactive hydroxyl radicals (Belikova, Vladimirov et al. 2006). 
 
Considering the pattern of resistance observed across the ETC associated genes 
tested, it is possible that equisetin and TA-289 target cardiolipin or the biosynthesis 
of cardiolipin. Binding of cardiolipin may result in many of the observations noted 
in this study, including 1) ROS generation; as cardiolipin is strongly associated with 
almost all complexes of the ETC, disrupting cardiolipin will inevitably disrupt the 
function of the ETC complexes, most likely resulting in induction of ROS from 
complexes known to be sources of ROS, including complex III (bc1 complex) and 
complex I. Aditionally, oxidation of cardiolipin itself will create free radicals; and 2) 
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changes in mitochondrial morphology; conformational changes in cardiolipin will 
result in changes in mitochondrial morphology, and also protons trapped in the lipid 
(Haines and Dencher 2002) are released, disrupting the proton gradient and 
potentially disrupting ATP synthesis. 
 
5.3 Microsomal translocation 
Previous evidence showing inhibition of SecA in vitro (Sugie, al et al. 2002) and 
translocation of post-translational proteins to the ER (Patham, Duffy et al. 2009) by 
equisetin, coupled with the ER and endosome/vacuole processes identified in the 
chemical genomic profile of TA-289 suggests a possible interaction of TA-289 and 
equisetin at multiple sites, namely the ER and the mitochondrion. The experiments 
conducted in these chapters do not allow for definite distinction of either a direct 
site-of-action at the mitochondrion or at the ER, as they are intimately associated 
organelles. The ER and mitochondria are organelles that co-mediate many key 
processes, including phospholipid biosynthesis (Gaigg, Simbeni et al. 1995), and ion 
signalling and homeostasis (Decuypere 2011). Mitochondrial phospholipid synthesis 
is restricted to the formation of three main lipids: phosphatidylethanolamine, 
phosphatidylglycerol, and cardiolipin. Microsomal transport of phosphatidylserine 
from the ER is required in order for mitochondria to synthesise 
phosphatidylethanolamine (Gaigg, Simbeni et al. 1995). Specialized microsomal 
fractions have been shown to form a complex with the outer and inner 
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mitochondrial membrane to synthesize phosphatidylserine, 
phosphatidylethanolamine, and phosphatidylcoline (Ardail, Gasnier et al. 1993).  
 
The assays performed in this study identify a probable similar mode-of-action for 
TA-289 and equisetin, most likely owing to their structural similarity. Our results 
from the cell cycle analyses, chemical genomic profiling screens, ROS detection and 
mitochondrial morphology assays indicate that the effects by which TA-289 and 
equisetin induce cell growth inhibition is dependent on mitochondrial-mediated 
ROS production as a result of drug-target binding, of which the production 
presumably stems from complex III of the ETC. Furthermore, resistance to other 
oxidants displayed by the TA-289 resistant mutant generated in this study indicates 
the importance of the cell’s survival through mediating ROS production and 
antioxidant capacity in the presence of TA-289. Follow-up testing of genes involved 
in the ETC and previously described putative gene targets of equisetin have not 
allowed for strong conclusions on the exact target(s) of TA-289 and equisetin. This, 
in combination with the reported inhibitory activity of equisetin on the 
translocation of post-translational protein import to the ER (Patham, Duffy et al. 
2009), suggests a possible site-of-action not directly at one of the ETC complexes, 
but at a site that is tightly associated with the respiratory chain and ER, such as 
through targeting cardiolipin. Therefore, further studies into the mechanisms of 
both TA-289 and equisetin will need to be conducted to determine the exact sites-
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of-action of the two compounds, with particular emphasis on the mitochondria and 
the ER. 
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6. FUTURE DIRECTIONS_______________________________ 
 
6.1 Chemical genomic profiling 
The chemical genomic profiling screens of TA-289 performed in this study were 
conducted under fermenting conditions. As such, genes essential for respiration that 
may be hypersensitive to TA-289 and equisetin may not be truly represented. To 
compare the list of genes sensitizing to either compound, a chemical genomic profile 
screen conducted in non-fermentable carbon sources such as glycerol will allow the 
identification of genes and processes affected by TA-289 and equisetin that may not 
have been significantly affected in glucose. Additionally, performing these screens in 
glycerol may avoid ROS-related hits, and may thus be more directed towards the 
actual targets of TA-289 and equisetin. 
 
 
6.2 Mitochondria 
 
6.2.1. Mitochondrial transmembrane potential 
Currently, there is no direct evidence from the studies conducted here that 
treatment with TA-289 and equisetin ultimately results in the collapsing of the 
mitochondrial transmembrane potential (ΔΨm); this was not observed in a previous 
study performed in isolated rat mitochondria (König, Kapus et al. 1993). Probes 
specifically sensitive to the ΔΨm can be applied to detect any changes of the ΔΨm 
upon TA-289 and equisetin treatment. ATP synthesis is a process that is dependent 
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on the mitochondrial proton gradient. As such, ATP depletion can be an indicator of 
a collapse in the ΔΨm. Measuring intracellular ATP may also provide insight into 
the effects of TA-289 and equisetin on the energy generating capacity of the 
mitochondria, as a functioning ΔΨm is required for ATP-synthesis. 
 
6.2.2. Mitochondrial deficient mutants 
To determine that TA-289 and equisetin do indeed act on the mitochondria, it can 
be postulated that mitochondria deficient mutants such as petite yeast mutants will 
be resistant to TA-289 and equisetin. If mitochondria deficient mutants prove not to 
be resistant, it could suggest that TA-289 and equisetin either do not act at the 
mitochondria, or have multiple targets within the cell. 
 
6.2.3. Cytochrome c release 
The release of cytochrome c from the mitochondria triggers a sequence of pro-
apoptotic effectors leading to cell death. If treatment with TA-289 and equisetin 
causes the release of cytochrome c, it is likely that these compounds kill yeast by 
apoptosis. However, caspase-independent cell death can also occur. Although the 
deletion mutant did not display resistance, the detection of the translocation of 
apoptosis-inducing factor AIF1 from the mitochondria to the nucleus for example, 
will determine whether induction of cell death (if there is cell death) is caspase-
dependent or caspase-independent. 
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6.2.4. Cardiolipin 
To determine whether TA-289 and equisetin bind directly to cardiolipin, a 
cardiolipin rescue assay can be performed by competitive-binding of exogenous 
cardiolipin with TA-289 and equisetin. Observation of cell growth upon treatment 
with TA-289 and equisetin in the presence of exogenous cardiolipin, compared to 
growth inhibition in the absence of exogenous cardiolipin will indicate that both 
compounds bind cardiolipin. The effects of TA-289 and equisetin on a mutant strain 
lacking in cardiolipin synthase CRD1 may also be tested to determine the 
significance of cardiolipin in the ability for both compounds to elicit damage via the 
production of ROS. In the case where the crd1Δ mutant displays strong resistance to 
TA-289 and equisetin suggests that CRD1 may indeed be the target. 
 
6.2.5. Calcium signalling 
Intracellular calcium (Ca2+) homeostasis is part regulated by mitochondria and the 
ER. Disruption in the dynamics of Ca2+ signalling has been shown to result in a 
cascade of processes (including mitochondrial and ER dysfunction and ROS 
generation), leading to cell death (Pozniakovsky, Knorre et al. 2005). Treatment 
with amiodarone leads to an increase in intracellular Ca2+, causing a loss of 
mitochondrial membrane potential, ROS production at complex III, and cytochrome 
c release (Pozniakovsky, Knorre et al. 2005). Equisetin has been previously shown to 
potently inhibit Ca2+ uptake (König, Kapus et al. 1993). Testing for the increase or 
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decrease in cytostolic Ca2+ in TA-289 and equisetin treated cells may infer a similar 
or dissimilar mechanism to amiodarone. 
 
 
6.3 The effect of fermentable and non-fermentable carbon sources 
Further study can be done on the growth inhibitory effects of TA-289 and equisetin 
in different carbon sources. The ability for cells to grow in the presence of TA-289 
and equisetin under one carbon source and when forced to switch metabolism upon 
exposure to a different carbon source will assess whether this will result in increased 
sensitivity to TA-289 and equisetin, or resistance. The ability for TA-289 and 
equisetin to induce ROS in glycerol should also be tested to determine if these 
effects are more pronounced in glucose (fermentative) or in glycerol (respiratory). 
 
 
6.4 Oxidative stress rescue 
Cells have various defence mechanisms which are employed against ROS and 
oxidative stress. In the case where TA-289 and equisetin cause ROS production 
leading to oxidative stress in yeast cells, antioxidants and uncouplers may be used to 
determine if cell growth inhibition by TA-289 and equisetin can be rescued. 
Glutathione plays an integral role in detoxifying intracellular ROS (Madeo, Frohlich 
et al. 1999). Addition of glutathione may rescue ROS generated as a result of TA-289 
and equisetin. Other antioxidants may be tested, including caffeic acid and 
ascorbate. Uncouplers such as 2,4-dinitrophenol, which inhibit ATP synthesis 
178 
 
without affecting the ETC by inhibiting the coupling between electron transfer and 
phosphorylation reactions, have been shown to prevent mitochondrial-ROS 
production (Terada 1990; Barros, Bandy et al. 2004).  Likewise, co-treatment with 
known inhibitors of the ETC may alleviate the ROS production caused by TA-289 
and equisetin. Moreover, the inhibition of TA-289- and equisetin-induced ROS by 
ETC inhibitors may give an indication as to where in the ETC TA-289 and equisetin 
target. For example, the complex III inhibitor antimycin A causes ROS production at 
complex III (Lai, Zhang et al. 2005). Inhibition at complex IV by KCN does not 
alleviate the ROS production caused by antimycin A (Turrens 2003). However, 
inhibition with myxothiazol reduces ROS production caused by antimycin A as 
myxothiazol prevents the oxidation of Coenzyme Q quinol molecules required to 
generate ROS (Thierbach and Reichenbach 1981). Moreover, inhibition with the 
complex I inhibitor rotenone may also reduce ROS induction by antimycin A, as 
electron flow is halted up-stream of complex III (Chen, Vazquez et al. 2003; Li, 
Ragheb et al. 2003). 
 
 
6.5 Testing additional genes 
Validation of select genes significantly sensitizing to TA-289 in the HET screen 
should be performed to identify any potential gene targets not directly related to the 
ETC. These include the autophagy-related gene AUT7, which displayed greatest 
sensitivity to TA-289, and mitochondrial inorganic pyrophosphatase PPA2, which 
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has been shown to be required for mitochondrial function. A more comprehensive 
collection of genes associated with the ETC may also be tested. 
 
 
6.6 ER stress and ROS 
The mitochondrion, while it is a major source of ROS, is not the only source. The ER 
has been implicated in producing H2O2 during protein folding (Pollard, Travers et al. 
1998; Sevier, Qu et al. 2007). The accumulation of mis-folded proteins that lead to 
ER stress can lead to ROS production within both the ER and the mitochondria 
(Haynes, Titus et al. 2004). If TA-289 and equisetin disrupt the ER and cause stress 
which leads to mitochondrial ROS, then it can be implied that both compounds may 
have multiple targets within the cell, as equisetin was previously shown to act 
directly at isolated mitochondria (König, Kapus et al. 1993). The source of ROS in 
this instance can be determined by using mitochondria-deficient petite yeast 
mutants. ER morphology of petite mutants treated with TA-289 and equisetin can be 
assessed using fluorescent protein probes visualized using a high-throughput 
confocal microscope. 
 
6.7 Phosphatidylserine import 
Phosphatidylserine is transported by specialized subfractions of the ER known as 
microsomes into the mitochondria in order for the synthesis of 
phosphatidylethanolamine, one of the key phospholipids synthesized at the 
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mitochondria. The conversion of phosphatidylserine into phosphatidylethanolamine 
indicates the level of phosphatidylserine import into the mitochondria, and may 
serve to suggest that if TA-289 and equisetin target microsomal translocation (which 
may explain the previously described inhibitory activities of equisetin on transport 
by translocon (Patham, Duffy et al. 2009)), there will be reduced conversion of 
phosphatidylserine to phosphatidylethanolamine. 
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APPENDIX 1_________________________________________ 
 
1.1 Biologically active compounds 
Of the 88 compounds screened initially, 22 small molecules were identified as 
bioactive in wt (BY4742) cells (> 70% growth inhibition compared to DMSO carrier 
controls). Ten additional “hits” were observed in the pdr1Δ mutant strain 
(highlighted in blue) which, did not appear when screened against the wt strain. 
Commercial names of the small molecules were provided by Dr. Stephen Bloor, and 
a brief description of each compound is detailed; tetramic-acid 289 (TA-289) and 
equisetin (highlighted in pink) were chosen to further target identification studies. 
A hit of “1” indicates that the compound is biologically active in the described yeast 
strain. A hit of “0” indicates that the compound displayed no biological activity in 
the described yeast strain. 
Wt 
“hit” 
pdr1Δ 
“hit” 
Compound 
name 
Description 
1 1 402 Pyrone Novel, uncharacterized. 
1 1 citrinin 
Induces mitochondrial permeability 
transition and inhibits microtubule 
polymerization (Chan 2007; Iwahashi, 
Kitagawa et al. 2007). 
1 1 
tetramic acid-
289 (TA-289) 
Novel, uncharacterized. 
1 1 traversianal 
Causes cellular leakage, shown to lyse 
human red blood cells (Stoessl, Cole et al. 
1989). 
1 1 sterigmatocystin DNA synthesis inhibitor. Precursor of 
aflatoxin, a known carcinogen (Cary, 
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Ehrlich et al. 2009). 
1 1 zaragozic acid 
Inhibits both fungal and mammalian 
squalene synthases. Stimulates alpha-
secretase activity (Kojro, Fuger et al. 
2010).  
1 1 fumonisin B2 
Analogue of fumonisin B1. Inhibits 
ceramide synthase and induces apoptosis 
(Desai, Sullards et al. 2002). 
1 1 pamamycin 
Alters membrane-associated cellular 
functions, inhibits uptake of nucleosides 
(Chou and Pogell 1981; Chou and Pogell 
1981). 
1 1 phoslactomycin 
Inhibits phosphotase 2A (Usui, Marriott et 
al. 1999). 
1 1 actinomycin 
DNA synthesis inhibitor (Flamee 1985; 
Sobell 1985). 
1 1 talaro TS1-14 Novel, uncharacterized. 
1 1 candin 
Inhibits beta-1,3-glucan synthase 
(Denning 2003). 
1 1 
N-OH 
apiosporamide 
Antifungal activity (Alfatafta, Gloer et al. 
1994). 
1 1 reveromycin 
Inhibits isoleucyl-tRNA synthetase 
activity. Induces apoptosis (Shimizu, Usui 
et al. 2002; Woo 2007). 
1 1 avenociolide 
Uncharacterized (Chen, Narkunan et al. 
1999). 
1 1 arthrinic acid Novel, Antifungal activity (Bloor 2008). 
1 1 pycnidione Novel, uncharacterized. 
1 1 fumifungin 
Antifungal activity (Mukhopadhyay, Roy 
et al. 1987).  
1 1 equisetin 
Antibacterial activity. Inhibitory activity 
against human immunodeficiency virus 
type 1 (HIV-1) integrase (Vesonder, Tjarks 
et al. 1979; Hazuda, Blau et al. 1999). 
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1 1 borrelidin 
Inhibits threonyl tRNA synthase and 
activates Caspase-8/3 pathway (Saisivam, 
Bhikshapathi et al. 2008; Bhikshapathi, 
Kumar et al. 2010). 
1 1 niphimycin A 
Antifungal activity Structurally related to 
amphotericin B, a known ergosterol 
binder (Usuki, Matsumoto et al. 2006; 
Ogita, Matsumoto et al. 2007). 
1 1 
viridicatum 
toxin 
Antibiotic activity (Zheng, Yu et al. 2008). 
0 1 angucyclinone 
Antibiotic activity (Schimana, Fiedler et 
al. 2000). 
0 1 calbistrin 
Antifungal activity (Tatsuta, Itoh et al. 
1997; Stewart, Capon et al. 2005). 
0 1 cladosporin 
Inhibits uptake of nucleosides (Scott, 
Vanwalbe.W et al. 1971; Anke 1979). 
0 1 paxisterol 
Antifungal activity (Nakano, Hara et al. 
1988). 
0 1 epoxyphomin Novel, uncharacterized. 
0 1 cytochalasin F 
Actin depolymerizer (Binder and Tamm 
1973). 
0 1 S39163F1 Novel, uncharacterized. 
0 1 radicicol 
Antibiotic activity. Binds to N-terminal 
domain of heat shock protein 90 (Hsp90) 
(Nozawa and Nakajima 1979; Schulte, 
Akinaga et al. 1998). 
0 1 kampanol A 
Farnesyl-protein transferase (FPTase) 
inhibitor (Singh, Zink et al. 1998). 
0 1 calbistrin 
Antifungal activity (Tatsuta, Itoh et al. 
1997; Stewart, Capon et al. 2005). 
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1.2 Liquid-dose response assays of TA-289 and equisetin in varying pH 
conditions 
The graphs below display the biological activity of TA-289 and equisetin against wt 
(BY4742) and pdrΔ cells under two standard media conditions, SC and YPD, at low 
and high pH (4.0 and 7.0-8.0). 
 
 
pH 7.0 
pH 7.0 
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1.3 Cell morphology of TA-289 cells 
The photographs below show the small-size phenotype displayed by pdrΔ cells after 
18 h treatment with TA-289 at 30 µM and 100 µM compared to untreated controls. 
Untreated control: 
 
30 µM TA-289: 
 
100 µM TA-289: 
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1.4 Cell cycle analysis by flow cytometry: Time-course histograms 
The figures below show time-course cell cycle analysis of wt (BY4742) and pdrΔ 
cells treated with TA-289 and equisetin. The following histograms show time-course 
of equisetin-treated cells, and TA-289-treated wt cells, and the corresponding wt 
control. Reported time-course histograms for pdrΔ cells treated with TA-289 and the 
corresponding pdrΔ control have been previously described in chapter two results 
figure 2.8. pdrΔ cells treated with equisetin (top right) did not recover from 
treatment with equisetin after 90 mins of washing. In both wt cell samples treated 
with TA-289 (bottom left) and equisetin (bottom right), cells recovered slowly after 
washing. 
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1.5 Cluster analysis 
Full clustergram with both TA-289 HOM screens highlighted in blue. 
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1.6 TA-289 HOM screen overlaps with L-Dopa and MPP+ 
The Venn diagram below illustrates the number of gene overlaps identified between 
the two combined HOM screens for TA-289 and L-Dopa and MPP+. 
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The table below details the gene hits of L-Dopa and MPP+ (Hillenmeyer 2008) 
compared to the two HOM screens of TA-289. The values indicate the log2 ratios of 
treated/untreated control, and a threshold was set where values > 0.5 were deemed 
as a sensitive hit and values < -1 were deemed as resistant. Highlighted in blue are 
the genes localised to the mitochondrion and the ER (41 genes), and in pink are 
genes involved in DNA damage and repair and/or oxidative stress (16 genes) that 
overlap between the TA-289 HOM screens and the L-Dopa and MPP+ screens. 
KEY: Golgi = Golgi apparatus, Mito = Mitochondrion, Cyt = Cytoplasm, ER = 
Endoplasmic reticulum, Nuc = Nucleus, Vac = Vacuole, Mem = Plasma membrane, 
Perox = Peroxisome, Endo = Endosome. 
ORF 
L-Dopa   
12.5 µg/mL 
MPP+    
250 µg/mL 
TA-289 
HOM1 
TA-289 
HOM2 
Cellular 
Component 
YAL026C 0.73 0.00 0.00 0.59 Golgi 
YAR014C 0.84 0.00 0.00 0.56 Bud neck 
YBL022C 3.75 0.00 0.00 0.90 Mito 
YBL047C 0.00 2.27 0.00 0.72 Bud neck 
YBL051C 2.57 2.57 0.57 0.00 Cyt 
YBL065W 0.52 0.81 0.00 3.56 N/A 
YBL081W 0.00 0.64 0.00 1.10 N/A 
YBL101C 0.00 1.26 0.00 0.55 Cyt 
YBR003W 0.55 0.00 0.00 0.58 Mito 
YBR006W 0.00 1.58 0.00 0.65 Cyt 
YBR015C 2.05 0.00 0.00 0.62 Golgi 
YBR036C 0.00 1.13 0.00 2.70 ER 
YBR075W 0.62 1.20 0.00 0.52 N/A 
YBR098W 1.00 0.00 0.00 0.00 Nuc 
YBR134W 0.00 0.71 0.00 0.56 N/A 
YBR173C 1.42 1.51 0.00 -1.53 Cyt, Nuc 
YBR174C 1.22 0.00 0.66 0.00 N/A 
YBR175W 0.00 0.63 0.55 0.00 Nuc 
YBR213W 0.00 0.82 0.00 -1.35 N/A 
YBR244W 0.53 0.00 0.00 0.00 Cyt, Nuc 
YBR278W 0.00 1.81 0.00 1.23 Nuc 
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YBR284W 0.00 1.48 0.54 0.00 N/A 
YBR295W 0.00 1.54 0.00 0.62 Mem 
YBR298C 0.00 4.05 0.00 1.61 Mem 
YBR300C 0.00 1.36 0.00 0.91 N/A 
YCL005W 1.24 0.00 1.36 0.55 Mito 
YCL008C 1.34 4.77 0.00 0.80 Endo 
YCL011C 0.81 0.00 0.60 0.72 Nuc 
YCL032W 1.22 0.00 0.51 0.00 Cyt 
YCL037C 3.13 0.00 0.00 0.00 Polysome 
YCL061C 0.91 0.00 0.61 0.73 Nuc 
YCR008W 0.00 0.91 0.00 0.62 N/A 
YCR010C 1.41 0.00 0.00 0.62 Mito 
YCR024C 0.00 3.12 0.00 -1.54 Mito 
YCR025C 2.34 2.47 0.00 0.54 N/A 
YCR049C 0.00 1.29 0.56 0.00 N/A 
YCR061W 2.93 3.80 0.84 0.70 Cyt 
YCR065W 2.61 0.00 0.00 0.60 Cyt, Nuc 
YCR076C 0.88 0.00 0.56 0.00 N/A 
YCR087W 3.84 1.01 0.00 0.66 N/A 
YCR095C 0.00 1.96 0.00 0.67 Cyt 
YDL001W 1.55 0.65 0.00 0.75 Cyt 
YDL062W 0.52 0.00 0.00 0.51 N/A 
YDL074C 0.66 0.80 0.00 0.56 Nuc 
YDL100C 0.00 0.96 0.00 0.53 ER 
YDL133W 0.00 1.34 0.00 0.91 Mem 
YDL162C 3.49 0.00 0.55 0.00 N/A 
YDL241W 4.10 0.00 0.62 0.59 N/A 
YDR034C 0.95 0.00 -1.07 0.00 Nuc 
YDR076W 2.75 1.16 0.00 0.00 Nuc 
YDR105C 0.87 0.64 0.00 -1.10 Vac 
YDR126W 0.77 0.00 0.00 0.75 ER 
YDR149C 3.31 0.74 0.00 0.78 N/A 
YDR162C 2.11 0.00 0.00 0.00 Cyt, Nuc 
YDR270W 0.83 1.21 0.00 0.51 Golgi 
YDR272W 0.78 0.56 0.00 0.97 Cyt 
YDR293C 2.62 0.00 0.00 1.27 Bud neck 
YDR310C 0.00 7.61 0.53 0.00 Nuc 
YDR335W 0.57 0.00 0.00 0.68 Cyt, Nuc 
YDR438W 1.87 0.00 0.68 0.00 Mito 
YDR441C 0.72 0.00 0.51 2.08 Cyt 
YDR452W 0.00 0.69 0.00 1.02 Vac 
YDR463W 0.62 0.54 0.00 0.73 Cyt, Nuc 
YDR484W 3.62 0.76 0.00 0.80 Golgi 
YDR520C 0.94 1.35 0.00 1.19 Cyt, Nuc 
YDR522C 2.12 0.00 0.53 0.00 Mem 
YEL011W 0.59 0.00 0.00 0.50 Cyt 
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YEL015W 2.11 0.00 0.00 0.96 Cyt 
YEL031W 0.00 4.45 0.00 -1.45 ER 
YER034W 0.57 0.00 0.00 0.59 N/A 
YER078C 1.42 1.94 0.00 2.30 Mito 
YER114C 4.92 0.00 0.00 0.68 Bud neck 
YER169W 0.00 1.14 0.56 0.00 Nuc 
YFL025C 3.24 0.00 0.80 0.61 ER 
YFR007W 0.00 0.68 0.61 0.70 N/A 
YFR040W 2.82 0.00 0.00 0.78 Cyt 
YGL054C 1.01 0.00 0.00 0.75 ER 
YGL066W 2.51 0.00 0.00 1.55 Cyt, Nuc 
YGL071W 5.16 1.44 0.00 2.09 Cyt, Nuc 
YGL086W 1.02 0.00 0.00 0.89 Nuc 
YGL087C 0.00 1.71 0.00 0.74 Cyt, Nuc 
YGL115W 1.92 0.00 0.76 0.00 Cyt, Nuc 
YGL147C 0.00 2.58 0.58 0.73 Cyt, Nuc 
YGL148W 0.61 0.00 0.00 0.69 Cyt 
YGL198W 0.63 0.00 0.66 0.00 Golgi 
YGL212W 0.71 0.00 0.00 -1.24 Vac 
YGL229C 0.64 0.73 0.00 1.66 Mito 
YGL236C 0.51 0.00 0.59 0.00 Mito 
YGL249W 0.59 0.00 0.00 0.71 Nuc 
YGL254W 0.98 0.00 0.77 0.82 Nuc 
YGR034W 0.65 0.00 0.00 -1.05 Cyt, Nuc 
YGR106C 0.53 0.00 0.00 0.57 ER 
YGR135W 1.60 0.87 0.00 -0.50 Mito, Nuc 
YGR166W 0.57 0.00 0.00 0.60 Golgi 
YGR184C 0.00 0.52 0.00 0.73 Cyt 
YGR201C 0.59 0.55 0.00 0.00 N/A 
YGR210C 0.96 0.74 0.00 0.73 Cyt 
YHL005C 1.92 1.67 0.00 0.00 N/A 
YHL026C 2.08 0.00 0.00 0.56 N/A 
YHR039C 1.61 1.03 0.00 1.20 ER 
YHR046C 2.07 0.00 0.00 1.02 Cyt/ Nuc 
YHR051W 1.05 0.71 0.00 0.71 Mito 
YHR129C 5.07 0.00 0.00 1.01 Cyt 
YHR134W 2.13 0.00 0.00 0.00 Nuc 
YHR154W 1.41 1.02 0.00 1.13 Nuc 
YHR179W 5.89 0.00 0.57 0.00 Mito 
YIL012W 5.63 0.00 0.00 0.59 N/A 
YIL029C 0.55 2.47 0.56 0.00 N/A 
YIL034C 1.20 0.00 0.00 -1.11 Bud neck 
YIL035C 2.72 1.63 0.00 1.16 Cyt, Nuc 
YIL085C 0.00 0.75 0.54 0.00 Golgi 
YIL097W 0.00 0.77 0.58 0.00 Cyt, Nuc 
YIL103W 2.36 1.56 0.00 0.78 Cyt, Nuc 
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YIL105C 0.88 0.00 0.00 0.58 Mem 
YIL132C 0.84 0.00 0.00 0.00 Cyt, Nuc 
YIL139C 0.76 1.59 0.00 0.00 Mito 
YIL157C 4.03 1.53 0.00 1.83 Mito 
YIL170W 0.66 0.00 0.53 0.00 N/A 
YIR037W 0.50 1.00 0.00 0.64 N/A 
YJL047C 2.92 0.00 0.00 0.00 Cyt, Nuc 
YJL092W 1.83 3.08 0.00 0.00 Nuc 
YJL126W 0.00 1.05 0.00 0.65 N/A 
YJL141C 5.14 0.00 0.00 0.79 Cyt, Nuc 
YJL145W 0.00 0.74 -1.07 0.00 ER 
YJL154C 0.79 0.00 0.65 0.75 Endo 
YJL162C 0.00 1.43 0.63 0.00 N/A 
YJL192C 5.50 0.00 0.00 0.63 ER 
YJL204C 0.61 0.00 0.00 0.00 Golgi, Endo 
YJL217W 1.41 0.00 0.72 0.56 Cyt 
YJR010C-A 0.00 0.80 0.00 0.56 ER 
YJR043C 2.37 0.00 0.00 0.50 Nuc 
YJR102C 3.45 4.31 0.00 1.90 Endo, Vac 
YJR128W 0.00 0.61 0.00 0.59 N/A 
YJR140C 0.00 1.31 0.00 0.57 Nuc 
YKL037W 0.00 1.11 0.00 1.47 Mito 
YKL136W 1.18 0.00 0.63 0.00 N/A 
YKL149C 4.24 0.00 0.00 -1.33 Nuc 
YKL150W 0.67 1.46 0.00 0.63 Mito 
YKL197C 0.00 3.50 0.00 -1.14 Perox 
YKR017C 0.70 0.00 0.00 0.65 N/A 
YKR035W-
A 1.30 0.00 0.00 0.56 Cyt, Endo 
YKR074W 3.38 2.34 0.00 0.54 Cyt 
YLL014W 1.03 0.00 0.00 0.58 ER 
YLR025W 0.00 5.10 0.00 1.53 Endo 
YLR027C 4.88 0.00 0.00 1.10 Perox 
YLR032W 3.21 0.73 0.63 0.00 Nuc 
YLR049C 0.56 0.66 0.00 0.83 N/A 
YLR125W 0.81 0.00 0.72 0.00 N/A 
YLR386W 0.51 0.00 0.00 -1.38 Vac 
YLR402W 3.71 0.00 0.00 0.51 N/A 
YLR417W 0.54 5.33 0.00 1.12 Endo 
YLR418C 0.00 1.92 0.00 0.55 Nuc 
YML013W 4.37 0.00 0.00 0.70 ER 
YML071C 0.60 0.00 0.61 0.73 Golgi 
YML097C 0.57 0.00 1.15 0.00 Vac 
YML121W 0.87 0.00 0.00 1.04 Cyt, Endo 
YMR077C 0.87 4.30 0.00 1.54 Endo 
YMR098C 1.31 1.26 0.00 1.53 Mito 
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YMR115W 0.53 0.00 0.00 -1.00 Mito 
YMR121C 0.00 1.16 0.00 0.69 Cyt 
YMR152W 1.36 0.00 0.00 1.09 Mito, Cyt 
YMR179W 1.50 0.66 0.00 0.93 Nuc 
YMR263W 1.04 3.85 0.00 0.66 Nuc 
YMR272C 0.00 1.15 0.00 1.13 ER 
YMR304C-
A 0.80 0.51 0.00 0.50 N/A 
YNL041C 5.73 0.00 0.67 0.00 Golgi 
YNL071W 2.20 4.27 0.00 0.55 Mito 
YNL077W 0.00 2.41 0.00 0.56 Mito 
YNL084C 3.02 0.00 0.00 1.21 Bud neck 
YNL097C 0.00 4.03 0.78 0.75 Nuc 
YNL098C 0.94 0.64 0.00 0.64 Mem 
YNL129W 0.00 0.54 0.00 0.54 Cyt 
YNL148C 1.05 0.96 0.00 0.61 Cyt, Nuc 
YNL187W 0.69 0.77 0.00 2.38 Nuc 
YNL196C 1.35 1.51 0.52 0.00 N/A 
YNL201C 0.00 0.90 0.00 0.00 Nuc 
YNL211C 5.22 0.58 0.00 0.64 Mito 
YNL212W 2.24 1.28 0.59 0.00 Cyt 
YNL299W 0.00 0.62 0.00 -1.06 Nuc 
YNL316C 2.43 0.00 0.00 0.59 Cyt 
YNL322C 6.07 0.00 0.00 0.71 Mem 
YNR050C 0.60 0.00 0.00 0.60 Cyt 
YOL003C 0.69 0.00 0.00 0.70 ER 
YOL059W 0.00 0.69 0.58 0.00 Mito 
YOL070C 0.00 0.66 0.00 0.69 Bud neck 
YOL081W 6.93 4.59 0.00 0.57 Mito, Cyt 
YOL089C 1.28 0.00 0.00 0.56 Mito, Nuc 
YOL106W 0.66 0.00 0.00 0.56 N/A 
YOL118C 0.00 0.51 1.05 0.00 N/A 
YOL128C 0.68 0.00 0.00 0.53 N/A 
YOR051C 0.00 1.23 0.00 0.57 Nuc 
YOR182C 2.36 0.80 0.00 0.61 Cyt 
YOR253W 0.52 0.00 0.00 0.53 Cyt 
YOR265W 2.68 2.12 0.00 -1.06 Cyt 
YOR316C 0.86 0.73 0.55 0.00 Vac 
YOR352W 0.53 0.00 0.00 3.88 Cyt, Nuc 
YOR359W 1.54 0.00 0.57 0.00 Cyt, Nuc 
YOR360C 1.09 1.71 0.63 0.98 Cyt, Nuc 
YOR364W 0.00 1.19 0.00 0.65 N/A 
YOR371C 1.77 1.74 0.53 0.00 Mem, Cyt 
YOR384W 0.76 0.00 0.00 0.52 Mito 
YPL002C 0.00 5.19 0.00 1.08 Endo 
YPL037C 0.68 0.00 0.00 0.51 Cyt 
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YPL056C 0.00 0.67 0.55 0.00 N/A 
YPL057C 0.00 1.60 0.00 2.07 Mem 
YPL065W 1.24 5.69 0.00 0.68 Endo 
YPL164C 0.57 0.00 0.00 0.72 Nuc 
YPL180W 2.38 0.00 0.00 1.47 Vac 
YPL194W 0.00 0.64 0.00 0.00 Nuc 
YPL197C 0.64 0.00 0.00 -1.17 N/A 
YPL215W 0.74 0.00 0.00 0.52 Mito 
YPL232W 1.08 0.00 0.00 0.71 Mem 
YPL260W 0.00 0.98 0.00 0.76 Cyt, Nuc 
YPL269W 1.38 0.00 0.00 0.62 Bud neck 
YPR040W 2.65 0.00 0.00 0.00 Cyt, Nuc 
YPR173C 2.99 0.00 0.00 0.66 Cyt, Endo 
YPR197C 0.00 10.15 0.52 0.00 N/A 
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1.7 Cell death assays: Glucose vs. Glycerol as a carbon source 
The cell death assays were also performed with equisetin. As with TA-289, equisetin 
killed BY4742 wt (A) and pdrΔ (B) yeast cells within the first hour of treatment 
when glucose is used as a carbon source, including wt as equisetin is more potent 
than TA-289. 
 
Wherein glycerol-ethanol is used, cells are more resistant to equisetin (below). 
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APPENDIX 2_________________________________________ 
 
2.1 Resistant mutants and cross-resistance scores 
The table below details the 22 TA-289 resistant mutants (TA1-22) and 21 equisetin 
resistant mutants (EQ1-21) isolated from both EMS mutagenesis and resistance that 
arose spontaneously. The mutants were tested for cross-resistance to both 
compounds and were scored according to their level of resistance. TA-289 resistant 
mutants were sorted according to their resistance score to TA-289 (60 µM), and 
equisetin resistant mutants according to their score to equisetin of the same 
concentration. 
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2.2 Generating an isogenic MATa wild-type strain 
 
2.2.1 Isogenic wild-type creation and confirmation 
An isogenic MATa strain of the same parental background as the pdrΔ strain used to 
generate resistant mutants was created in order to cross with the resistant mutants 
for dominance/recessiveness studies. This involved transforming a pdr1Δ::kanR yeast 
strain with a URA3 deletion cassette containing region homology with the ORFs of 
PDR3, creating a pdr1Δ::kanR pdr3∆::URA3 strain (YCG387). The URA3 deletion 
cassette was amplified from a purified pAG60 carrier plasmid by PCR. The figure 
below shows the expected band sizes for the pAG60 plasmid (4000 bp) and the 
amplified URA3 deletion cassette (1600 bp). 
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Then, the pdr1Δ::kanR strain was transformed with the PCR product, after which a 
colony PCR was performed to confirm the correct insertion of the URA3 cassette 
(and thus the deletion of PDR3). Expected band sizes (880 bp and 710 bp) of both 
forward and reverse internal and external primers observed under gel 
electrophoresis validates that the transformation was indeed successful. 
 
 
2.2.2 Making heterozygous diploid mutants 
Heterozygous diploid mutants were generated by crossing the isogenic wt strain 
YCG387 with the selected resistant mutant, TA8. This was achieved by chevron 
creation on rich media, then replica-plated onto selection media. To select for 
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diploids specifically, diploid strains (successful mating of YCG387 with the resistant 
mutants) were selected on SD –Ura +G418 +NAT. These heterozygous diploids were 
then re-streaked onto SD –Ura +G418 +NAT petri plates to attain single colonies for 
determining dominance and/or recessiveness of the mutants. See figure below for 
the method of chevron creation and selection of heterozygous diploids. 
 
(A) Method of chevron creation; (B) YPD +G418 selection to select for YCG387; (C) SD –Ura 
+NAT to select for parental strain YCG326 and the resistant mutants; (D) Diploid selection on 
SD –Ura +G418 +NAT. 
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2.3 Calculating growth rates 
The growth rate of the TA8 mutant was determined and compared to parental pdrΔ 
cells. OD of both strains was plotted against time, and the area of exponential 
growth for both strains was used to calculate growth rates. 
 
The model equation for exponential growth used was: 
Nt = Ni.eµt 
Where Nt is the OD value at any given time point, Ni is the y-intercept, µ is the 
gradient, and t is time. This was log-transformed to fit a straight line: 
lnNt = µt + lnNi 
The gradient and y-intercept for both TA8 and pdrΔ strains were obtained by 
performing a LINEST function in Microsoft Excel on the log-transformed data: 
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Strain y-intercept (lnNi) gradient (µ) 
TA8 -2.4 0.003 
pdrΔ -2.08 0.0039 
 
Using these values, the doubling time for the TA8 mutant strain was calculated as 
follows: 
Therefore lnNt = 0.003t + (-2.4) 
When lnNt  = -2.4, t = 0. When lnNt = -1.2 (double of -2.4), t = χ. 
Therefore t = (-1.2) + 2.4 / 0.003 
Therefore t = 400 mins / 60 mins 
Therefore t = 6.6 h 
 
The doubling time for the pdrΔ parental strain was calculated as follows: 
lnNt = 0.0039t + (-2.08) 
When lnNt  = -2.08, t = 0. When lnNt = -1.04 (double of -2.08), t = χ. 
Therefore t = (-1.04) + 2.08 / 0.0039 
Therefore t = 260 mins / 60 mins 
Therefore t = 4.3 h 
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APPENDIX 3_________________________________________ 
 
3.1 High salt does not sequester potency of TA-289 and equisetin 
The figures below indicate 24 h liquid dose response assays performed with TA-289 
and equisetin in the presence (red squares) or absence (green triangles) of high salt 
(0.7 M NaCl). Both wt (A above and below) and pdrΔ (B above and below) strains 
were tested. 
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